Page last updated: 2024-12-05

amphetamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3007
CHEMBL ID405
CHEBI ID132233
CHEBI ID2679
SCHEMBL ID8858
MeSH IDM0001012

Synonyms (219)

Synonym
allodene
amfetamina
benzolone
novydrine
psychedrine
amfetamine
sympamine
simpatedrin
rhinalator
anorexine
ortedrine
profamina
weckamine
isoamyne
benzebar
anfetamina
elastonon
oktedrin
norephedrane
isomyn
raphetamine
propisamine
mecodrin
fenopromin
percomon
sympatedrine
phenedrine
desoxynorephedrine
benzeneethanamine, .alpha.-methyl-, (.+/-.)-
phenethylamine, .alpha.-methyl-, (.+/-.)-
benzeneethanamine, .alpha.-methyl-, (s)-
nsc27159
.alpha.-methylbenzeneethanamine
1-phenyl-2-propylamine
2-amino-1-phenylpropane
.beta.-aminopropylbenzene
protioamphetamine
phenethylamine, .alpha.-methyl-
1-methyl-2-phenylethylamine
3-phenyl-2-propylamine
.beta.-phenylisopropylamin
wln: zy1&1r
benzeneethanamine, .alpha.-methyl-
(phenylisopropyl)amine
60-15-1
1-phenyl-2-aminopropane
.beta.-phenylisopropylamine
dexedrine
.alpha.-methylphenethylamine
1-phenyl-2-amino-propan
nsc-27159
.alpha.-methylphenylethylamine
KBIO1_000991
DIVK1C_000991
D03740
dea no. 1100
delcobese
dyanavel (tn)
adzenys (tn)
amfetamin (tn)
D07445
amfetamine (inn)
1-phenylpropan-2-amine
dl-alpha-methylphenethylamine
(s)-.alpha.-phenylethylamine
(+)-.alpha.-methylphenethylamine
d-.alpha.-methylphenethylamine
amphetamine, (d)
benzeneethanamine, (s)-
nsc73713
wln: zy1&1r -d
s(+)-amphetamine
component of amodex
.alpha.-methylphenethylamine, d-form
(s)-(+)-.beta.-phenylisopropylamine
component of biphetamine
phenethylamine, d-
dexacaps
(+)-.alpha.-methylphenylethylamine
phenethylamine, (+)-
OPREA1_447423
IDI1_000991
racemic-desoxynor-ephedrine
anfetamina [spanish]
benzeneethanamine, alpha-methyl-, (+-)-
einecs 206-096-2
fenylo-izopropylaminyl [polish]
nsc 27159
amfetamine [inn:ban]
beta-aminopropylbenzene (van)
adipan
phenethylamine, alpha-methyl-
amfetamina [italian]
anorexide
1-phenyl-2-propanamine
1-phenyl-2-aminopropane (van)
hsdb 3287
benzeneethanamine, alpha-methyl-
simpatina
einecs 200-458-3
phenethylamine, alpha-methyl-, (+-)-
(+-)-alpha-methylbenzeneethanamine
actedron
amfetamina [inn-spanish]
finam
beta-phenylisopropylamin [german]
(+-)-benzedrine
(+-)-alpha-methylphenethylamine
ai3-02438
amfetaminum [inn-latin]
1-phenyl-2-amino-propan [german]
desoxynorephedrin
amphetamine
C07514
300-62-9
DB00182
(+-)-alpha-methylphenylethylamine
beta-phenylisopropylamine
rac-(2r)-1-phenylpropan-2-amine
alpha-methylbenzeneethaneamine
rac-amphetamine
beta-aminopropylbenzene
alpha-methylphenethylamine
NINDS_000991
CHEBI:132233
L000864
CHEMBL405
amfetamin
chebi:2679
amphetamine, dl-
dyanavel
HMS503G03
3-amino-1-propylbenzene
alpha-methylphenylethylamine
bdbm50005246
amfetaminum
beta-phenylisopropylamin
amphetamin
1-phenylpropan-2-amin
adzenys xr-odt
isoamycin
dl-1-phenyl-2-aminopropane
(+/-)-benzedrine
(+/-)-desoxynorephedrine
dl-amphetamine
dl-benzedrine
(+/-)-beta-phenylisopropylamine
ck833kgx7e ,
adderall xr
nt-0201
adzenys er
unii-ck833kgx7e
fenylo-izopropylaminyl
dyanavel xr
beta-phenyl-isopropylamine
alpha-methylbenzeneethanamine
AB07478
(plusmn)-amphetamine
gtpl4804
amfetamine [who-dd]
amphetamine [vandf]
benzeneethanamine, .alpha.-methyl-, (+/-)-
amphetamine [mi]
amphetamine [orange book]
amphetamine [hsdb]
amfetamine [inn]
selegiline hydrochloride impurity b [ep impurity]
amfetamine [mart.]
(+/-)-.alpha.-methylphenethylamine
SCHEMBL8858
3-phenylpropan-2-amine
alpha-methyl phenethylamine
norephedrine, deoxy-
zedrine (salt/mix)
fabedrine (salt/mix)
(.+/-.)-.alpha.-methylphenethylamine
sympametin (salt/mix)
(.+/-.)-desoxynorephedrine
(.+/-.)-benzedrine
(.+/-.)-.beta.-phenylisopropylamine
ortenal (salt/mix)
.alpha.-methylbenzeneethaneamine
dl-.alpha.-methylphenethylamine
fenamin (salt/mix)
(.+/-.)-.alpha.-methylphenylethylamine
noclon (salt/mix)
adderal
vapedrine (salt/mix)
stimulan (salt/mix)
euphodyn (salt/mix)
oraldrina (salt/mix)
DTXSID4022600 ,
rac-amphetamine 1.0 mg/ml in methanol
d/l-amphetamine hydrochloride
Q179452
amphetamine-
benzeneethanamine, alpha-methyl-,(+-)
amfetamine (mart.)
(+-)-desoxynorephedrine
phenethylamine, alpha-methyl
dtxcid402600
(+-)-beta-phenylisopropylamine
amfetamina (inn-spanish)
amfetaminum (inn-latin)
acetedron
alpha-methyl-beta-phenylethylamine
adzenys
racemic desoxy-nor-ephedrine
(+-)-alpha-methyl phenethylamine
(+-)-phenylisopropylamine
(+-)-alpha-methylbenzene-ethanamine
(+-)-amphetamine
(+-)-alpha-methylphenyl ethylamine
benzeneethanamine, alpha-methyl-, (+/-)-
(+/-)-alpha-methylphenethylamine
amphetaminium
n06ba01
racemic amphetamine
(+-)-1-phenyl-2-aminopropane

Research Excerpts

Overview

Methamphetamine (METH) is an amphetamine-type stimulant that is highly toxic to the central nervous system (CNS) Amphetamine (AMPH) is a systemic stimulant used to treat a variety of diseases including Attention Deficit Hyperactive Disorder, narcolepsy and obesity.

ExcerptReferenceRelevance
"Amphetamine use is a risk factor for psychosis, which imposes a substantial burden on society. "( Risk of psychosis in illicit amphetamine users: a 10 year retrospective cohort study.
Huang, CL; Lee, CW; Tsai, IJ, 2022
)
2.46
"Amphetamine (AMPH) is a psychostimulant drug frequently related to addiction, which is characterized by functional and molecular changes in the brain reward system, favoring relapse development, and pharmacotherapies have shown low effectiveness. "( Tactile Stimulation in Adult Rats Modulates Dopaminergic Molecular Parameters in the Nucleus accumbens Preventing Amphetamine Relapse.
Burger, ME; D'Àvila, LF; Metz, VG; Milanesi, LH; Rosa, HZ; Rosa, JLO; Rossato, DR, 2022
)
2.37
"Methamphetamine abuse is a global epidemic associated with a wide-ranging array of adverse effects on the cardiovascular system including dilated cardiomyopathy, malignant and benign arrhythmias, coronary vasospasm, and atherosclerotic coronary artery disease. "( Cardiovascular disease associated with methamphetamine use: a review.
Afari, ME; Sawyer, DB; Song, SJ; Tobolski, J, 2022
)
1.54
"Methamphetamine (METH) is an amphetamine-type stimulant that is highly toxic to the central nervous system (CNS). "( The Role of Non-coding RNAs in Methamphetamine-Induced Neurotoxicity.
Chen, Q; Chen, X; Huang, Y; Li, L; Qiao, D; Xu, L, 2023
)
1.75
"Amphetamine is a psychostimulant drug with a high risk of toxicity and death when misused. "( Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database.
Abdullah, A; Alqahtani, SS; Alshahrani, S; Attafi, I; Banji, D; Banji, OJF; Khardali, I; Muqri, S; Sherwani, W; Tumayhi, M, 2023
)
3.8
"Amphetamine (AMPH) is a systemic stimulant used to treat a variety of diseases including Attention Deficit Hyperactive Disorder, narcolepsy and obesity. "( Prolonged Amphetamine Treatments Cause Long-Term Decrease of Dopamine Uptake in Cultured Cells.
Carvelli, L; Ferdous, N; Kudumala, S; Sossi, S, 2020
)
2.4
"Methamphetamine (MA) is a highly addictive central nervous system stimulant. "( Characteristics of Korean patients with methamphetamine use disorder based on the quantitative analysis of methamphetamine and amphetamine in hair.
Jang, WJ; Jeong, CH; Kim, S; Lee, S; Seo, MJ; Song, SH, 2020
)
1.38
"Methamphetamine (MA) is a highly addictive central nervous system stimulant. "( Revealing Metabolic Perturbation Following Heavy Methamphetamine Abuse by Human Hair Metabolomics and Network Analysis.
Jang, WJ; Jeong, CH; Kim, J; Kim, S; Lee, S; Lee, SK; Yu, H, 2020
)
1.37
"Amphetamine is an illicit central nervous system stimulant that is also used for the treatment of attention-decific/hyperacticity disorder (ADHD). "( [Harmonized measurement and reporting of chiral amphetamine in the follow-up of ADHD treatment].
Helander, A; Villen, T; Widing, E, 2020
)
2.26
"Amphetamine is a potent psychostimulant also used to treat attention deficit/hyperactivity disorder and narcolepsy. "( Caenorhabditis elegans as an in vivo Model to Assess Amphetamine Tolerance.
Carvelli, L; Hossain, M; Kudumala, S; Torres Valladares, D, 2020
)
2.25
"Amphetamine (AMPH) is an addictive psychostimulant highly used worldwide and its consumption is related to neurotoxic effects. "( Cannabidiol prevents amphetamine relapse and modulates D1- and D2-receptor levels in mesocorticolimbic brain areas of rats.
Burger, ME; da Rosa, JLO; Metz, VG; Milanesi, LH; Pase, CS; Rossato, DR, 2021
)
2.38
"Amphetamine (AMPH) is a drug of appetite suppressant, which exerts its effect by decreasing the expression of hypothalamic neuropeptide Y (NPY) and increasing that of cocaine- and amphetamine-regulated transcript (CART)."( Role of hypothalamic leptin-LepRb signaling in NPY-CART-mediated appetite suppression in amphetamine-treated rats.
Chen, JR; Chen, PN; Chu, SC; Hsieh, YS; Kuo, DY; Yu, CH, 2018
)
1.42
"Amphetamine abuse is a major public health concern for which there is currently no effective treatment. "( An unsuspected role for organic cation transporter 3 in the actions of amphetamine.
Apuschkin, M; Boehm, S; Chiba, P; Daws, LC; Gether, U; Gould, GG; Koek, W; Kudlacek, O; Mayer, FP; Owens, WA; Salzer, I; Schmid, D; Sitte, HH; Williams, PH; Wu, HH, 2018
)
2.16
"Amphetamine (AMPH) abuse is a serious public health problem due to the high addictive potential of this drug, whose use is related to severe brain neurotoxicity and memory impairments. "( Omega-3 decreases D1 and D2 receptors expression in the prefrontal cortex and prevents amphetamine-induced conditioned place preference in rats.
Barcelos, RCS; Burger, ME; Dias, VT; Emanuelli, T; Maurer, LH; Metz, VG; Pase, CS; Segat, HJ; Stiebe, J, 2019
)
2.18
"Amphetamine (AMPH) acts as a substrate of the dopamine transporter (DAT) and causes a dramatic increase in extracellular dopamine (DA). "( G protein-coupled receptor signaling in VTA dopaminergic neurons bidirectionally regulates the acute locomotor response to amphetamine but does not affect behavioral sensitization.
Dencker, D; Gether, U; Runegaard, AH; Wörtwein, G, 2019
)
2.16
"Amphetamine is a major drug of abuse in Sweden and in the other Nordic countries. "( Amphetamine abuse in Sweden: subject demographics, changes in blood concentrations over time, and the types of coingested substances.
Holmgren, A; Jones, AW, 2013
)
3.28
"As amphetamine is a base and >99% protonated at physiological pH, this enhanced affinity is attributed to the ion-exchange phase in the coating."( Elucidating the sorption mechanism of "mixed-mode" SPME using the basic drug amphetamine as a model compound.
Bosman, IJ; Droge, ST; Groothuis, FA; Hermens, JL; Peltenburg, H, 2013
)
1.13
"Amphetamine is a highly addictive psychostimulant, which is thought to generate its effects by promoting release of dopamine through reverse activation of dopamine transporters. "( Amphetamine activates an amine-gated chloride channel to generate behavioral effects in Caenorhabditis elegans.
Bianchi, L; Carvelli, L; Lor, C; Safratowich, BD, 2013
)
3.28
"Methamphetamine (METH) abuse is a worldwide threat, without any FDA approved medications. "( Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering.
Celikel, R; Nanaware-Kharade, N; Peterson, EC; Thakkar, S; Varughese, KI, 2014
)
1.21
"Methamphetamine (METH) abuse is a growing health problem worldwide, and METH use during pregnancy not only endangers the mother's health but also the developing fetus. "( Sex differences in methamphetamine pharmacokinetics in adult rats and its transfer to pups through the placental membrane and breast milk.
Bubenikova-Valesova, V; Bumba, J; Kacer, P; Rambousek, L; Slamberova, R; Syslova, K, 2014
)
1.27
"Amphetamine is a central nervous system psychostimulant with a high potential for abuse. "( Amphetamine potency varies with dopamine uptake rate across striatal subregions.
Calipari, ES; Jones, SR; Siciliano, CA, 2014
)
3.29
"Amphetamine (AMPH) is an addictive psychostimulant drug whose use has been related to neurotoxicity. "( Cross-Generational trans Fat Consumption Favors Self-Administration of Amphetamine and Changes Molecular Expressions of BDNF, DAT, and D1/D2 Receptors in the Cortex and Hippocampus of Rats.
Bürger, ME; de Freitas, DL; Dias, VT; Emanuelli, T; Kuhn, FT; Pase, CS; Roversi, K; Veit, JC; Vey, LT, 2015
)
2.09
"Amphetamine (AMPH) abuse is a world concern and a serious public health problem. "( m-Trifluoromethyl-diphenyldiselenide as a pharmacological tool to treat preference symptoms related to AMPH-induced dependence in rats.
Barcelos, RCS; Brüning, CA; Burger, ME; Martini, F; Nogueira, CW; Segat, HJ, 2016
)
1.88
"Methamphetamine is a globally abused drug that is metabolized to amphetamine, which also produces abuse-related behavioral effects. "( Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys.
Banks, ML; Kisor, DF; Poklis, JL; Smith, DA, 2016
)
1.23
"Amphetamine serves as a substrate for the dopamine transporter and reverses the transporter to cause an increase in extracellular dopamine."( PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux.
Gnegy, ME; Kennedy, RT; Mikelman, SR; Zestos, AG, 2016
)
1.46
"Amphetamine (AM) is a powerful psychostimulant existing in two enantiomeric forms. "( Accelerated quantification of amphetamine enantiomers in human urine using chiral liquid chromatography and on-line column-switching coupled with tandem mass spectrometry.
Bruni, PS; Frübis, M; Hädener, M; König, S; Weinmann, W, 2017
)
2.19
"Amphetamine (AMPH) is a commonly abused psychostimulant that induces neuronal cell death/degeneration in humans and experimental animals. "( The neurotoxic mechanisms of amphetamine: Step by step for striatal dopamine depletion.
Chang, ST; Huang, CL; Huang, NK; Tung, CS, 2017
)
2.19
"Amphetamine is a neurotoxic psychostimulant that causes dopamine depletion and neuronal death in the rodent striatum. "( Amphetamine causes dopamine depletion and cell death in the mouse olfactory bulb.
Atianjoh, FE; Cadet, JL; Krasnova, IN; Ladenheim, B, 2008
)
3.23
"Amphetamine (AMPH) is a highly addictive drug of abuse which exhibits toxicity to dopaminergic neurons in long-term abusers. "( Attenuation of estradiol on the reduction of striatal dopamine by amphetamine in ovariectomized rats.
Lee, TS; Pan, WH; Wang, PS; Wang, SW; Wu, CI; Yu, PL, 2009
)
2.03
"Amphetamine is a stimulant drug that enhances attention and feelings of alertness. "( More aroused, less fatigued: fatty acid amide hydrolase gene polymorphisms influence acute response to amphetamine.
de Wit, H; Dlugos, AM; Goldman, D; Hamidovic, A; Hodgkinson, CA; Palmer, AA, 2010
)
2.02
"Amphetamine (AMPH) is a highly abused drug that presents potent stimulating effects on the CNS and has been shown to induce behavioral, biochemical and immunological effects."( Amphetamine modulates cellular recruitment and airway reactivity in a rat model of allergic lung inflammation.
Damazo, AS; de Oliveira, AP; Farsky, SH; Hamasato, EK; Hebeda, CB; Lino-Dos-Santos-Franco, A; Palermo-Neto, J; Quinteiro-Filho, W; Tavares-de-Lima, W, 2011
)
2.53
"Methamphetamine (METH) is a powerful stimulant drug of abuse that has steadily gained popularity worldwide. "( Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9.
Ambrósio, AF; Baptista, S; Borges, F; Gonçalves, J; Leal, E; Lendoiro, E; López-Rivadulla, M; Martins, T; Milhazes, N; Quintela, O; Ribeiro, CF; Silva, AP, 2011
)
1.49
"Amphetamine is a major drug of abuse worldwide. "( Quantitative analysis of amphetamine in femoral blood from drug-poisoning deaths compared with venous blood from impaired drivers.
Ahlner, J; Holmgren, A; Jones, AW, 2011
)
2.12
"Amphetamine is a psychostimulant drug that produces long-lasting neurotoxic effects on the central nervous system. "( Effect of melatonin on D-amphetamine-induced neuroglial alterations in postnatal rat hippocampus and prefrontal cortex.
Govitrapong, P; Mukda, S; Permpoonputtana, K, 2012
)
2.13
"Amphetamine (AMPH) is a drug of abuse that causes the degeneration of striatal dopamine terminals in mammals. "( cDNA array analysis of gene expression profiles in the striata of wild-type and Cu/Zn superoxide dismutase transgenic mice treated with neurotoxic doses of amphetamine.
Cadet, JL; Krasnova, IN; Ladenheim, B; McCoy, MT, 2002
)
1.95
"Amphetamine is an indirect dopamine receptor agonist and increases glutamate release in the striatum. "( Amphetamine increases phosphorylation of extracellular signal-regulated kinase and transcription factors in the rat striatum via group I metabotropic glutamate receptors.
Choe, ES; Chung, KT; Mao, L; Wang, JQ, 2002
)
3.2
"Amphetamine (AMPH) is an indirect sympathomimetic compound classified as a substrate-type releaser that distinguishes it from other stimulants that act as uptake 1 blockers, such as cocaine (COC). "( Antisense knockdown of the Shaker-like Kv1.1 gene abolishes the central stimulatory effects of amphetamines in mice and rats.
Banchelli, G; Galeotti, N; Ghelardini, C; Livi, S; Pirisino, R; Quattrone, A; Raimondi, L, 2003
)
1.98
"Amphetamine is a substrate of the plasmalemmal transporters for both dopamine and norepinephrine."( The effect of phosphorylation on amphetamine-mediated outward transport.
Gnegy, ME, 2003
)
1.32
"Amphetamine (AMPH) is a well-known anorectic agent. "( Amphetamine, an appetite suppressant, decreases neuropeptide Y immunoreactivity in rat hypothalamic paraventriculum.
Hsieh, YS; Kuo, DY; Yang, SF, 2005
)
3.21
"Amphetamine (AMPH) is a psychostimulant whose chronic abuse may cause impairments in attention and memory in humans. "( Amphetamine induces apoptosis of medium spiny striatal projection neurons via the mitochondria-dependent pathway.
Cadet, JL; Krasnova, IN; Ladenheim, B, 2005
)
3.21
"Amphetamine is a well-characterised inducer of sensitisation."( Pleiotrophin gene transcription in the rat nucleus accumbens is stimulated by an acute dose of amphetamine.
Le Grevès, P, 2005
)
1.27
"Methamphetamine (METH) is a psychostimulant that induces excessive release of dopamine (DA) in the striatum. "( Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors.
Angulo, JA; Xu, W; Zhu, JP, 2005
)
1.13
"Amphetamine (AMPH) is a potent dopamine (DA) transporter (DAT) inhibitor that markedly increases extracellular DA levels. "( Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent.
Boudanova, E; Melikian, HE; Navaroli, DM, 2008
)
3.23
"Methamphetamine is a drug that is often consumed at dance parties or nightclubs where the ambient temperature is high. "( High ambient temperature increases intravenous methamphetamine self-administration on fixed and progressive ratio schedules in rats.
Callaghan, PD; Clemens, KJ; Cornish, JL; Dawson, B; McGregor, IS; Thompson, MR, 2008
)
1.16
"Amphetamine (AMPH) is a widely abused psychostimulant that acts as a substrate for the human dopamine transporter (hDAT). "( Currents in response to rapid concentration jumps of amphetamine uncover novel aspects of human dopamine transporter function.
Erreger, K; Galli, A; Grewer, C; Javitch, JA, 2008
)
2.04
"Amphetamine is a strong competitive antagonist of brain synaptosomal [3H]norepinephrine ([3H]NE) uptake. "( Conformational requirements for norepinephrine uptake inhibition by phenethylamines in brain synaptosomes. Effects of alpha-alkyl substitution.
de Jong, AP; Fesik, SW; Makriyannis, A, 1982
)
1.71
"Amphetamine is a sympathomimetic drug that may be used for preconditioning."( Drug-induced heat-shock preconditioning improves postischemic ventricular recovery after cardiopulmonary bypass.
Das, DK; Deaton, DW; Engelman, RM; Flack, JE; Liu, X; Maulik, N; Rousou, JA; Wei, Z, 1995
)
1.01
"The amphetamine-treated rat is a useful preparation for investigating this notion in an unconstrained animal whose behavior is still not as complex and variable as that of the normal animal."( Coordination of side-to-side head movements and walking in amphetamine-treated rats: a stereotyped motor pattern as a stable equilibrium in a dynamical system.
Benjamini, Y; Golani, I; Kafkafi, N; Levi-Havusha, S, 1996
)
1.02
"D-Amphetamine (AM) is a potent inducer of conditioned taste aversion (CTA) the mechanism of which differs from that induced by lithium. "( Protein kinase C in the parabrachial nucleus of rats during conditioned taste aversion induced by amphetamine.
Krivanek, J, 1997
)
1.24
"Amphetamine is a highly addictive psychostimulant that promotes the release of the catecholamines dopamine and norepinephrine. "( Amphetamine selectively blocks inhibitory glutamate transmission in dopamine neurons.
Fiorillo, CD; Morikawa, H; Paladini, CA; Williams, JT, 2001
)
3.2
"Amphetamine is an addictive drug, possessing reinforcing properties that are believed to be associated with an environmental cue, which resembles a behavioral learning process. "( Impairing the amphetamine conditioning in rats through the inhibition of hippocampal calcium/calmodulin-dependent protein kinase II activity.
Tan, SE, 2002
)
2.12
"Amphetamine is a potent and very effective drug for conditioning taste aversions, but much less is known about the possible effects of flavour-amphetamine pairings on aspects of behaviour other than eating and drinking. "( Suppression of fixed-interval responding by flavour-amphetamine pairings in rats.
D'Mello, GD; Stolerman, IP, 1978
)
1.95
"Amphetamine, which is an indirect catecholaminergic agonist, mobilizes neuronal catecholamines and fosters their various effects."( [Pharmacological and molecular aspects of the regulation of eating behavior. With special reference to the role of catecholamines and effects of amphetamine].
Costentin, J,
)
1.05

Effects

Amphetamine has a significant potential for abuse and addiction. It displaces intraneuronal stores of catecholamines, delaying their reuptake and inhibiting catabolism.

Amphetamine withdrawal has been less studied although it is a common problem with a prevalent rate of 87% among amphetamine users. Amphetamine psychosis has been considered to be a pharmacologic model of schizophrenia.

ExcerptReferenceRelevance
"d-Amphetamine has a mechanism independent of neuronal firing rate, displacing intraneuronal stores of catecholamines, delaying their reuptake and inhibiting catabolism by monoamine oxidase."( The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
Cheetham, SC; Heal, DJ; Smith, SL, 2009
)
0.91
"Amphetamine has a significant potential for abuse and addiction. "( Abstinence from repeated amphetamine treatment induces depressive-like behaviors and oxidative damage in rat brain.
Andreazza, AC; Che, Y; Cui, YH; Tan, H; Wang, JF; Young, LT, 2013
)
2.14
"Amphetamine intake has traditionally not been considered to cause nystagmus."( Nystagmus among suspected amphetamine impaired drivers.
Gjerde, H; Høiseth, G; Strand, MC, 2023
)
1.93
"Amphetamine use disorder has been recently classified as an epidemic condition. "( Serum proteomic profiling of patients with amphetamine use disorder.
Alanazi, IO; Alasmari, AF; Alasmari, F; Alfadda, AA; Alhazzani, K; Alsanea, S; Alshammari, MA; Benabdelkamel, H; Masood, A; Musambil, M, 2020
)
2.26
"Amphetamine derivatives have been used in a wide variety of pathologies because of their pharmacological properties as psychostimulants, entactogens, anorectics, and antidepressants. "( Pharmacological Characterization of 4-Methylthioamphetamine Derivatives.
España, RA; Guajardo, FG; Iturriaga-Vásquez, P; Núñez-Vivanco, G; Raby, D; Reyes-Parada, M; Sotomayor-Zárate, R; Velásquez, VB, 2020
)
2.26
"Amphetamine has been shown to improve consolidation of information (0.02 ≥ P ≤ 0.05), leading to improved recall."( Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review.
Bagot, KS; Kaminer, Y, 2014
)
1.12
"Amphetamine treatment has been shown to produce recovery from visual, frontal, and sensorimotor cortex damage in animals and this recovery may be the result of axonal growth originating from the opposite, unlesioned hemisphere."( The time-dependent and persistent effects of amphetamine treatment upon recovery from hemispatial neglect in rats.
Brenneman, MM; Corwin, JV; Hylin, MJ, 2015
)
1.4
"Amphetamine stimulants have been used medically since early in the twentieth century, but they have a high abuse potential and can be neurotoxic. "( Potential adverse effects of amphetamine treatment on brain and behavior: a review.
Berman, SM; Kuczenski, R; London, ED; McCracken, JT, 2009
)
2.09
"Low amphetamine doses have been associated with enhanced performance in studies of sleep-deprived subjects."( [Driving under the influence of amphetamine and metamphetamine].
Lia, K; Slørdal, L; Spigset, O, 2009
)
1.12
"d-Amphetamine has a mechanism independent of neuronal firing rate, displacing intraneuronal stores of catecholamines, delaying their reuptake and inhibiting catabolism by monoamine oxidase."( The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
Cheetham, SC; Heal, DJ; Smith, SL, 2009
)
0.91
"Amphetamine has the added mechanism of reverse transport of intracellular DA through the DAT."( Cocaine-insensitive dopamine transporters with intact substrate transport produced by self-administration.
Ferris, MJ; Jones, SR; Mateo, Y; Roberts, DC, 2011
)
1.09
"Amphetamine has a significant potential for abuse and addiction. "( Abstinence from repeated amphetamine treatment induces depressive-like behaviors and oxidative damage in rat brain.
Andreazza, AC; Che, Y; Cui, YH; Tan, H; Wang, JF; Young, LT, 2013
)
2.14
"Amphetamine has been shown to increase striatal particulate protein kinase C (PKC) activity [Giambalvo (1992b) Neuropharmacology 31:1211-1222]. "( Differential effects of amphetamine transport vs. dopamine reverse transport on particulate PKC activity in striatal synaptoneurosomes.
Giambalvo, CT, 2003
)
2.07
"Amphetamine has been known to induce cardiac dysrhythmia and sudden death. "( Amphetamine activates connexin43 gene expression in cultured neonatal rat cardiomyocytes through JNK and AP-1 pathway.
Lee, CC; Lin, S; Shyu, KG; Tsai, SC; Wang, BW; Yang, YH, 2004
)
3.21
"Amphetamine salts have been helpful in treating bipolar children with comorbid ADHD, but no data are available on treating comorbid depression in bipolar children."( Recognizing and managing bipolar disorder in children.
Wozniak, J, 2005
)
1.05
"Amphetamine (AMPH) has been shown to decrease simultaneously DAT cell-surface expression and [(3)H]DA uptake."( Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution.
Galli, A; Garcia, BG; Javitch, JA; Lin, RZ; Moron, JA; Wei, Y, 2005
)
1.31
"Amphetamine has been used in Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, and as an appetite suppressant either as the racemate or in different proportions of its enantiomers. "( Quantitation of R-(-)- and S-(+)-amphetamine in hair and blood by gas chromatography-mass spectrometry: an application to compliance monitoring in adult-attention deficit hyperactivity disorder treatment.
Ahlner, J; Kronstrand, R; Nyström, I; Trygg, T; Woxler, P, 2005
)
2.05
"Amphetamine has been shown to enhance consolidation in a variety of memory paradigms. "( Post-training and post-reactivation administration of amphetamine enhances morphine conditioned place preference.
Blaiss, CA; Janak, PH, 2006
)
2.02
"Amphetamine (AMPH) has been proposed as a treatment for post-stroke motor deficits when coupled with symptom-relevant physical rehabilitation. "( No improvement by amphetamine on learned non-use, attempts, success or movement in skilled reaching by the rat after motor cortex stroke.
Alaverdashvili, M; Lim, DH; Whishaw, IQ, 2007
)
2.12
"Amphetamine has been shown previously to increase the apportioning of associative strength to weak predictors in appetitive Pavlovian conditioning procedures such as latent inhibition and overshadowing. "( Amphetamine effects in appetitive acquisition depend on the modality of the stimulus rather than its relative validity.
Cassaday, HJ; Horsley, RR, 2008
)
3.23
"Amphetamine has become one of the most popular drugs of abuse in Taiwan area in recent years. "( Analysis of drug abuse among adolescent psychiatric inpatients at Veterans General Hospital-Taipei.
Chen, YS; Sim, CB; Yeh, HS, 1995
)
1.73
"Amphetamine has been shown previously to increase levels of the inducible 70-kDa heat shock protein (hsp70i) in mouse liver. "( Protection against hepatotoxicity by a single dose of amphetamine: the potential role of heat shock protein induction.
Roberts, SM; Salminen, WF; Voellmy, R, 1997
)
1.99
"Amphetamine has no effect on the slow inward Ca2+ current (I(Ca)-L), the inwardly rectifying K+ current (I(K1) and the outward K+ delayed rectifier (I(K)) and sustained (I(SS)) currents."( Effects of amphetamine on calcium and potassium currents in rat heart.
Casis, O; Espiña, L; Gallego, M, 2000
)
1.42
"Amphetamine withdrawal has been less studied although it is a common problem with a prevalent rate of 87% among amphetamine users. "( Treatment for amphetamine withdrawal.
Jarusuraisin, N; Kittirattanapaiboon, P; Srisurapanont, M, 2001
)
2.11
"Amphetamine has different effects on DAT when given pre- or post-training. "( Effects of amphetamine on the plus-maze discriminative avoidance task in mice.
Carvalho, RC; Costa, KL; Frussa-Filho, R; Kameda, SR; Rigo, GS; Silva, RH; Taricano, ID, 2002
)
2.15
"Amphetamine has been shown to keep the memory at precisely the level exhibited by the labile, cycloheximide-resistant memory trace at the time of injection."( Modulation of cycloheximide-resistant memory by sympathomimetic agents.
Gibbs, ME, 1976
)
0.98
"Amphetamine psychosis has been considered to be a pharmacologic model of schizophrenia. "( Amphetamine psychosis and psychotic symptoms.
Janowsky, DS; Risch, C, 1979
)
3.15
"Amphetamine has complex behavioral actions in the rat that depend upon the release of dopamine in striatal and mesolimbic brain regions. "( Differential down-regulation of D1-stimulated adenylate cyclase activity in rat forebrain after in vivo amphetamine treatments.
Gnegy, ME; Iwaniec, LM; Roberts-Lewis, JM; Roseboom, PH, 1986
)
1.93
"Amphetamine, which has both direct and indirect actions when applied locally, was not antagonized."( Investigation of the failure of parenterally administered haloperidol to antagonize dopamine released from micropipettes in the caudate.
Freedman, R; Hoffer, BJ; Johnson, SW, 1986
)
0.99

Actions

Amphetamine can increase conditioning to poor predictors of reinforcement in selective learning tasks. An amphetamine challenge may cause neurotoxicity in the human brain due to a decrease in omega-3 fatty acids and an increase in oxidative products. If amphetamine can enhance the therapeutic effects of TCT, this would provide strong support for a "PACT" treatment paradigm for schizophrenia.

ExcerptReferenceRelevance
"An amphetamine challenge may cause neurotoxicity in the human brain due to a decrease in omega-3 fatty acids and an increase in oxidative products."( Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database.
Abdullah, A; Alqahtani, SS; Alshahrani, S; Attafi, I; Banji, D; Banji, OJF; Khardali, I; Muqri, S; Sherwani, W; Tumayhi, M, 2023
)
2.87
"If amphetamine can enhance the therapeutic effects of TCT, this would provide strong support for a "PACT" treatment paradigm for schizophrenia."( Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients.
Alvarez, AI; Bhakta, SG; Hughes, EL; Light, GA; Rana, B; Swerdlow, NR; Talledo, J; Tarasenko, M; Vinogradov, S, 2017
)
2.41
"Amphetamine abuse increase risk of hemorrhagic stroke and may result in cerebral vasospasm. "( [Cerebral vasospasm in patient with hemorrhagic stroke after amphetamine intake--case report].
Kochanowicz, J; Lewko, J; Rutkowski, R; Turek, G; Łysoń, T, 2008
)
2.03
"The amphetamine-induced increase in limbic met-enkephalin content was suppressed by SCH-23390 but not by raclopride pre-treatment."( Decrease of lymphoproliferative response by amphetamine is mediated by dopamine from the nucleus accumbens: influence on splenic met-enkephalin levels.
Assis, MA; Cancela, LM; García-Keller, C; Sotomayor, C; Valdomero, A, 2011
)
1.11
"Amphetamine and cocaine increase extracellular levels of DA by acting on the DAT; thus, variations in DAT binding sites or activity might influence the action of some drugs of abuse."( Selective decreases in amphetamine self-administration and regulation of dopamine transporter function in diabetic rats.
France, CP; Frazer, A; Galici, R; Galli, A; Gould, GG; Jones, DJ; Lin, RZ; Sanchez, TA; Saunders, C, 2003
)
1.35
"Amphetamine can increase conditioning to poor predictors of reinforcement in selective learning tasks (e.g. "( Amphetamine increases aversive conditioning to diffuse contextual stimuli and to a discrete trace stimulus when conditioned at higher footshock intensity.
Cassaday, HJ; Norman, C, 2003
)
3.2
"The amphetamine-induced increase in PKC activity was attenuated by pretreatment with DA uptake blockers (nomifensine, GBR 12935, and bupropion), even though these drugs by themselves also incr"( Differential effects of amphetamine transport vs. dopamine reverse transport on particulate PKC activity in striatal synaptoneurosomes.
Giambalvo, CT, 2003
)
1.11
"Amphetamine is known to increase dopamine (DA) release by acting directly on dopamine transporters (DAT), primarily through a mechanism that is independent of impulse flow. "( In vivo evidence that genetic background controls impulse-dependent dopamine release induced by amphetamine in the nucleus accumbens.
Alcaro, A; Mandolesi, L; Puglisi-Allegra, S; Ventura, R, 2004
)
1.98
"The amphetamine-induced increase in rCBV in the accumbens in animals pre-treated with eticlopride was paralleled by a similar percentage increase in DA release measured by means of microdialysis."( Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging.
Andersen, SL; Chen, YC; Choi, JK; Jenkins, BG; Rosen, BR, 2005
)
0.81
"Amphetamine is thought to produce its stimulant effects mainly via the dopamine system, but its effects may also be influenced by other systems. "( Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants.
Baune, BT; Cook, EH; de Wit, H; Deckert, J; Hohoff, C; McDonald, JM, 2005
)
2.03
"The amphetamine isomers produce different BOLD responses in brain areas related to cognition, pleasure, pain processing and motor control probably because of variations on brain amine systems such as dopamine and noradrenaline. "( Differential effects of the D- and L- isomers of amphetamine on pharmacological MRI BOLD contrast in the rat.
Easton, N; Fone, KC; Marsden, CA; Marshall, F, 2007
)
1.15
"Amphetamine did not produce tolerance or affect subsequent caffeine-induced activity."( Caffeine reduces amphetamine-induced activity in asymmetrical interaction.
Crumbie, PM; Harkins, D; Haswell, KL; Kassab, CD; White, BC, 1984
)
1.33
"Amphetamine appears to cause definite reciprocal alterations of the patterns studied: activation of the catecholamine-dependent mediation and inhibition of the serotoninergic reactions."( [The mechanism of amphetamine action of the neuromediator system of the brain].
Dovedova, EL,
)
1.19
"The amphetamine-induced increase in activity was progressively augmented with repeated exposures over 7 days."( A comparison of the motor-activating effects of acute and chronic exposure to amphetamine and methylphenidate.
Davidson, ES; McNamara, CG; Schenk, S, 1993
)
1
"The amphetamine-mediated increase in the content of phosphoser41-neuromodulin was less sensitive to extrasynaptosomal calcium."( Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes.
Gnegy, ME; Hewlett, GH; Iwata, S, 1997
)
2.22
"3. Amphetamine-induced increase in striatal extracellular dopamine level was attenuated by one day and by chronic (21 days) treatment with selegiline (0.25 mg kg(-1), s.c.)."( Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.
Finberg, JP; Lamensdorf, I; Porat, S; Simantov, R, 1999
)
1.04
"Amphetamine did not cause greater locomotor responses in -/- mice, suggesting that the increased sensitivity of -/- mice to cocaine does not generalize to other psychomotor stimulants."( Increased acute cocaine sensitivity and decreased cocaine sensitization in GABA(A) receptor beta3 subunit knockout mice.
Homanics, GE; Jung, BJ; Peris, J; Resnick, A, 1999
)
1.02
"The amphetamine-evoked increase in extracellular glutamate levels was determined to be 39% calcium-sensitive by lowering the calcium concentration in the perfusate."( Delta opioid receptors regulate calcium-dependent, amphetamine-evoked glutamate levels in the rat striatum: an in vivo microdialysis study.
McGinty, JF; Rawls, SM, 2000
)
1.04
"Both amphetamine and cocaine increase norepinephrine (NE) via stimulation of release and inhibition of reuptake, respectively."( Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
Baumann, MH; Carroll, FI; Dersch, CM; Partilla, JS; Rice, KC; Romero, DV; Rothman, RB, 2001
)
2.21
"Amphetamine did not cause a hyperthermia in thyroidectomized rats."( [Effects of hyper-and hypothyroidism on central nervous system with special reference to its effects on rectal temperature and brain norepinephrine levels in rats].
Arai, E; Kobayashi, M; Nomura, T; Sawa, K; Wakamatsu, Y, 1975
)
0.98
"Amphetamine was found to cause a more persistent increase of extracellular DA in the dorsolateral striatum than in the nucleus accumbens."( Amphetamine enhances extracellular concentrations of dopamine and acetylcholine in dorsolateral striatum and nucleus accumbens of freely moving rats.
Guix, T; Hurd, YL; Ungerstedt, U, 1992
)
2.45
"Amphetamine induced an increase in levels of nosing and rooting and of locomotion."( Behavioural responses to amphetamine and apomorphine in pigs.
De Rosa, G; Illius, AW; Ladewig, J; Lawrence, AB; Terlouw, EM, 1992
)
1.31
"Amphetamine caused an increase in blood pressure (34%) and heart rate (31%)."( Effect of amphetamine on cerebral blood flow and capillary perfusion.
Chi, OZ; Hall, W; Russo, KE; Sinha, AK; Weiss, HR, 1991
)
1.41
"d-Amphetamine, in doses lower than required to increase motor activity, reduced mouse spontaneous locomotor activity when this was assessed using cages equipped with photocell units, using treadwheels, or the measurement of spontaneous climbing behaviour. "( 5-Hydroxytryptamine involvement in the locomotor activity suppressant effects of amphetamine in the mouse.
Bradbury, AJ; Costall, B; Naylor, RJ; Onaivi, ES, 1987
)
1.22
"Thus amphetamine and cocaine increase dopamine in a behavior reinforcement system which is normally activated by eating."( Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis.
Hernandez, L; Hoebel, BG, 1988
)
0.73
"Amphetamine induced an increase followed by a decrease in the specific activity of released DA which reflects an initial release of newly synthesized DA followed by the release of stored amine."( Involvement of intraterminal dopamine compartments in the amine release in the cat striatum.
Guibert, B; Leviel, V, 1987
)
0.99

Treatment

Amphetamine (AMPH) treatment can suppress appetite and increase oxidative stress in the brain. Treatment may be harmful in stroke recovery by making the brain more vulnerable to ischaemia.

ExcerptReferenceRelevance
"Amphetamine treatment impaired prepulse inhibition in wildtype and heterozygous orexin-deficient mice, but had no effects in homozygous orexin-deficient mice."( Orexin deficiency affects sensorimotor gating and its amphetamine-induced impairment.
Demidova, A; Fendt, M; Kahl, E, 2022
)
1.69
"Amphetamine treatment also reversed escalated cocaine intake and decreased motivation to obtain cocaine as measured in a behavioral economics task, thereby linking tolerance to multiple facets of cocaine use."( Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation.
Calipari, ES; Chen, R; Fordahl, SC; Jones, SR; Khoshbouei, H; Saha, K; Siciliano, CA, 2018
)
2.64
"Amphetamine treatment decreased serotonin turnover in the fluoxetine-treated HC rats, but increased it in fluoxetine-treated LC rats."( Chronic stress sensitizes amphetamine-elicited 50-kHz calls in the rat: Dependence on positive affective phenotype and effects of long-term fluoxetine pretreatment.
Harro, J; Kaldmäe, M; Kõiv, K; Laugus, K; Metelitsa, M; Shimmo, R; Tiitsaar, K; Vares, M, 2018
)
1.5
"Amphetamine treatment may be harmful in stroke recovery by making the brain more vulnerable to ischaemia."( Amphetamine makes caudate tissue more susceptible to oxygen and glucose deprivation.
Davidson, C; Tana, A, 2013
)
2.55
"Amphetamine treatment in adolescence, but not in adulthood, also produces an increase in salience attribution to a previously drug-paired context in adulthood."( Amphetamine in adolescence disrupts the development of medial prefrontal cortex dopamine connectivity in a DCC-dependent manner.
Cermakian, N; Flores, C; Kiessling, S; Makowski, CS; Reynolds, LM; Yogendran, SV, 2015
)
2.58
"Amphetamine (AMPH) treatment can suppress appetite and increase oxidative stress in the brain. "( Involvement of oxidative stress in the regulation of NPY/CART-mediated appetite control in amphetamine-treated rats.
Chen, CH; Chen, PN; Hsieh, YS; Kuo, DY; Tsai, TT; Yu, CH, 2015
)
2.08
"Amphetamine-treated rats displayed higher 50 kHz USV emissions and locomotor activity than vehicle-treated rats, and emitted conditioned vocalizations on test cage re-exposure. "( Involvement of Glutamate NMDA Receptors in the Acute, Long-Term, and Conditioned Effects of Amphetamine on Rat 50 kHz Ultrasonic Vocalizations.
Costa, G; Morelli, M; Simola, N, 2015
)
2.08
"Amphetamine treatment has been shown to produce recovery from visual, frontal, and sensorimotor cortex damage in animals and this recovery may be the result of axonal growth originating from the opposite, unlesioned hemisphere."( The time-dependent and persistent effects of amphetamine treatment upon recovery from hemispatial neglect in rats.
Brenneman, MM; Corwin, JV; Hylin, MJ, 2015
)
1.4
"Amphetamine treatment increased CRF(2) receptor densities in most subregions of the dRN, and CRF(2) receptors were still elevated following 6 weeks of withdrawal."( Amphetamine treatment increases corticotropin-releasing factor receptors in the dorsal raphe nucleus.
Forster, GL; Lukkes, JL; Mouw, NJ; Pringle, RB, 2008
)
2.51
"Amphetamine pretreatment induced behavioral sensitization in both rat strains similarly. "( The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?
Feldon, J; Hauser, J; Peleg-Raibstein, D; Yee, BK, 2009
)
2.35
"Amphetamine (AM) treatment has been shown to alter behavioral recovery after ischemia caused by embolism, permanent unilateral occlusion of the common carotid and middle cerebral arteries, or unilateral sensorimotor cortex ablation in rats. "( Post-treatment with amphetamine enhances reinnervation of the ipsilateral side cortex in stroke rats.
Castillo, P; Harvey, BK; Liu, HS; Lu, H; Shen, H; Wang, Y; Yang, Y, 2011
)
2.14
"Amphetamine treatment in acute stroke may be warranted due to reduced detrimental effects of hypotension and improved brain plasticity."( Acute but not delayed amphetamine treatment improves behavioral outcome in a rat embolic stroke model.
Johansen, FF; Kristiansen, U; Overgaard, K; Rasmussen, RS, 2011
)
1.41
"Amphetamine treatment during adolescence causes long-term cognitive deficits in rats. "( Periadolescent amphetamine treatment causes transient cognitive disruptions and long-term changes in hippocampal LTP depending on the endogenous expression of pleiotrophin.
Del Olmo, N; Fole, A; Gramage, E; Herradón, G; Martín, YB, 2013
)
2.19
"An amphetamine treatment regimen that produced behavioral sensitization increased the density of dendritic spines on MSNs in both the NAcc and dorsolateral CPu."( The location of persistent amphetamine-induced changes in the density of dendritic spines on medium spiny neurons in the nucleus accumbens and caudate-putamen.
Kolb, B; Li, Y; Robinson, TE, 2003
)
1.13
"Amphetamine-treated animals show similar deficits in analogous tasks, thereby providing a model of the stimulus-selection deficits observed in schizophrenia."( The effect of amphetamine on Kamin blocking and overshadowing.
Joseph, MH; Moran, PM; O'Tuathaigh, CM; Pickering, AD; Salum, C; Young, AM, 2003
)
1.4
"Amphetamine treatment increased the expression of NGFI-B mRNA in the mPFC, CC, striatum and NAcc in both control and lesioned animals of both ages."( Neonatal ventral hippocampus lesion leads to reductions in nerve growth factor inducible-B mRNA in the prefrontal cortex and increased amphetamine response in the nucleus accumbens and dorsal striatum.
Beaudry, G; Bhardwaj, SK; Levesque, D; Quirion, R; Srivastava, LK, 2003
)
1.24
"Amphetamine treatment augmented both social and sexual preferences."( Amphetamine modulation of paced mating behavior.
Clark, AS; Guarraci, FA, 2003
)
2.48
"Amphetamine-pretreated animals demonstrated a transient increase in errors on nonsignal trials following escalating amphetamine administration. "( Transient disruption of attentional performance following escalating amphetamine administration in rats.
Burk, JA; Kondrad, RL, 2004
)
2
"In amphetamine-pretreated cells, amphetamine elicited a greater increase in intracellular Ca2+; this increase depended upon the presence of extracellular Ca2+ and N- and L-type Ca2+ channel activity."( Repeated amphetamine couples norepinephrine transporter and calcium channel activities in PC12 cells.
Gnegy, ME; Guptaroy, B; Kantor, L; Park, YH; Zhang, M, 2004
)
1.25
"Amphetamine treatment caused a marked disruption of PPI in Galpha(z) knockouts (average PPI 22+/-2%), but less so in controls (average PPI 42+/-3%)."( Enhanced effect of dopaminergic stimulation on prepulse inhibition in mice deficient in the alpha subunit of G(z).
Brosda, J; Hendry, I; Leck, KJ; Martin, S; Matthaei, KI; van den Buuse, M, 2005
)
1.05
"Amphetamine treatment may also occlude some cognitive advantages normally associated with living in a complex environment."( Enhancement of auditory fear conditioning after housing in a complex environment is attenuated by prior treatment with amphetamine.
Briand, LA; Maren, S; Robinson, TE,
)
1.06
"Both amphetamine-treated groups showed significantly more selective conditioned responding than saline controls."( Post-training amphetamine administration enhances memory consolidation in appetitive Pavlovian conditioning: Implications for drug addiction.
Setlow, B; Simon, NW, 2006
)
1.15
"Amphetamine-pretreated Ca(v)1.3 wild-type (Ca(v)1.3(+/+)) mice exhibited sensitized behavior and a significant increase in D(2)L and D(2)S mRNA compared with saline-pretreated mice Amphetamine-pretreated homozygous Ca(v)1.3 knockout (Ca(v)1.3(-/-)) mice did not exhibit sensitized behavior."( Up-regulation of dopamine D(2)L mRNA levels in the ventral tegmental area and dorsal striatum of amphetamine-sensitized C57BL/6 mice: role of Ca(v)1.3 L-type Ca(2+) channels.
Giordano, TP; Kosofsky, BE; Rajadhyaksha, AM; Satpute, SS; Striessnig, J, 2006
)
1.27
"Amphetamine pretreatment produced psychomotor sensitization and also accelerated the subsequent escalation of cocaine intake."( Amphetamine pretreatment accelerates the subsequent escalation of cocaine self-administration behavior.
Ferrario, CR; Robinson, TE, 2007
)
2.5
"Amphetamine treatment reduced locomotor activity in coloboma mice, but induced a robust increase in dopamine overflow suggesting that abnormal regulation of dopamine efflux does not account for the behavioral effect."( D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD.
Fan, X; Hess, EJ, 2007
)
1.31
"In amphetamine-pretreated animals, valproate administration reversed citrate synthase activity inhibition induced by amphetamine."( Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania.
Amboni, G; Assis, LC; Corrêa, C; Kapczinski, F; Martins, MR; Quevedo, J; Streck, EL, 2007
)
0.85
"Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups."( Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats.
Choy, KH; van den Buuse, M, 2008
)
1.07
"Amphetamine pre-treatment as well as the conditioning procedure itself potentiated an increase in dopamine levels during formation, but not expression of a conditioned fear response."( Effects of withdrawal from an escalating dose of amphetamine on conditioned fear and dopamine response in the medial prefrontal cortex.
Feldon, J; Peleg-Raibstein, D, 2008
)
1.32
"Amphetamine- pre-treated mice, drug-challenged in the environment in which they received drug treatments (Paired), as well as repeatedly stressed mice expressed robust sensitization to the locomotor effects of amphetamine."( DeltaFosB accumulation in ventro-medial caudate underlies the induction but not the expression of behavioral sensitization by both repeated amphetamine and stress.
Bonito-Oliva, A; Cabib, S; Colelli, V; Conversi, D; Orsini, C, 2008
)
1.27
"Amphetamine-treated rats developed tolerance to these ingestive effects and to weight loss, whereas nicotine-injected rats did not."( Nicotine and amphetamine: differential tolerance and no cross-tolerance for ingestive effects.
Baettig, K; Classen, W; Martin, JR, 1980
)
1.35
"Amphetamine treatment was associated with the induction of mRNAs for HSP 27, HSP 70, and HSP 89 in all the vital organs, including heart, lung, liver, kidney, and brain."( Drug-induced heat-shock preconditioning improves postischemic ventricular recovery after cardiopulmonary bypass.
Das, DK; Deaton, DW; Engelman, RM; Flack, JE; Liu, X; Maulik, N; Rousou, JA; Wei, Z, 1995
)
1.01
"Amphetamine treatments induced Fos immunoreactivity in the substantia nigra in non-dopamine neurons."( Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons.
Bloch, B; Cador, M; Dumartin, B; Jaber, M; Normand, E; Stinus, L, 1995
)
1.35
"Amphetamine-treated rats exhibited robust behavioral sensitization at both time points as compared to saline-treated rats."( Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization.
Brooderson, RJ; Khansa, MR; Nassar, R; White, FJ; Wolf, ME, 1993
)
1.23
"The amphetamine-treated rat is a useful preparation for investigating this notion in an unconstrained animal whose behavior is still not as complex and variable as that of the normal animal."( Coordination of side-to-side head movements and walking in amphetamine-treated rats: a stereotyped motor pattern as a stable equilibrium in a dynamical system.
Benjamini, Y; Golani, I; Kafkafi, N; Levi-Havusha, S, 1996
)
1.02
"Both amphetamine treated groups exhibited increased locomotion in response to saline injection."( Context-dependent cross-sensitization between cocaine and amphetamine.
Bonate, PL; Silverman, PB; Swann, A, 1997
)
1
"In amphetamine-treated rats, the baseline extracellular dopamine concentration, preceding the morning treatment, increased from 0.43 +/- 0.01 on day 1 up to 0.59 +/- 0.02 pmol/40 microliters sample on day 3 of treatment."( Reduction of dopamine release and synthesis by repeated amphetamine treatment: role in behavioral sensitization.
Carta, G; Casu, MA; Gessa, GL; Imperato, A; Mascia, MS; Obinu, MC, 1996
)
1.05
"Amphetamine-treated animals displayed no significant improvement in beam-walking ability either during or after drug intoxication (from days 3 to 5 after brain injury)."( Lack of delayed effects of amphetamine, methoxamine, and prazosin (adrenergic drugs) on behavioral outcome after lateral fluid percussion brain injury in the rat.
Dhillon, HS; Dose, JM; Kraemer, PJ; Maki, A; Prasad, RM, 1997
)
1.32
"amphetamine-pretreated animals."( Enduring enhancement of amphetamine sensitization by drug-associated environmental stimuli.
Badiani, A; Camp, DM; Robinson, TE, 1997
)
1.33
"In amphetamine-pretreated rats tested 2 days after the last injection, both the decrease during SKF-82958 perfusion and the delayed increase in glutamate efflux were attenuated."( Amphetamine and D1 dopamine receptor agonists produce biphasic effects on glutamate efflux in rat ventral tegmental area: modification by repeated amphetamine administration.
Wolf, ME; Xue, CJ, 1998
)
2.26
"Amphetamine treatment caused an acute rise in core body temperature to 40 degrees C for at least 1 hr and increased hsp25 and hsp70i levels, as measured by Western blotting, at 6, 24, 48, and 72 hr with no apparent induction of other hsps (hsp60, hsc70, or hsp90)."( Protection against hepatotoxicity by a single dose of amphetamine: the potential role of heat shock protein induction.
Roberts, SM; Salminen, WF; Voellmy, R, 1997
)
1.27
"Amphetamine pretreatment caused an increase in the electrically evoked release of [(3)H]dopamine from nucleus accumbens, caudate putamen, and medial prefrontal cortex slices and of [(14)C]acetylcholine from accumbens and caudate slices."( A single exposure to amphetamine is sufficient to induce long-term behavioral, neuroendocrine, and neurochemical sensitization in rats.
De Vries, TJ; Schmidt, ED; Schoffelmeer, AN; Tilders, FJ; Van Moorsel, CA; Vanderschuren, LJ, 1999
)
1.34
"In amphetamine-treated rats, a higher proportion of cortical cells fired in bursts, and a larger proportion of accumbens and prefrontal cortical neurons exhibited bistable membrane oscillations."( Amphetamine withdrawal alters bistable states and cellular coupling in rat prefrontal cortex and nucleus accumbens neurons recorded in vivo.
Grace, AA; Onn, SP, 2000
)
2.26
"Amphetamine treatment produced in Wistar rats a substantial decrease in basal adenylyl cyclase activity."( Different activity of adenylyl cyclase in prefrontal cortex in three rat strains. The effect of amphetamine.
Hynie, S; Klenerová, V; Sída, P, 1998
)
1.24
"Amphetamine pretreatment produced long-term reductions in both striatal PKA activity and DA content."( Long-term effects of postnatal amphetamine treatment on striatal protein kinase A activity, dopamine D(1)-like and D(2)-like binding sites, and dopamine content.
Crawford, CA; Karper, PE; McDougall, SA; Zavala, AR,
)
1.14
"The amphetamine treatment produced a significantly higher mean number of avoidances in this procedure compared to saline-treated animals during trials 1-20."( Avoidance responding following amphetamine-induced dopamine depletion.
Coyne, T; Halladay, AK; Seto, J; Sharifi, J; Wagner, GC, 2000
)
1.07
"When amphetamine-treated rats were pretreated with U69593, a kappa agonist (0.16 or 0.32 mg/kg s.c.), there was a significant decrease in behavioral activity."( Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum.
McGinty, JF; Tzaferis, JA, 2001
)
1.03
"Amphetamine-treated patients did not show any increase in motor function or ADL as compared to the control group."( A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke.
Lökk, J; Nilsson, CG; Nordström, M; Sonde, L; Viitanen, M, 2001
)
1.28
"When amphetamine-treated rats were pretreated with LY306740 (35 and 20 nmoles per side, intrastriatally), there was a significant decrease in amphetamine-induced behavioral activity."( NK-1 receptor blockade decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum.
Gonzalez-Nicolini, V; McGinty, JF, 2002
)
1.05
"Amphetamine treatment at 4 mg/kg abolished the response to novel objects while lower doses (1.5 and 2 mg/kg) did not affect it."( The playground maze: a new method for measuring directed exploration in the rat.
Mellanby, J; Nicholls, B; Springham, A, 1992
)
1
"Amphetamine treatment enhanced lever-pressing for 1-2 h."( Effects of acute and chronic fenfluramine on self-stimulation and its facilitation by amphetamine.
Olds, ME; Yuwiler, A, 1992
)
1.23
"Amphetamine-treated rats fail to gate; in this respect, they resemble schizophrenic humans."( Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating.
Fuller, LL; Rose, GM; Stevens, KE, 1991
)
1.26
"All amphetamine treatments diminished the potassium-stimulated (50 mM) release of preloaded labelled dopamine from superfused striatal and frontal cortical slices in vitro."( Animal models of amphetamine psychosis: neurotransmitter release from rat brain slices.
Lillrank, SM; Oja, SS; Saransaari, P; Seppälä, T, 1991
)
1.1
"In amphetamine-treated rats, hsc70 mRNA relative levels increased at body temperatures greater than 39 degrees C, whereas hsp70 mRNA synthesis was induced at temperatures greater than 40 degrees C."( Expression of heat shock protein 70 and heat shock cognate 70 messenger RNAs in rat cortex and cerebellum after heat shock or amphetamine treatment.
Miller, EK; Morrison-Bogorad, M; Raese, JD, 1991
)
1
"Amphetamine and L-dopa pretreatment attenuated the increases in apomorphine-induced stereotypy and aggression in REMSD rats, but ECS selectively reduced apomorphine-induced aggression."( Reversal of the increase in apomorphine-induced stereotypy and aggression in REM sleep deprived rats by dopamine agonist pretreatments.
Braz, S; Ferreira, TM; Silveira Filho, NG; Troncone, LR; Tufik, S, 1988
)
1
"Amphetamine-treated rats incorporated environmentally contingent bodily postures into their forms of stereotyped behavior."( Initial environment influences amphetamine-induced stereotypy: subsequently environment change has little effect.
Beck, CH; Chow, HL; Cooper, SJ, 1986
)
1.28
"Treatment with amphetamine 0.5 mg/kg did not have effect in sham and CLP groups; D-amphetamine 1 mg/kg increased locomotor and exploratory activities only in sham group, and D-amphetamine 2 mg/kg increased in both sham and CLP groups."( Effects of acute treatment with amphetamine in locomotor activity in sepsis survivor rats.
Barichello, T; Comim, CM; Constantino, LS; Dal-Pizzol, F; de Souza, B; Petronilho, F; Quevedo, J, 2009
)
0.98
"Treatment with amphetamine was associated with non-significant trends to increased death (OR 2.78 (95% CI, 0.75-10.23), n=329, 11 trials) and improved motor scores (WMD 3.28 (95% CI -0.48-7.04) n=257, 9 trials) but had no effect on the combined outcome of death and dependency (OR 1.15 (95% CI 0.65-2.06, n=206, 5 trials)."( Speeding stroke recovery? A systematic review of amphetamine after stroke.
Bath, PM; Sprigg, N, 2009
)
0.95
"Treatment with amphetamine caused significant disruption of prepulse inhibition in SHR and WKY rats, but not SD rats."( Prepulse inhibition of acoustic startle in spontaneously hypertensive rats.
van den Buuse, M, 2004
)
0.66
"Treatment with amphetamine, apomorphine and MK-801 also significantly reduced PPI, however, there was no difference between the strains."( Prepulse inhibition in fawn-hooded rats: increased sensitivity to 5-HT1A receptor stimulation.
Lawrence, AJ; Martin, S; van den Buuse, M, 2004
)
0.66
"Treatment with amphetamine resulted in a significant increase of lung virus titers and pulmonary vascular permeability."( Effects of amphetamine on influenza virus infection in mice.
Couceiro, J; Fernández-Rial, JC; Freire-Garabal, M; Gómez-Fernández, DE; Núñez, MJ; Rey-Méndez, M; Suárez, JA, 1993
)
1.02
"Pretreatment with amphetamine had variable effects on the paw-reaching task which persisted in subsequent drug-free trials, suggesting that a conditioning mechanism may be involved."( Dopamine-rich grafts in the neostriatum and/or nucleus accumbens: effects on drug-induced behaviours and skilled paw-reaching.
Abrous, DN; Dunnett, SB; Shaltot, AR; Torres, EM, 1993
)
0.61
"Treatment with amphetamine (AMPH) and diazepam has been reported to decrease macrophage activity."( Effects of treatment with amphetamine and diazepam on Mycobacterium bovis-induced infection in hamsters.
Domingues-Junior, M; Guerra, JL; Palermo-Neto, J; Pinheiro, SR, 2000
)
0.95
"Pretreatment with amphetamine did not result in a significant augmentation of the amphetamine-induced increase in DA efflux in the NAC."( Repeated pretreatment with amphetamine sensitizes increases in cortical acetylcholine release.
Bruno, JP; Nelson, CL; Sarter, M, 2000
)
0.93
"Pretreatment with amphetamine sensitizes the ability of amphetamine to stimulate cortical ACh efflux. "( Repeated pretreatment with amphetamine sensitizes increases in cortical acetylcholine release.
Bruno, JP; Nelson, CL; Sarter, M, 2000
)
0.94
"Treatment with amphetamine induced decrease of GAP-43 mRNA expression, that was detected also during recovery period, up to 14 days after the last day of 7 days treatments."( Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein GAP-43.
Kanazir, S; Rakic, L; Ruzdijic, S; Veskov, R; Vukosavic, S, 2001
)
0.96
"Pretreatment with amphetamine (2.5 or 3.0 mg/kg) for 4-6 days did not alter baseline DA or its metabolites in caudate or accumbens 48 h or 6 days after the last injection."( In vivo microdialysis reveals a diminished amphetamine-induced DA response corresponding to behavioral sensitization produced by repeated amphetamine pretreatment.
Kuczenski, R; Segal, DS, 1992
)
0.87
"Rats treated with d-amphetamine showed an enhanced ability to switch to cue-directed behaviours in comparison with rats treated with AD."( The involvement of the nucleus accumbens in the ability of rats to switch to cue-directed behaviours.
Cools, AR; van den Bos, R, 1989
)
0.59
"Pretreatment with amphetamine did not alter the mean spontaneous firing rate of these cells, but in some instances it appeared to produce periods of irregular bursting."( Serotonergic dorsal raphe neurons: subsensitivity to amphetamine with long-term treatment.
Basse-Tomusk, AE; Heidenreich, BA; Rebec, GV, 1987
)
0.85
"Treatment with amphetamine both prevented and antagonized the bretylium-induced adrenergic neurone blockade and most of the accompanying changes in the subcellular distribution of noradrenaline.4."( The effects of bretylium on the subcellular distribution of noradrenaline and on adrenergic nerve function in rat heart.
Abbs, ET; Pycock, CJ, 1973
)
0.59

Toxicity

We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System. The amphetamine-induced toxic effects were less prominent in CD-1 mice, which have much higher levels of Cu/Zn SOD activity.

ExcerptReferenceRelevance
" In male albino mice, determination of 6 hr LD50's indicated PMA to be most toxic although 24 hr LD50's showed nearly equal toxicity."( Comparison of cardiovascular, hyperthermic, and toxic effects of para-methoxyamphetamine (PMA) and 3, 4-methylenedioxyamphetamine (MDA).
Ilhan, M; Long, JP; Nichols, DE, 1975
)
0.48
" LD50 values of three of these compounds were assessed after intraperitoneal administration with a special emphasis on interactions with drugs increasing catecholaminergic neurotransmission."( Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Männistö, PT; Törnwall, M, 1991
)
0.28
" Initially, considerable information will have to be gathered from various laboratories to form the background data on which decisions of toxic effects can be made."( Correlation between behavioral and pathological changes in the evaluation of neurotoxicity.
Beyrouty, P; Broxup, B; Losos, G; Robinson, K, 1989
)
0.28
" Toxic medical effects of amphetamine-related compounds seen in our patients are discussed."( Amphetamine toxicity: experience with 127 cases.
Derlet, RW; Horowitz, BZ; Lord, RV; Rice, P,
)
1.87
"In summary, we have shown that MA is toxic to both 5-HT and DA cells and we have proposed a mechanism that would account for this response, namely, the conversion of the transmitters to neurotoxins."( Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections.
Axt, K; Commins, DL; Marek, G; Seiden, LS; Vosmer, G, 1988
)
0.27
"Neuroleptic primed Cebus apella monkeys have proven reliable in screening antipsychotics for extrapyramidal side effect (EPS) potential in humans, and the ratio EPS liability/antiamphetamine efficacy ["therapeutic index" (TI)] has fit well with clinical results."( New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.
Gerlach, J; Peacock, L, 1999
)
0.72
" All drugs were given SC, in increasing doses until two animals had dystonia/other adverse effects (AE), and in decreasing doses with a fixed dose of dextroamphetamine producing motor unrest and stereotypies, to find the minimum significant antiamphetamine dose (AA)."( New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.
Gerlach, J; Peacock, L, 1999
)
0.72
" DOD 647 up to 2 mg/kg had no adverse effects."( New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.
Gerlach, J; Peacock, L, 1999
)
0.53
" The amphetamine-induced toxic effects were less prominent in CD-1 mice, which have much higher levels of Cu/Zn SOD activity (0."( Amphetamine-induced toxicity in dopamine terminals in CD-1 and C57BL/6J mice: complex roles for oxygen-based species and temperature regulation.
Cadet, JL; Huestis, MA; Jayanthi, S; Krasnova, IN; Ladenheim, B; Moran, TH; Oyler, J, 2001
)
2.27
" Amphetamine was more toxic to isolated mice subjected to foot-shock than to isolated mice housed under normal conditions."( Hyperpyrexia as a contributory factor in the toxicity of amphetamine to aggregated mice.
ASKEW, BM, 1962
)
1.4
"Neurotoxicity may be defined as any adverse effect on the structure or function of the central and/or peripheral nervous system by a biological, chemical, or physical agent."( Biomarkers of adult and developmental neurotoxicity.
Bowyer, JF; Slikker, W, 2005
)
0.33
" These results indicate anti-METH mAb6H4 can safely reduce the hemodynamic and locomotor effects of METH given one day after anti-METH IgG, and that the mAb is safe when administered in the absence of METH."( Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
Berg, RJ; Gentry, WB; Laurenzana, EM; Owens, SM; Terlea, T; West, JR; Williams, DK, 2006
)
0.6
" Adverse events and vital signs were assessed."( Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
Adler, LA; Michelson, D; Moore, RJ; Spencer, TJ; Williams, DW, 2008
)
0.35
" Adverse events consisted primarily of pharmacologically (noradrenergic) expected effects."( Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
Adler, LA; Michelson, D; Moore, RJ; Spencer, TJ; Williams, DW, 2008
)
0.35
" Because the pharmacokinetics of amphetamines differ between children and adults, reevaluation of the potential for adverse effects of chronic treatment of adults is essential."( Potential adverse effects of amphetamine treatment on brain and behavior: a review.
Berman, SM; Kuczenski, R; London, ED; McCracken, JT, 2009
)
0.93
"Safety concerns about central nervous system stimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) include adverse cardiac effects."( Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
Gerhard, T; Saidi, A; Shuster, J; Winterstein, AG, 2009
)
0.62
" They are generally safe in special populations."( Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
Kuchibhatla, A; Merkel, RL, 2009
)
0.35
"Safety assessments included adverse events (AEs), vital signs, physical examination, clinical laboratory tests, the Pediatric Daytime Sleepiness Scale, and the Pittsburgh Side Effects Rating Scale."( Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Ginsberg, LD; Greenbaum, M; Murphy, WR; Spencer, TJ, 2009
)
0.35
"Coadministration of GXR and MPH or AMP was generally safe and associated with statistically significant and clinically meaningful ADHD symptom improvement in children and adolescents."( Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Ginsberg, LD; Greenbaum, M; Murphy, WR; Spencer, TJ, 2009
)
0.35
"2,4-Dichlorophenoxyacetic acid (2,4-D), a worldwide-used herbicide, has been shown to produce a wide range of adverse effects in the health--from embryotoxicity and teratogenicity to neurotoxicity--of animals and humans."( Adverse effects of 2,4-dichlorophenoxyacetic acid on rat cerebellar granule cell cultures were attenuated by amphetamine.
Bongiovanni, B; Brusco, A; Duffard, R; Evangelista de Duffard, AM; Ferri, A; Lopez, LM; Rassetto, M, 2011
)
0.58
" In addition, the side-effect profile was established by measuring catalepsy, antipsychotic-induced weight gain, plasma levels of prolactin, and anxiogenic potential."( AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
Arad, M; Barak, S; Black, MD; Borowsky, B; Cohen, C; De Levie, A; Featherstone, RE; Giardino, O; Griebel, G; Pichat, P; Rogacki, N; Senyah, Y; Stemmelin, J; Stevens, RJ; Varty, GB; Weiner, I, 2011
)
0.37
" In addition, an improved side-effect profile was seen, with potential to ameliorate the EPS and weight gain issues with currently available treatments."( AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
Arad, M; Barak, S; Black, MD; Borowsky, B; Cohen, C; De Levie, A; Featherstone, RE; Giardino, O; Griebel, G; Pichat, P; Rogacki, N; Senyah, Y; Stemmelin, J; Stevens, RJ; Varty, GB; Weiner, I, 2011
)
0.37
" Results of studies to evaluate the effect of Mn and DA on cell viability in control and DAT-transfected HEK cells reveal that Mn is equally toxic to both cell lines whereas DA was only toxic to cells containing DAT."( The effect of manganese on dopamine toxicity and dopamine transporter (DAT) in control and DAT transfected HEK cells.
Khoshbouei, H; Li, Z; Roth, JA; Sridhar, S, 2013
)
0.39
" Mice treated with PGW5 (25 and 50mg/kg/d) for 28 days did not show toxic effects in terms of weight gain and blood-chemistry analysis."( A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.
Bidder, M; Gil-Ad, I; Kramer, M; Portnoy, M; Taler, M; Tarasenko, I; Weizman, A, 2014
)
0.4
"PGW5 is a novel and safe antipsychotic, efficacious against schizophrenia-like positive and negative symptoms at nonsedative doses."( A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.
Bidder, M; Gil-Ad, I; Kramer, M; Portnoy, M; Taler, M; Tarasenko, I; Weizman, A, 2014
)
0.4
" Safety assessments included physical examination, chemistry, hematology, vital signs, and treatment-emergent adverse events (TEAEs)."( The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
Brams, M; Childress, AC; Cutler, AJ; Kollins, SH; Northcutt, J; Padilla, A; Turnbow, JM, 2015
)
0.68
"Administration of amphetamine and methamphetamine can elicit psychiatric adverse effects at acute administration, binge use, withdrawal, and chronic use."( Neuropsychiatric Adverse Effects of Amphetamine and Methamphetamine.
Harro, J, 2015
)
1.03
"8% of subjects experienced any transient adverse effects."( Safety of Oral Amphetamine Administered during Positron Emission Tomography Scans in Medically Screened Humans.
Frankle, WG; Narendran, R; Paris, A; Weidner, LD, 2015
)
0.77
" Abuse potential and amphetamine-like adverse effects are causes for concern."( Safety and efficacy of fenproporex for obesity treatment: a systematic review.
de Oliveira, AC; Paumgartten, FJ; Pereira, SS, 2016
)
0.75
"Patient-reported outcomes associated with adverse events (AEs) reported with generics have not been evaluated."( Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study.
Iyer, G; Marimuthu, SP; Segal, JB; Singh, S, 2017
)
0.68
"We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System after reviewing 1237 case reports in the US FDA's Adverse Event Reporting System (FAERS; 2011-2013)."( Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study.
Iyer, G; Marimuthu, SP; Segal, JB; Singh, S, 2017
)
0.91
" Safety and tolerability assessments were treatment-emergent adverse events, vital sign and weight changes, Columbia-Suicide Severity Rating Scale responses, and electrocardiogram results."( Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
Arnold, V; Greenbaum, M; Jaffee, M; Robertson, B; Weisler, RH; Yan, B; Yu, M, 2017
)
0.73
" Treatment-emergent adverse events reported (>5%) with SHP465 MAS were decreased appetite, dry mouth, insomnia, headache, anxiety, initial insomnia, irritability, and bruxism."( Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
Arnold, V; Greenbaum, M; Jaffee, M; Robertson, B; Weisler, RH; Yan, B; Yu, M, 2017
)
0.73
" Safety was assessed measuring adverse events (AEs) and vital signs."( Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.
Belden, HW; Berry, SA; Brams, MN; Childress, AC; Pincus, Y; Turnbow, JM; Wigal, SB, 2018
)
0.79
") of amfetamine or methamfetamine after naltrexone treatment, adverse events and physiological changes (e."( Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials.
Anand, S; Chan, EW; Lam, L; Li, X; Tse, ML; Zhao, JX, 2019
)
0.51
" Both amfetamine and methamfetamine studies showed good tolerability of naltrexone, with few adverse events seen."( Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials.
Anand, S; Chan, EW; Lam, L; Li, X; Tse, ML; Zhao, JX, 2019
)
0.51
" Safety assessments included vital signs and adverse events (AEs)."( Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.
Childress, AC; Herman, BK; Kando, JC; King, TR; Pardo, A, 2019
)
0.77
" These may also be triggered by drugs and appear as adverse drug reactions (ADRs)."( Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Carnovale, C; Clementi, E; Gentili, M; Mazhar, F; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S,
)
0.13
"We mined data from the US Food and Drug Administration Adverse Event Reporting System pharmacovigilance database, focused on methylphenidate, atomoxetine, amphetamine, lisdexamfetamine, and their derivatives."( Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Carnovale, C; Clementi, E; Gentili, M; Mazhar, F; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S,
)
0.33
"We conclude that real-world data from the US Food and Drug Administration Adverse Event Reporting System are consistent with previous evidence from meta-analyses."( Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Carnovale, C; Clementi, E; Gentili, M; Mazhar, F; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S,
)
0.13
" In conclusion, the current study revealed that the S-100β serum level could be used as an outcome predictor in hospital admission cases due to toxic amphetamine exposure and offers an idea about the cardiac and neuronal involvement."( Potential Role of Serum S-100β Protein as a Predictor of Cardiotoxicity and Clinical Poor Outcome in Acute Amphetamine Intoxication.
Al-Asmari, AZ; Elsheikh, E; Gameel, DE; Sharif, AF, 2021
)
1.03
"Methamphetamine (METH) is an amphetamine-type stimulant that is highly toxic to the central nervous system (CNS)."( The Role of Non-coding RNAs in Methamphetamine-Induced Neurotoxicity.
Chen, Q; Chen, X; Huang, Y; Li, L; Qiao, D; Xu, L, 2023
)
1.75
" The present work provides a comprehensive review on neurotoxic mechanisms of synthetic cathinones highlighting intoxication cases and fatalities in humans, as well as the toxic effects on animals (in particular rats, mice and zebrafish larvae)."( Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review.
Bambagiotti, G; Daziani, G; Giorgetti, R; Goteri, G; Lo Faro, AF; Montana, A; Montana, V; Montanari, E; Pesaresi, M, 2023
)
0.91

Pharmacokinetics

The results suggest that the potentiation of the action of amphetamine by mianserin is mainly due to pharmacodynamic synergism and depends on the blockade of central serotonergic receptors. serum half-life and unchanged methamphetamine urine clearance were unaffected by any radiation dose. maximum methamphetamine concentrations and methamphetamine and amphetamine metabolite were not affected.

ExcerptReferenceRelevance
" The results suggest that the potentiation of the action of amphetamine by mianserin is mainly due to pharmacodynamic synergism and depends on the blockade of central serotonergic receptors by mianserin."( Pharmacokinetic interaction of psychotropic drugs. I. Divergent effect of mianserin on pharmacokinetics and pharmacodynamics of amphetamine.
Cenajek, D; Chodera, A; Godlewski, J,
)
0.58
"0 mg/kg) and pharmacodynamic interactions of insecticide were studied with centrally acting drugs viz."( Pharmacodynamic interactions of cypermethrin and centrally acting drugs in mice.
Kanwar, RS; Varshneya, C, 1995
)
0.29
"1 and 1 mg/kg) with a half-life of washout of 55 min."( High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain.
Ansari, MS; Clanton, JA; de Paulis, T; Ebert, MH; Holdeman, KP; Kessler, RM; Manning, RG; Pfeffer, R; Schmidt, DE; Votaw, JR, 1993
)
0.29
" This study aimed at examining whether the plasma pharmacokinetic parameters of cabergoline and selegiline are modified when given in combination."( Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D, 1995
)
0.29
" As plasma levels of selegiline are very low and the elimination half-life is very short being about 9 minutes, therefore, a very sensitive and selective method for determining the 3 main metabolites desmethylselegiline (DMS), methamphetamine (MA) and amphetamine (A) was developed."( Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Kikuta, C; Ludwig, G; Mascher, HJ; Millendorfer, A; Schiel, H, 1997
)
0.7
" The pharmacokinetic profiles of selegiline and the metabolites were examined from serum samples for 24 hours (i."( Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Anttila, M; Heinonen, E; Huupponen, R; Laine, K; Mäki-Ikola, O,
)
0.13
" One potentially critical issue relates to pharmacokinetic differences between the species."( Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse.
Cho, AK; Kuczenski, R; Melega, WP; Segal, DS, 2001
)
0.55
"Our studies examined pharmacokinetic mechanisms involved in high-affinity (K(d) approximately 11 nM) monoclonal antibody-based antagonism of (+)-methamphetamine-induced locomotor effects."( Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats.
Abraham, P; Byrnes-Blake, KA; Carroll, FI; Gentry, WB; Landes, RD; Laurenzana, EM; Owens, SM, 2003
)
0.75
" From a clinical pharmacokinetic perspective, amfetamine-type stimulants are rather homogeneous."( Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.
de la Torre, R; Farré, M; Navarro, M; Pacifici, R; Pichini, S; Zuccaro, P, 2004
)
0.32
" The period of escalating doses (EDs) is likely associated with development of tolerance to aspects of METH's pharmacologic and toxic effects but the relative contributions of pharmacokinetic and pharmacodynamic factors have not been well defined."( Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge.
Cho, AK; Kuczenski, R; Lacan, G; Melega, WP; O'Neil, ML; Segal, DS, 2006
)
0.54
" Pharmacokinetic calculations based on these measured values were used to estimate initial METH body burdens, the median value being 52 mg."( Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling.
Cho, AK; Harvey, D; Laćan, G; Melega, WP, 2007
)
0.9
" The main pharmacokinetic parameters (C(max), t(max), t1/2beta, AUC(0-6), AUC(0-infinity)) have been calculated."( Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
Lengyel, J; Magyar, K; Szatmáry, I; Szebeni, G, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Blood samples were collected predose and 0 to 96 hours postdose for pharmacokinetic analysis."( Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
Buckwalter, M; Ermer, JC; Haffey, MB; Homolka, R; Lasseter, KC; Martin, P; Zhang, P, 2009
)
0.56
" h/mL, for Cmax and AUCinf, respectively."( Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
Buckwalter, M; Ermer, JC; Haffey, MB; Homolka, R; Lasseter, KC; Martin, P; Zhang, P, 2009
)
0.56
" However, approximately 50% of subjects receiving MAS XR showed an earlier Tmax while on omeprazole, indicating unpredictable release of active drug by the second bead of MAS XR, most likely related to reduced stomach acid while on a PPI compromising the pulsed delivery of MAS XR."( Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
Buckwalter, M; Ermer, JC; Haffey, MB; Homolka, R; Lasseter, KC; Martin, P; Zhang, P, 2009
)
0.56
" A new formulation, an orally disintegrating tablet (ODT), has recently been introduced to overcome these pharmacokinetic problems by avoiding its presystemic metabolism."( The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Magyar, K; Szökő, E; Tábi, T; Vécsei, L, 2013
)
0.39
"The authors summarize the pharmacokinetic and clinical efficacy data of selegiline ODT and compare them with the more conventional oral selegiline."( The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Magyar, K; Szökő, E; Tábi, T; Vécsei, L, 2013
)
0.39
"Selegiline ODT shows a clear pharmacokinetic advantage over the conventional form."( The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Magyar, K; Szökő, E; Tábi, T; Vécsei, L, 2013
)
0.39
"In this pharmacokinetic (PK) study in healthy adults, we sought to: (1) compare the PK properties of a novel amphetamine extended-release orally disintegrating tablet formulation (Adzenys XR-ODT™ [AMP XR-ODT]) to a reference extended-release mixed amphetamine salts (MAS ER) formulation and (2) assess the effect of food on AMP XR-ODT."( A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults.
Engelking, D; McMahen, R; Sikes, C; Stark, JG, 2016
)
0.88
" Maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), elimination half-life (T1/2), area under the concentration-time curve from time zero to last quantifiable concentration (AUClast), from time zero to infinity (AUCinf), relevant partial AUCs, and weight-normalized clearance (CL/F/kg) were assessed."( A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults.
Engelking, D; McMahen, R; Sikes, C; Stark, JG, 2016
)
0.67
" When AMP XR-ODT was administered with food, there was a slight decrease in the d-and l-amphetamine Cmax and approximately a 2-hour delay in Tmax."( A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults.
Engelking, D; McMahen, R; Sikes, C; Stark, JG, 2016
)
0.89
" The pharmacokinetic profiles of d- and l-AMP were comparable across treatment groups."( A Randomized Phase I Study to Assess the Effect of Alcohol on the Pharmacokinetics of an Extended-release Orally Disintegrating Tablet Formulation of Amphetamine in Healthy Adults.
Adcock, S; McMahen, R; Newcorn, JH; Sikes, C; Stark, JG, 2017
)
0.65
"Varying concentrations of alcohol (4%-40%) did not significantly alter the pharmacokinetic profile of AMP XR-ODT."( A Randomized Phase I Study to Assess the Effect of Alcohol on the Pharmacokinetics of an Extended-release Orally Disintegrating Tablet Formulation of Amphetamine in Healthy Adults.
Adcock, S; McMahen, R; Newcorn, JH; Sikes, C; Stark, JG, 2017
)
0.65
" We anticipate that DISSECTIV will be used to expose unidentified active chemical species and resolve pharmacodynamic interactions within other chemically complex systems, such as those found in counterfeit or illegal drug preparations, post-metabolic tissue samples and natural product extracts."( Vaccine-driven pharmacodynamic dissection and mitigation of fenethylline psychoactivity.
Janda, KD; Wenthur, CJ; Zhou, B, 2017
)
0.46
" Oral fluid (OF) has been successfully used as an alternative matrix for blood testing in several pharmacokinetic studies."( Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
Chen, L; Duan, G; Shen, B; Shi, Y; Wang, S; Xiang, P; Yan, H; Yu, Y, 2019
)
0.78
" d- and l-amphetamine were measured and pharmacokinetic (PK) was calculated (90% confidence intervals of the ratios of the plasma levels) for AUC0-t, AUC0-∞, and Cmax."( Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension.
Herman, BK; Kando, JC; King, TR; Pardo, A; Rafla, E, 2020
)
1.24
" Oral fluid and blood samples were collected for up to 72 h and urine for up to 120 h post-drug administration for the pharmacokinetic evaluation of intact LDX and d-AMPH."( Lisdexamfetamine and amphetamine pharmacokinetics in oral fluid, plasma, and urine after controlled oral administration of lisdexamfetamine.
Barreto, F; Carlos, G; Comiran, E; Fröehlich, PE; Limberger, RP; Pechanksy, F, 2021
)
0.94
"25 mg, the pharmacokinetic profile of plasma d-amphetamine and l-amphetamine was generally consistent among participants."( Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.
Ilic, K; Kugler, AR; McNamara, N; Yan, B, 2022
)
1.22
"While serum half-life and unchanged methamphetamine urine clearance were unaffected by any radiation dose, maximum methamphetamine concentrations and methamphetamine and amphetamine metabolite area under the serum concentration-time curve values from 0 to 300 min were significantly reduced after 6 Gy radiation exposure."( Radiation Effects on Methamphetamine Pharmacokinetics and Pharmacodynamics in Rats.
Allard, FD; Blough, ER; Coward, L; Findley, DL; Gorman, G; Hambuchen, MD; Mazur, A; McGill, MR; Powers, A; Yee, EU, 2022
)
1.29
"As outlined in changes to the US prescribing information for all methylphenidate and risperidone products, health care professionals should be aware that changes to this combination may be associated with a pharmacodynamic drug-drug interaction resulting in acute hyperkinetic movement disorder."( Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.
Burkhart, K; Chen, Q; Cheng, C; Croteau, D; Demczar, D; Kortepeter, C; Mohamoud, M; Stone, M; Volpe, DA,
)
0.13

Compound-Compound Interactions

The effect of amphetamine sulfate (AMPH) on beta-phenylethylamine (PEA) and 3-methoxytyramine (3MT) levels in the rat frontal and cingulate cortices, the nucleus accumbens, and the striatum were evaluated. Our findings indicate the involvement of cyclic AMP in the regulation of neurohypophysis as well as the increase in total adenylyl cyclase.

ExcerptReferenceRelevance
" If pentobarbital was the CS and d-amphetamine or nicotine sulfate the US, then after about four drug-drug pairings the pentobarbital CS produced a higher heart rate (HR) than control conditions."( Drug-drug heart rate conditioning in rats: effective USs when pentobarbital is the CS.
Reilly, S; Revusky, S, 1992
)
0.56
"A series of agents were tested for their ability to interact with the analgetic actions of either d-amphetamine (d-AMP) or l-amphetamine (l-AMP), or morphine in rats using the hot plate procedure."( Differential analgetic actions of amphetamine enantiomers in the mouse: a drug-drug interaction study.
Maickel, RP; Spratto, GR; Tocco, DR, 1985
)
0.76
"The effect of amphetamine sulfate (AMPH) on beta-phenylethylamine (PEA) and 3-methoxytyramine (3MT) levels in the rat frontal and cingulate cortices, the nucleus accumbens, and the striatum were evaluated after the administration of either cocaine or reserpine alone and in combination with AMPH."( Effects of the administration of amphetamine, either alone or in combination with reserpine or cocaine, on regional brain beta-phenylethylamine and dopamine release.
Karoum, F; Mosnaim, AD; Wolf, ME,
)
0.77
" Our findings indicate the involvement of cyclic AMP in the regulation of neurohypophysis as well as the increase in total adenylyl cyclase both after application of immobilization stress combined with water immersion and after chronic amphetamine treatment."( Effects of immobilization stress combined with water immersion and chronic amphetamine treatment on the adenylyl cyclase activity in rat neurohypophysis.
Englisová, D; Hynie, S; Kaminský, O; Klenerová, V; Nazarov, E; Sída, P; Stöhr, J, 1999
)
0.72
" By contrast, the same drug combination treatment did not reduce the somatic signs of nicotine withdrawal indicating symptom-specific neurobiological abnormalities."( Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Harrison, AA; Liem, YT; Markou, A, 2001
)
0.52
" In the current paper, this new extraction technique was combined with liquid chromatography-mass spectrometry (LC-MS) for the first time."( Liquid-phase microextraction based on carrier mediated transport combined with liquid chromatography-mass spectrometry. New concept for the determination of polar drugs in a single drop of human plasma.
Anthonsen, HS; Ho, TS; Pedersen-Bjergaard, S; Rasmussen, KE; Reubsaet, JL, 2005
)
0.33
" Specifically, suspect and non-target screening, combined with a prioritization approach based on similarity measures between detected features and mass loads of MDMA and amphetamine was implemented."( Retrospective suspect and non-target screening combined with similarity measures to prioritize MDMA and amphetamine synthesis markers in wastewater.
Been, F; Boucheron, T; de Voogt, P; Emke, E; Esseiva, P; Reymond, N; Ter Laak, T, 2022
)
1.13
"As outlined in changes to the US prescribing information for all methylphenidate and risperidone products, health care professionals should be aware that changes to this combination may be associated with a pharmacodynamic drug-drug interaction resulting in acute hyperkinetic movement disorder."( Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.
Burkhart, K; Chen, Q; Cheng, C; Croteau, D; Demczar, D; Kortepeter, C; Mohamoud, M; Stone, M; Volpe, DA,
)
0.13

Bioavailability

Evaluate the relative bioavailability of single-dose amphetamine extended-release tablet (AMPH ER TAB) 20 mg, swallowed whole or chewed. It is characterized by improved bioavailability allowing dose reduction and a lower exposure to amphetamine metabolites.

ExcerptReferenceRelevance
" The 1:20 complex, pure drug, and combination formulations showed comparable bioavailability after 48 hr."( Sustained-release applications of montmorillonite interaction with amphetamine sulfate.
Lach, JL; McGinity, JW, 1977
)
0.49
" bioavailability and a relatively long duration of action."( Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Awouters, F; Janssen, PA; Meert, TF; Megens, AA; Niemegeers, CJ; Schellekens, KH, 1988
)
0.27
" The analytical methods were set up to study the pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administrations of different doses of transdermal nicotine systems."( High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine.
Dubois, JP; Parisot, C; Sandrenan, N; Sioufi, A, 1989
)
0.28
" Dose-dependent changes in rate and extent of absorption, bioavailability (saturation of first-pass metabolism), distribution (saturation of protein binding sites) and metabolism are discussed."( Pharmacokinetics of drug overdose.
Benowitz, NL; Pond, S; Rosenberg, J,
)
0.13
"An open-label, four-way crossover, single dose pharmacokinetic study comparing the bioavailability of 10 mg selegiline hydrochloride administered to healthy young males as a solution by the oral route (in the stomach) and by a nasoenteric tube to the following three sites: duodenum, jejunum and terminal ileum was conducted."( Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett, JS; De Witt, KE; Ireland, J; Morales, RJ; Rajewski, G; Rohatagi, S; Szego, P, 1996
)
0.29
"A bioavailability study of 2 different selegiline preparations were conducted in 20 healthy volunteers to test the bioequivalence."( Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Kikuta, C; Ludwig, G; Mascher, HJ; Millendorfer, A; Schiel, H, 1997
)
0.51
"To assess the bioavailability of three test formulations of a single dose of extended-release Adderall 20-mg capsules compared with two doses of immediate-release Adderall 10-mg tablets, and to assess the bioequivalence of a single 30-mg dose of the chosen extended-release Adderall formulation (designated as SLI381) administered in applesauce (sprinkled) and the same dose administered as an intact capsule with or without food."( SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration.
McLean, A; Tulloch, SJ; Wolf, KN; Zhang, Y, 2002
)
0.54
" Both BW 467C60 and BW 392C60 were well absorbed from the alimentary tract."( Adrenergic neurone blockade and other acute effects caused by N-benzyl-N'N"-dimethylguanidine and its ortho-chloro derivative.
BOURA, AL; GREEN, AF, 1963
)
0.24
" Bioavailability was determined using AUC and peak plasma concentrations (C(max))."( A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Brewer, F; Clarke, A; Corn, TH; Hartig, F; Johnson, ES; Mallard, N; Taylor, S, 2003
)
0.32
" Their oral bioavailability is good, with a high distribution volume (4 L/kg) and low binding to plasma proteins (less than 20%)."( Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.
de la Torre, R; Farré, M; Navarro, M; Pacifici, R; Pichini, S; Zuccaro, P, 2004
)
0.32
" The application schedule was validated, and the bioavailability of the compound determined, by means of a HPLC-pharmacokinetic study."( FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia.
Boeckler, F; Feldon, J; Ferger, B; Gmeiner, P; Hübner, H; Löber, S; Russig, H; Schetz, J; Zhang, W, 2004
)
0.32
" Potent and specific inhibitors of the CYP2A6 enzyme can be used in the future to increase nicotine bioavailability and thus make oral nicotine administration feasible in smoking cessation therapy."( Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Juvonen, RO; Poso, A; Rahnasto, M; Raunio, H; Wittekindt, C, 2005
)
0.33
"The aim of this study was to assess the efficacy of a structurally novel, potent, selective mGlu2/3 receptor agonist with improved bioavailability (LY404039) in animal models predictive of antipsychotic and anxiolytic efficacy."( In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Griffey, KI; Johnson, BG; Knitowski, KM; McKinzie, DL; Monn, JA; Perry, KW; Rorick-Kehn, LM; Salhoff, CR; Schoepp, DD; Tizzano, JP; Witkin, JM, 2007
)
0.34
" (-)-Deprenyl is well absorbed after oral and parental treatment."( Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
Lengyel, J; Magyar, K; Szatmáry, I; Szebeni, G, 2007
)
0.34
" Oral bioavailability was not affected (F = 64 ± 4 versus 59 ± 11; knockout versus wild type)."( Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
Bedwell, DW; Higgins, JW; Zamek-Gliszczynski, MJ, 2012
)
0.38
" It is characterized by improved bioavailability allowing dose reduction and a lower exposure to amphetamine metabolites."( The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Magyar, K; Szökő, E; Tábi, T; Vécsei, L, 2013
)
0.61
" The water solubility and improved bioavailability may help reduce medication frequency associated with l-DOPA treatment of PD."( DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas, D, 2016
)
0.43
" Deviations from suggested routes of administration such as crushing, chewing, intravenous administration, or snorting stimulant medication may alter the release rate, absorption, and bioavailability of the active drug."( Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications.
Jain, R; Stark, JG, 2016
)
0.43
" This study was performed to determine if administration with food affected the rate of absorption or bioavailability of AMP XR-OS."( Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
Engelking, D; McMahen, R; Sikes, C; Stark, JG, 2017
)
0.76
" Comparative relative bioavailability between formulations was determined when ratios were within 80% and 125%."( Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension.
Herman, BK; Kando, JC; King, TR; Pardo, A; Rafla, E, 2020
)
0.84
"To evaluate the relative bioavailability of a single dose of amphetamine extended-release oral suspension (AMPH EROS) compared with a single dose of extended-release mixed amphetamine salts (ER MAS) in healthy, fasted adult subjects."( A single-dose, comparative bioavailability study comparing amphetamine extended-release oral suspension with extended-release mixed amphetamine salts capsules.
Bouhajib, M; Kando, JC; King, TR; Pardo, A; Rafla, E, 2022
)
1.21
" Relative bioavailability between the products was determined by a statistical comparison of the area under the curve and maximum concentration (Cmax) for d-amphetamine and l-amphetamine."( A single-dose, comparative bioavailability study comparing amphetamine extended-release oral suspension with extended-release mixed amphetamine salts capsules.
Bouhajib, M; Kando, JC; King, TR; Pardo, A; Rafla, E, 2022
)
1.16

Dosage Studied

Amphetamine failed to improve performance in preshocked rats but retarded escape in restrained (no-shock) controls. The ability of amphetamine to alter taste preference increased with dosage level and this effect interacted with age.

ExcerptRelevanceReference
"The dose-response relationship for d-amphetamine (0."( Actions and interactions of amphetamine on self-stimulation in rats.
Aulakh, CS; Pradhan, SN, 1979
)
0.83
" FS-32 showed anti-reserpine activity in a dose-dependent manner, whereas imipramine exhibited a bell-shaped dose-response pattern."( Pharmacological studies on a new thymoleptic antidepressant, 1-[3-(dimethylamino)propyl]-5-methyl-3-phenyl-1H-indazole (FS-32).
Fujimura, Y; Ikeda, Y; Iwasaki, T; Koide, T; Matsushita, H; Nagashima, R; Shindo, M; Shiraki, Y; Suzuki, S; Takano, N, 1979
)
0.26
"Using measures of locomotor activity and stereotypy, dose-response curves to several psychomotor stimulant drugs were obtained on rats reared in deprived or normal environments."( The effects of psychomotor stimulants on stereotypy and locomotor activity in socially-deprived and control rats.
Iversen, SD; Morgan, MJ; Robbins, TW; Sahakian, BJ, 1975
)
0.25
" Dose-response functions were determined for d- and l-amphetamine, alpha-methyltyrosine, and haloperidol."( Free-operant and auto-titration brain self-stimulation procedures in the rat: a comparison of drug effects.
Holtzman, SG; Schaefer, GJ, 1979
)
0.51
" The ability of amphetamine to alter taste preference increased with dosage level and this effect interacted with age."( Developmental changes in amphetamine-induced taste aversions.
Infurna, RN; Spear, LP, 1979
)
0.91
" In studying the dose-response relationship there appears to be a relationship between drug dose and polysome disaggregation in both groups of animals, although the effects were always greater in crowded mice."( Effect of crowding on amphetamine-induced disaggregation of brain polyribosomes.
Blackshear, MA; Proctor, CD; Wade, LH, 1979
)
0.57
" With increase of antidepressants dosage received by a subordinate rat its competing ability becomes enhanced too; this may cause a change in domination."( [Effect of pharmacologic substances on the dominance-submission relationship in a pair of rats].
Kampov-Polevoi, AB, 1978
)
0.26
" The toxicity of peroral triftazine administered to mice and rats is the same for both dosage forms, it being somewhat higher for intraperitoneal triftazine syrup."( [Pharmacologic characteristics of triftazin syrup].
Blinkova, NF; Parin, VV; Shcherbakova, OV; Shmar'ian, MI; Tolmacheva, NS,
)
0.13
" The stimulation of mouse locomotor activity caused by dl- and d-amphetamine in mice treated with adenine was less than that caused by equal dosage of these agents in mice not treated with adenine."( Reversal of adenine-induced depression of mouse locomotor activity by amphetamine.
Akintonwa, A; Auditore, JV, 1978
)
0.73
" The combination of a 1:20 drug-montmorillonite complex with pure drug in a 1:1 ratio, based on amphetamine content, resulted in recovery profiles resembling those obtained from prolonged-release dosage forms."( Sustained-release applications of montmorillonite interaction with amphetamine sulfate.
Lach, JL; McGinity, JW, 1977
)
0.71
" Both drugs also shift to the left the dose-response curves for noradrenaline and adrenaline on isolated strips, cocaine being most potent."( Uptake and release of catecholamines in sympathetic nerve fibres in the spleen of the cod, Gadus morhua.
Holmgren, S; Nilsson, S, 1976
)
0.26
" Strength of the conditioned reinforcer, measured in terms of responding on a lever for the stimulus plus infusion of saline solution, was proportional to the unit dosage of morphine employed in pairings of buzzer and drug."( Role of conditioned reinforcers in the initiation, maintenance and extinction of drug-seeking behavior.
Davis, WM; Smith, SG,
)
0.13
" Although directly related to daily dosage of levodopa, the myoclonus was specifically blocked by the serotonin antagonist, methysergide."( Levodopa-induced myoclonus.
Bergen, D; Goetz, C; Klawans, HL, 1975
)
0.25
" Dextroamphetamine in lower dosage also reduced disability by some 17 percent."( Amphetamines in the treatment of Parkinson's disease.
Asselman, P; Bovill, KT; Marsden, CD; Parkes, JD; Phipps, JA; Rose, P; Tarsy, D, 1975
)
2.15
" Making water available before the session lowered the amphetamine dose-response curve along the vertical axis, suggesting that amphetamine did not mimic satiation."( Interresponse time changes as a function of water deprivation and amphetamine.
Brown, BM; Seiden, LS, 1975
)
0.74
" Second, dose-response relationships were established for the amphetamine enantiomers."( Differences between (+)- and (-)-amphetamine in effects on locomotor activity and L-dopa potentiating action in mice.
Strömberg, U; Svensson, TH, 1975
)
0.78
" For the inhibition of the hypotensive action of clonidine by protriptyline a parallel shift of the dose-response curve was obtained, indicating the possibility of a competitive antagonism."( Interaction between centrally acting hypotensive drugs and tricyclic antidepressants.
van Zwieten, PA, 1975
)
0.25
" Prolonged pretreatment with suprathreshold doses of amphetamine decreased the threshold dosage of both amphetamine and apomorphine necessary to elicit stereotyped behavior."( Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias.
Crossett, P; Dana, N; Klawans, HL, 1975
)
0.84
"Mice were given several atropine injections at a high dosage level."( Sensitivity changes to morphine and other drugs induced by cholinergic blockade.
Contreras, E; Quijada, L; Tamayo, L, 1975
)
0.25
" Both At and Sc in a wide range of dosage protect against the tonic phase of convulsions produced by electroshock."( Central action of drugs acting on the cholinergic muscarinic receptor. III. Influence of atropine and scopolamine injected intraventricularly on behavior and levels of biogenic amines in the rat brain.
Kleinrok, Z; Poddubiuk, Z; Zebrowska-Lupina, I, 1975
)
0.25
" The dose-response curves for the compound 48/80-induced release of endogenous Hi and for the various amines taken up by the cells were compared."( Intracellular distribution of amines taken up by rat mast cells.
Bergendorff, A, 1975
)
0.25
"A procedure was developed to determine amphetamine salts in solid dosage forms."( Determination of amphetamine by Schiff base formation and quantitative gas-liquid chromatography.
Clark, CC, 1975
)
0.86
"Synaptoneurosomes, incubated with amphetamine, showed a biphasic dose-response change in activity of PKC and release of DA."( Protein kinase C and dopamine transport--2. Effects of amphetamine in vitro.
Giambalvo, CT, 1992
)
0.81
" However, whereas this dosage regimen revealed a profound behavioral sensitization in response to challenge with amphetamine (2."( In vivo microdialysis reveals a diminished amphetamine-induced DA response corresponding to behavioral sensitization produced by repeated amphetamine pretreatment.
Kuczenski, R; Segal, DS, 1992
)
0.76
" However, dose-response tests revealed that sensitized rats did not show increased hypophagia in a milk drinking task."( Effect of prior sensitization of stereotypy on the development of tolerance to amphetamine-induced hypophagia.
Kinney, GG; Wolgin, DL, 1992
)
0.51
" In addition, the effect of ITI length on the dose-response curve for pentobarbital, phencyclidine, D-amphetamine, and cocaine were determined."( Titrating matching-to-sample performance: effects of drugs of abuse and intertrial interval.
Kimball, KA; Wenger, GR, 1992
)
0.5
" In the second experiment, neither d-amphetamine nor nomifensine altered the discriminative stimulus properties of ICSS, but a dose-response increase occurred in the time to complete the test session and in total number of lever presses and in presses on the initiating lever."( Effects of amphetamine and nomifensine on intracranial self-stimulation discrimination behavior in rats.
Michael, RP; Schaefer, GJ, 1992
)
0.95
" The dose-response relation for LY171555 was bell-shaped, with a maximal effect being obtained with 10(-9) M) LY171555."( Opposing effects of dopamine D2 receptor stimulation on the spontaneous and the electrically evoked release of [3H]GABA on rat prefrontal cortex slices.
Besson, MJ; Penit-Soria, J; Rétaux, S, 1991
)
0.28
" With the multiple dosing regimen utilized neither drug alone resulted in any changes in serotonergic parameters, including 5-HT, 5-HIAA and the number of 5-HT uptake sites."( Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats.
Johnson, MP; Nichols, DE, 1991
)
0.52
" More importantly, if a subacute dosing regimen (every 12 hours for 4 days) was utilized, the combination of S-amphetamine with MDAI resulted in a marked long-term decrease in the levels of cortical, hippocampal and striatal 5-HT, 5-HIAA and the number of 5-HT uptake sites."( Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue.
Huang, XM; Johnson, MP; Nichols, DE, 1991
)
0.7
" A shift in the dose-response function of amphetamine that occurred during these weeks, however, precluded appropriate analysis of haloperidol's effects."( Rebound cue state following a single dose of haloperidol.
Barrett, RJ; Caul, WF; Jones, JR; Murphy, SM; Schmidt, TA, 1991
)
0.55
" Apomorphine-induced cage climbing behavior was partially decreased by lower dosages of GDEE, but was almost completely blocked by the highest dosage tested."( A possible role of AA2 excitatory amino acid receptors in the expression of stimulant drug effects.
Cannon-Spoor, HE; Freed, WJ, 1990
)
0.28
" Dose-response curves for the effects of PPA and amphetamine (administered IP, 15 min presession) were then determined (ED50 = 35."( Evaluation of the pharmacological similarities between phenylpropanolamine and amphetamine: effects on schedule-controlled behavior.
Jarvis, MF; Wagner, GC, 1990
)
0.76
"The present studies were undertaken to examine 1) whether d-amphetamine sulfate administered to rats well after thrombotic infarction of the vibrissal cortical barrel-field within the primary somatosensory cortex affected the rate and completeness of behavioral recovery and 2) whether a dose-response relation exists between d-amphetamine sulfate dose and recovery of function."( Amphetamine promotes recovery from sensory-motor integration deficit after thrombotic infarction of the primary somatosensory rat cortex.
Alonso, O; Dietrich, WD; Ginsberg, MD; Hurwitz, BE; McCabe, PM; Schneiderman, N; Watson, BD, 1991
)
1.97
" Survival was similar in dosed and control groups."( Decreases in spontaneous tumors in rats and mice after treatment with amphetamine.
Dunnick, JK; Eustis, SL, 1991
)
0.52
" The results demonstrate that magnesium dose dependently increases the potency of these drugs by producing greater behavioral effects at certain drug doses, by producing shifts to the left in dose-response functions, and by producing decreases in the ED50 as dose of magnesium increases."( Enhancement of apomorphine and l-amphetamine-induced behaviors by magnesium.
Adlerstein, LK; Kantak, KM, 1990
)
0.56
" In 5-min extinction tests with nicotine, rats maintained under the FR schedule yielded a clear dose-response curve with a bar-selection (quantal) index; in these rats, discrimination of nicotine appeared generally poor, and dose-response curves were shallow, when the percentage of drug-appropriate responding (quantitative index) was calculated."( Discriminative stimulus effects of nicotine in rats trained under different schedules of reinforcement.
Stolerman, IP, 1989
)
0.28
" In mice pretreated with reserpine and various doses of alpha methyl-p-tyrosine (alpha MPT, intraperitoneally), the degree of stimulation produced by (+)-amphetamine was dependent on the amount and frequency of alpha MPT dosage - the higher and more frequent the dose, the more effective the blockade."( The involvement of dopamine D1 and D2 receptors in the locomotor stimulation produced by (+)-amphetamine in naive and dopamine-depleted mice.
Edwards, SR; Jackson, DM; Ross, SB, 1989
)
0.69
" Dose-response comparisons revealed a significant relationship between AMPH-induced increases in behavioral perseveration and the magnitude and duration of the DA release."( Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis.
Kuczenski, R; Segal, D, 1989
)
0.5
" A treatment effect of methylmercury was clearly observed and a dose-response effect was also observed."( Behavioral teratogenic effect of methylmercury and d-amphetamine: meta-analysis and power analysis of data from the Collaborative Behavioral Teratology Study of National Center for Toxicological Research.
Tachibana, T, 1989
)
0.53
" In the third experiment, which looked at the dose-response curve for amphetamine-induced taste aversion learning in intact rats and rats with area postrema lesions, it was shown that both groups of rats acquired taste aversions following injection of amphetamine, although the rats with lesions showed a less severe aversion than the intact rats."( Interactions between radiation and amphetamine in taste aversion learning and the role of the area postrema in amphetamine-induced conditioned taste aversions.
Hunt, WA; Lee, J; Rabin, BM, 1987
)
0.78
" The same low dosage of amphetamine which improved the behavior and learning of hyperkinetic and violent dogs disrupted the behavior and produced disorientation in normal dogs with previously stable conditional responses."( Psychopharmacologic facilitation of psychosocial therapy of violence and hyperkinesis.
Corson, EO; Corson, SA, 1988
)
0.58
" A dose of 5 mg/kg of AMPH, but not 1 mg/kg of AMPH, caused a 2-fold shift to the right in the dose-response curve for DA in stimulating AC activity when compared with saline controls."( Desensitization of rat striatal dopamine-stimulated adenylate cyclase after acute amphetamine administration.
Barnett, JV; Kuczenski, R, 1986
)
0.5
" The amphetamine dose-response curve for stereotypy was shifted to the right by glucose but retained the same slope as the control curve, suggesting that glucose competes for amphetamine or dopamine receptors that mediate this behavior."( Effect of glucose on amphetamine-induced motor behavior.
Blackburn, J; White, NM, 1986
)
1.1
" Other than the use of different agents and dosing regimens in the two studies, all other characteristics of experimental design were identical."( Collaborative Behavioral Teratology Study: protocol design and testing procedures.
Adams, J; Buelke-Sam, J; Kimmel, CA; Nelson, BK; Nelson, CJ; Reiter, LW; Sobotka, TJ; Tilson, HA,
)
0.13
" In order to further study the mechanism of brain stimulation punishment, dose-response curves of two minor tranquilizers, chlordiazepoxide and pentobarbital, of two tryptamine antagonists, methysergide and cyproheptadine as well as of amphetamine on lever-pressing behavior of rats maintained by water reinforcement and punished by DPAG stimulation were determined."( Effect of minor tranquilizers, tryptamine antagonists and amphetamine on behavior punished by brain stimulation.
de Aguiar, JC; Graeff, FG; Morato de Carvalho, S, 1981
)
0.69
" Comparisons were made on the basis of dose-response relationships."( Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens.
Morton, EC; Vaupel, DB, 1982
)
0.26
" The response(s) of a drug is a complicated function of the concentration in the blood plasma, which in turn is some function of the dosage input."( Quantitative relationships between dynamics and kinetics of drugs: a systems dynamics approach.
Burgers, JP; van Rossum, JM, 1984
)
0.27
" This dosage of haloperidol had no effect on tactile placing in normal cats."( Amphetamine and apomorphine restore tactile placing after motor cortex injury in the cat.
Feeney, DM; Hovda, DA, 1983
)
1.71
" Amphetamine induces a dose-response partial reversal of the GBL effect."( gamma-Butyrolactone effects on behavior induced by dopamine agonists.
Dougherty, GG; Ellinwood, EH; Gonzalez, AE, 1983
)
1.18
" In addition to these salient features, the results of this study also have an impact on stimulus specificity, and further emphasize the importance of thorough dose-response relationships as related to tests of stimulus generalization."( MDA: a psychoactive agent with dual stimulus effects.
Glennon, RA; Young, R, 1984
)
0.27
" Caffeine pretreatment attenuated amphetamine activity in the rats without producing a horizontal shift in the dose-response curve."( Caffeine reduces amphetamine-induced activity in asymmetrical interaction.
Crumbie, PM; Harkins, D; Haswell, KL; Kassab, CD; White, BC, 1984
)
0.89
" The results indicate that the effects of DSIP on locomotor behavior were dependent on the dosage of the peptide and the time of measurement as well as the level of amphetamine stimulation."( Amphetamine-induced locomotor behavior of mice is influenced by DSIP.
Graf, M; Schoenenberger, GA; Zadina, JE,
)
1.77
"5 mg/kg) for a variable period of time (4 to 28 days), depending upon the dosage of the neuroleptic used (2."( Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes.
Merali, Z; Toth, G, 1982
)
0.49
" The effects of thorazine dose-response blocking on amphetamine-induced behavior were linear."( An assessment of spectral analysis of amphetamine-induced behavior.
Ellinwood, EH; Molter, DW; Stauderman, KA, 1981
)
0.78
"Behavioral rating scales, developed to measure phencyclidine (PCP)-induced stereotypy and ataxia in rats, were tested using acute dose-response and chronic paradigms with concomitant assessment of locomotor activity by automated counters."( Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats.
Adams, PM; Castellani, S, 1981
)
0.26
" All active compounds gave inverted U-shaped dose-response curves."( Cognition-activating properties of 3-(Aryloxy)pyridines.
Butler, DE; Marriott, JG; Poschel, BP, 1981
)
0.26
"Rats were administered chronic multiple injections of amphetamine (AMPH) using dosage regimens which produce tolerance to the AMPH facilitation of self-stimulation responding, or reverse tolerance (sensitization) to the locomotor stimulant and stereotypy-producing effects of the drug."( Chronic amphetamine: is dopamine a link in or a mediator of the development of tolerance and reverse tolerance?
Kuczenski, R; Leith, NJ, 1981
)
0.95
"Quantitative in situ hybridization histochemistry was used to compare the effects of AMPH administration on mRNAs coding for zif/268, a member of the zinc finger family of immediate early genes, and the opioid peptides, preprodynorphin (PPD) and preproenkephalin (PPE), in rat striatum after 3 dosing schedules: (1) acute; (2) once a day for 5 days, and (3) once a day for 5 days followed 10 days later by a challenge dose."( Alterations in striatal zif/268, preprodynorphin and preproenkephalin mRNA expression induced by repeated amphetamine administration in rats.
McGinty, JF; Wang, JQ, 1995
)
0.5
" The present study was undertaken to explore the possibility that one or the other measure may be a more sensitive in vivo indicator of dopamine release in the nucleus accumbens by determining if the amphetamine dose-response curves for these two behavioral measures were different."( Amphetamine sensitivity in open-field activity vs. the prepulse inhibition paradigm.
Mandel, RJ; Ott, DA, 1995
)
1.92
" To examine the properties of various pain rating methods we established dose-response relations for formalin injected in the plantar surface of one hind paw, and the analgesic effects of morphine and amphetamine using the most frequently reported behavioural measures of pain (favouring, lifting, licking and flinching/shaking of the injured paw) and combinations of these."( The formalin test: scoring properties of the first and second phases of the pain response in rats.
Abbott, FV; Franklin, KBJ; Westbrook, FR, 1995
)
0.48
" Four subjects used the inhaler as recommended by the manufacturer for five consecutive days; two subjects used double this dosage for three consecutive days."( Response of EMIT amphetamine immunoassays to urinary desoxyephedrine following Vicks inhaler use.
Moore, KA; Poklis, A, 1995
)
0.63
"Deprenyl (DPN) and its metabolites, desmethyl deprenyl (desmethyl DPN), methamphetamine (MA) and amphetamine (AP), in the hair of rats and humans dosed with DPN were analyzed by selected ion monitoring of gas chromatograph-mass spectrometry (GC-MS-SIM)."( Hair analysis for drugs of abuse. IX. Comparison of deprenyl use and methamphetamine use by hair analysis.
Kikura, R; Nakahara, Y, 1995
)
0.75
" This shift in the cocaine dose-response curve was apparent when conditioning commenced either 3 or 7, but not 14, days after the cessation of cocaine pretreatment."( Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics.
Heidbreder, C; Shippenberg, TS, 1995
)
0.29
" Mice and rats were given A5 intraperitoneally at three different dosage levels."( The influence of antineoplaston A5 on the central dopaminergic structures.
Burzynski, SR; Chodkowska, A; Feldo, M; Juszkiewicz, M; Kleinrok, Z; Majewska, B, 1994
)
0.29
" The assay exhibits a dose-response of approximately 90,000 dpm from 0 to 1000 ng/mL of D-amphetamine or D-methamphetamine with a minimum detectable dose for either drug of approximately 25 ng/mL."( 125I radioimmunoassay for the dual detection of amphetamine and methamphetamine.
McNally, AJ; Rusyniak, D; Salamone, SJ; Ward, C, 1994
)
0.77
"2 mg/kg, IP, 4 h before test) dose-dependently shifted the peak in the amphetamine dose-response function to the right, indicating an attenuation of conditioned reward."( Dopamine D1 and D2 antagonists attenuate amphetamine-produced enhancement of responding for conditioned reward in rats.
Beninger, RJ; Ranaldi, R, 1993
)
0.78
" Latency to acquisition of the lever discrimination for rats that had received prior exposure to amphetamine was shorter than for the saline-pretreated counterparts in each cocaine dosage group."( Development and expression of sensitization to cocaine's reinforcing properties: role of NMDA receptors.
Bankson, MG; Gibbs, S; Higley, D; Horger, BA; House, DT; McNamara, C; Schenk, S; Valadez, A, 1993
)
0.5
" Nevertheless, the dose-response curve of MMAI is parallel to those of (+)-fenfluramine (m-trifluoromethyl-N-ethylamphetamine) and p-chloroamphetamine."( Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan.
Marona-Lewicka, D; Nichols, DE, 1994
)
0.5
"5 to 37 fold) to the right of the dose-response curve for clonidine without significant change of maximum inhibitory effect, in a manner compatible with competitive antagonism (ED50B = 29."( Modulation by central postsynaptic alpha 2-adrenoceptors of the jaw-opening reflex induced by orofacial stimulation in rats.
Barturen, F; García-Sevilla, JA; García-Vallejo, P, 1994
)
0.29
" Dose-response curves indicated that, whereas caffeine and theophylline were equally effective at reversing escape deficits, amphetamine not only failed to improve performance in preshocked rats but retarded escape in restrained (no-shock) controls."( Stress and adenosine: I. Effect of methylxanthine and amphetamine stimulants on learned helplessness in rats.
Chang, WC; Minor, TR; Winslow, JL, 1994
)
0.74
" In the present study EGF is tested at a lower dosage starting administration at the time of lesion."( Effect of intracerebroventricular infusion of epidermal growth factor in rats hemitransected in the nigro-striatal pathway.
Ventrella, LL, 1993
)
0.29
" Cumulative dose-response curves for chlordiazepoxide were obtained before and during chronic chlordiazepoxide administration and during chronic saline administration."( Tolerance to the behavioral effects of chlordiazepoxide: pharmacological and biochemical selectivity.
Alastra, AJ; Cohen, C; Goldberg, SR; Marley, RJ; Sannerud, CA; Serdikoff, SL, 1993
)
0.29
" Both morphine and amphetamine shifted the dose-response curve for nicotine down and to the left, indicating increased efficacy and potency, respectively."( Nicotine and brain-stimulation reward: interactions with morphine, amphetamine and pimozide.
Huston-Lyons, D; Kornetsky, C; Sarkar, M, 1993
)
0.85
" Plasma levels of adrenocorticotropic hormone (ACTH) and corticosterone were increased by AMPH in a monotonic dose-response function, with highest levels measured in rats exhibiting the most intense stereotyped behaviors."( Pituitary-adrenal axis responses to acute amphetamine in the rat.
Cador, M; Hauger, RL; Koob, GF; Lorang, M; Swerdlow, NR, 1993
)
0.55
" A total of 214 urine specimens were collected either prior to dosing or at each micturition for a 12-h period post dose."( GC-MS determination of amphetamine and methamphetamine in human urine for 12 hours following oral administration of dextro-methamphetamine: lack of evidence supporting the established forensic guidelines for methamphetamine confirmation.
DeJohn, CA; Kearns, GL; Letzig, LG; Neri, DF; Shappell, SA; Sparks, C; Valentine, CR; Valentine, JL,
)
0.44
" Apomorphine at a low dosage (0."( Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression.
Guerra, MJ; Labandeira-Garcia, JL; Liste, I; Lopez-Martin, E; Rozas, G, 1996
)
0.29
" These results suggest that amphetamine may promote conditioned place preference or avoidance depending on dosage and individual susceptibility."( Dose-dependent aversive and rewarding effects of amphetamine as revealed by a new place conditioning apparatus.
Cabib, S; Genua, C; Le Moal, M; Piazza, PV; Puglisi-Allegra, S; Simon, H, 1996
)
0.84
" In the present study, dose-response effects of acute administration of these stimulants on preproenkephalin (PPE) mRNA expression in the rat striatum were investigated with quantitative in situ hybridization histochemistry 3 h after injection."( D1 and D2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine.
McGinty, JF; Wang, JQ, 1996
)
0.5
" The statistical distribution of the drug concentrations compared with the self-reported consumption behaviour of the users may possibly lead to a better understanding of the relationship between drug dosage and corresponding concentrations in hair."( Concentrations of delta 9-tetrahydrocannabinol, cocaine and 6-monoacetylmorphine in hair of drug abusers.
Kauert, G; Röhrich, J, 1996
)
0.29
" Thus, the present study was developed to further determine the dose-response curve for AMP's effects on sugar consumption in LOW and HIGH rats."( Individual differences in sugar consumption following systemic or intraaccumbens administration of low doses of amphetamine in nondeprived rats.
Sills, TL; Vaccarino, FJ, 1996
)
0.51
" While both AMP and MET exposure was equivalent at all dosing sites, DMS exposure was less (approximately 18%) at the terminal ileum."( Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett, JS; De Witt, KE; Ireland, J; Morales, RJ; Rajewski, G; Rohatagi, S; Szego, P, 1996
)
0.29
" AMP and MET metabolites were insensitive to dosing site consistent with their hepatic formation."( Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett, JS; De Witt, KE; Ireland, J; Morales, RJ; Rajewski, G; Rohatagi, S; Szego, P, 1996
)
0.29
" Microdialysis experiments were conducted to establish the dose-response curve of amphetamine-induced dopamine release and to document how pretreatment with the dopamine depleter alpha-methyl-para-tyrosine (alpha MPT) affects this response."( Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates.
al-Tikriti, MS; Baldwin, RM; Bradberry, CW; Charney, DS; Hoffer, PB; Innis, RB; Iyer, RN; Kung, HF; Laruelle, M; Malison, R; Zea-Ponce, Y; Zoghbi, SS, 1997
)
0.79
" At 7 weeks of age, dose-response curves were obtained with morphine (10, 31."( Influence of chronic prenatal and postnatal administration of naltrexone in locomotor activity induced by morphine in mice.
Luján Estrada, M; Medina Jiménez, M; Rodríguez, R, 1997
)
0.3
" In generalization tests, rats trained with either cytisine or nicotine showed steep dose-response curves (generalization gradients) for their respective training drug."( Discriminative stimulus properties of the nicotinic agonist cytisine.
Chandler, CJ; Stolerman, IP, 1997
)
0.3
" Dose-response tests revealed that the Before group retained tolerance, whereas the After and Saline groups lost tolerance."( Role of behavioral and pharmacological variables in the loss of tolerance to amphetamine hypophagia.
Hughes, KM; Wolgin, DL, 1997
)
0.53
" These results indicate that in vervet monkey striatum, an acute Amp or MeAmp drug dosage produces extensive striatal dopamine system neurotoxicity."( Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey.
Huang, SC; Lacan, G; Melega, WP; Phelps, ME; Raleigh, MJ; Stout, DB, 1997
)
0.55
" The sole recommended dosing regimen is 5 mg given in the morning and at noon with breakfast and lunch."( Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Barrett, JS; DeWitt, KE; Lessard, D; Morales, RJ; Rohatagi, S, 1997
)
0.3
" Because temporal and dosage parameters of the AMPH pretreatment regimen have been suggested to play a role in the appearance of an enhanced DA response, we utilized a variety of AMPH pretreatment regimens to assess the relationship between pretreatment dose of AMPH, duration of withdrawal and the DA response in caudate-putamen and nucleus accumbens to a subsequent AMPH challenge."( Behavioral sensitization and extracellular dopamine responses to amphetamine after various treatments.
Kuczenski, R; Segal, DS; Todd, PK, 1997
)
0.53
" The dose-response function of both those psychostimulants did not change in the course of the experiment."( The role of the nitric oxide (NO) pathway in the discriminative stimuli of amphetamine and cocaine.
Filip, M; Przegaliński, E, 1998
)
0.53
"The dose-response characteristics and time-course of amphetamine's effect on motor activity after a single injection given to rats at four different times of the light/dark cycle was investigated using a computerized infrared motor activity recording system."( Diurnal differences in rat's motor response to amphetamine.
Dafny, N; Gaytan, O; Swann, A, 1998
)
0.81
" Doses of (-)ephedrine and caffeine, which produced < or = 1% drug-appropriate responding when administered alone, were able to enhance each other's stimulus effects when administered in combination such that there was a twofold leftward shift in their respective dose-response curves."( (-)Ephedrine and caffeine mutually potentiate one another's amphetamine-like stimulus effects.
Gabryszuk, M; Glennon, RA; Young, R, 1998
)
0.54
"1 mg/kg 7-OH-DPAT on d-amphetamine (0-10 mg/kg) dose-response curves for the same behaviors were examined."( Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference.
Baker, DA; Fuchs, RA; Khroyan, TV; Manders, N; Neisewander, JL, 1998
)
0.88
"5 mg/kg) did not modify the dose-response curves of those psychostimulants."( Stimulation of serotonin (5-HT)1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats.
Filip, M; Przegaliñski, E, 1997
)
0.51
" Cocaine and amphetamine dose-response analyses were conducted on drug-naive mice from the tenth generation."( Sensitivity to cocaine and amphetamine among mice selectively bred for differential cocaine sensitivity.
Arros, DM; Henricks, KK; Marley, ME; Marley, RJ; Miner, LL, 1998
)
0.97
" dose of each compound caused a significant rightward shift in the dose-response curve for 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin]."( Electrophysiological comparison of 5-Hydroxytryptamine1A receptor antagonists on dorsal raphe cell firing.
Jackson, DM; Martin, LP; Wallsten, C; Waszczak, BL, 1999
)
0.3
" After animals were trained to discriminate PCP from saline, they were inoculated with LP-BM5 and the PCP dose-response functions repeatedly determined."( Increased discriminative stimulus potency of phencyclidine in C57B1/6 mice infected with the LP-BM5 retrovirus.
Bruce, KH; English, JA; Paul, IA, 1999
)
0.3
" AMPH at a dosage of 1 mg/kg significantly increased PEA concentration only in the striatum."( Effects of the administration of amphetamine, either alone or in combination with reserpine or cocaine, on regional brain beta-phenylethylamine and dopamine release.
Karoum, F; Mosnaim, AD; Wolf, ME,
)
0.41
" Next, a morphine dose-response curve (1."( Sensitization to daily morphine injections in rats with unilateral lesions of the substantia nigra.
Easterling, KW; Holtzman, SG; Kimmel, HL; Volpicelli, LA, 1999
)
0.3
"Brain temperature monitoring and microdialysis were performed simultaneously in the caudate/putamen (CPu) of conscious, freely moving rats dosed with d-amphetamine (AMPH)."( Time course of brain temperature and caudate/putamen microdialysate levels of amphetamine and dopamine in rats after multiple doses of d-amphetamine.
Bowyer, JF; Clausing, P, 1999
)
0.73
" Combination tests of glycineB ligands demonstrated that injection of a fixed dose of ACPC (200 mg/kg) or L-701,324 (3 mg/kg) together with different doses of AMPH or COC practically did not modify dose-response curves of the psychostimulants, nor did it affect their ED50 values."( Lack of effects of glycineB receptor ligands on the psychostimulant-induced discriminative stimuli in rats.
Filip, M; Papp, M; Przegaliński, E, 2000
)
0.31
" However, in Lewis rats amphetamine treatment increased the dose-response curve of forskolin stimulation."( Different activity of adenylyl cyclase in prefrontal cortex in three rat strains. The effect of amphetamine.
Hynie, S; Klenerová, V; Sída, P, 1998
)
0.83
" Rats that did not become hyperthermic when dosed with 15 mg/kg AMPH in a cold environment (10 degrees C) exhibited some hyperactivity and stereotypic behavior, but not overt convulsive behavior."( Seizure activity and hyperthermia potentiate the increases in dopamine and serotonin extracellular levels in the amygdala during exposure to d-amphetamine.
Bowyer, JF; Tor-Agbidye, J; Yamamoto, B, 2001
)
0.51
" Following 30 sessions of training, dose-response functions were determined for HA (0."( Schedule-dependent effects of haloperidol and amphetamine: multiple-schedule task shows within-subject effects.
Brindle, NA; Caul, WF, 2001
)
0.57
"To elucidate the role of drug basicity in the preferential incorporation of certain drugs into dark hair rather than light hair, Long-Evans rats were dosed with amphetamine or its non-basic analogue N-acetylamphetamine (N-AcAp) and their hair evaluated for drug content."( Amphetamine and N-acetylamphetamine incorporation into hair: an investigation of the potential role of drug basicity in hair color bias.
Borges, CR; Rollins, DE; Wilkins, DG,
)
1.77
" Here, we characterized acoustic and tactile startle reactivity, acoustic PPI, and both the amounts and spatial patterns of locomotor activity in C57BL/6J, 129SvEv (129S6), and 129SvJ (129X1) mice at baseline and in amphetamine dose-response studies."( Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice.
Geyer, MA; Paulus, MP; Ralph, RJ, 2001
)
0.79
"To investigate possible influences of ethanol (EtOH) on metabolism of methamphetamine (MA), dark agouti (DA) rats were assigned to 3 groups including EtOH mono-dosing group, MA mono-dosing group and combined dosing group of EtOH and MA."( Influence of ethanol on metabolism of methamphetamine in rats including hair analysis.
Hayashida, M; Nihira, M; Yamada, T, 2001
)
0.81
" These results suggest that MET is endowed with peculiar hypophagic effects at dosage levels that are not able to affect gross behaviour in mice."( Methylamine and benzylamine induced hypophagia in mice: modulation by semicarbazide-sensitive benzylamine oxidase inhibitors and aODN towards Kv1.1 channels.
Banchelli, G; Galeotti, N; Ghelardini, C; Pirisino, R; Raimondi, L, 2001
)
0.31
" Rehabilitation with amphetamine at this dosage and interval, combined with physiotherapy, did not promote motor recovery or functional capacity in patients suffering from stroke."( A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke.
Lökk, J; Nilsson, CG; Nordström, M; Sonde, L; Viitanen, M, 2001
)
0.87
" Both before and after this phase, dose-response (DR) tests were conducted."( Long-term retention of tolerance to amphetamine hypophagia following cessation of drug injections and feeding tests.
Hughes, KM; Wolgin, DL,
)
0.41
" The purpose of the study was to investigate the nature of the shift of the dose-response curve and generalization to cocaine (COC) as a function of training dose."( Effects of training dose on amphetamine drug discrimination: dose-response functions and generalization to cocaine.
Barrett, RJ; Caul, WF; Stadler, JR,
)
0.43
" amphetamine in a within-session design, which allows evaluation of a complete dose-response curve within a single session."( Amphetamine-induced locomotor activation in 5-HT(1B) knockout mice: effects of injection route on acute and sensitized responses.
Bronsert, MR; Hen, R; Mead, AN; Rocha, BA, 2001
)
2.66
" After t he initial application of the amphetamine, the higher BPC 157 dosage apparently attenuated the stereotyped behavior, while the lower dosage of BPC 157 did not reach a statistical significance."( Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances.
Anic, T; Aralica, G; Babic, S; Bedekovic, V; Boban-Blagaic, A; Buljat, G; Dodig, G; Jelovac, N; Jelovac-Gjeldum, A; Lovric-Bencic, M; Perovic, D; Petek, M; Prkacin, I; Rak, D; Rucman, R; Seiwerth, S; Separovic, J; Sikiric, P; Staresinic, M; Tonkic, A; Turkovic, B; Ziger, T; Zoricic, I, 2002
)
0.85
"5 mg/kg) did not modify dose-response curves of the psychostimulant, nor did it affect its ED50 value."( Serotonin1B receptor ligands in the nucleus accumbens shell do not affect the discriminative stimulus effects of amphetamine in rats.
Baran, L; Filip, M; Nowak, E; Przegaliński, E,
)
0.34
" Dose-response relationships were obtained for khat extract and D- and L-amphetamine given to mice by the intragastric route."( Comparison of effects of khat extract and amphetamine on motor behaviors in mice.
Connor, JD; Makonnen, E; Rostom, A, 2002
)
0.81
" As expected, regular Wean-21 animals showed an AMPH-induced hyperactivity and a profile of conditioned locomotion, whereas the same dosage failed to induce any change in Wean-15 and Wean-27 groups."( Spontaneous novelty seeking and amphetamine-induced conditioning and sensitization in adult mice: evidence of dissociation as a function of age at weaning.
Adriani, W; Laviola, G, 2002
)
0.6
"The current study defined the full dose-response relationship for amphetamine self-administration under FR1 and progressive ratio (PR) schedules of reinforcement in rats raised in either an enriched condition (EC) or an isolated condition (IC)."( Environmental enrichment decreases intravenous amphetamine self-administration in rats: dose-response functions for fixed- and progressive-ratio schedules.
Bardo, MT; Gehrke, BJ; Green, TA, 2002
)
0.81
" After implantation of the catheter, rats were allowed to acquire stable response patterns under an FR1 or PR schedule of reinforcement before determination of the dose-response function."( Environmental enrichment decreases intravenous amphetamine self-administration in rats: dose-response functions for fixed- and progressive-ratio schedules.
Bardo, MT; Gehrke, BJ; Green, TA, 2002
)
0.57
" Tolerance to the hypophagic effect was confirmed by dose-response tests in which milk was available in bottles."( Changes in behavioural contingencies produce a loss of tolerance to amphetamine hypophagia in rats despite continued feeding tests while drugged.
Hughes, KM; Wolgin, DL, 2002
)
0.55
"0 mg/ml) resulted in tolerance to the motor effects of an acute administration of caffeine, lack of tolerance to amphetamine, apparent tolerance to MSX-3 (shift to the left of its 'bell-shaped' dose-response curve), and true cross-tolerance to CPT."( Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration.
Antoniou, K; Ferré, S; Fuxe, K; Goldberg, SR; Justinova, Z; Karcz-Kubicha, M; Müller, CE; Pezzola, A; Popoli, P; Quarta, D; Reggio, R; Solinas, M; Terasmaa, A, 2003
)
0.53
" Bretylium and guanethidine depress the slopes of the dose-response curves for the pressor and nictitating membrane contracting effects of tyramine."( Comparison of bretylium and guanethidine: tolerance, and effects on adrenergic nerve function and responses to sympathomimetic amines.
BOURA, AL; GREEN, AF, 1962
)
0.24
" Thus, for example, NT69L after five daily injections at a fixed dosage was as effective at reversing cocaine-induced hyperactivity as after the first injection."( Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier.
Boules, M; Fauq, A; McCormick, D; McMahon, B; Richelson, E; Stewart, J; Wang, R; Warrington, L; Yerbury, S, 2003
)
0.32
" They were challenged on the eighth day with one dosage and sacrificed 3 h later."( Activation of metabotropic glutamate receptor 5 is associated with effect of amphetamine on brain neurons.
Li, LT; Lin, WW; Yin, HS; Yu, MF, 2003
)
0.55
" The present experiments were performed in order to obtain more information on the relationship between the OX-induced sensitization to AMPH and the OX dose and dosing regime (single or repeated), and to find out whether the environment associated with the acute effects of OX could affect the response to AMPH."( Alteration in behavioral sensitivity to amphetamine after treatment with oxotremorine. Effect of dose and test environment.
Gralewicz, S; Lutz, P; Tomas, T; Wiaderna, D, 2003
)
0.59
" The current study describes a rodent model of amphetamine-induced [11C]raclopride reduction, which allowed the characterisation of the dose-response and temporal dynamics of this reduction over a 24-h time course."( Temporal characterisation of amphetamine-induced dopamine release assessed with [11C]raclopride in anaesthetised rodents.
Goggi, JL; Grasby, PM; Hirani, E; Houston, GC; Hume, SP, 2004
)
0.87
" After 1-d or 14-d withdrawal from Amph, they were challenged on day 8 (W1d) or on day 21 (W14d) with a single same dosage and then perfused."( Age- and region-dependent alterations in the GABAergic innervation in the brain of rats treated with amphetamine.
Chen, CT; Lin, TY; Yin, HS, 2004
)
0.54
" Modafinil may be well suited for the treatment of obesity, although further studies with repeated dosing in overweight populations are warranted."( Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity.
Frederich, RC; Kelly, TH; Makris, AP; Rush, CR, 2004
)
0.54
" At the end of this experiment, a dose-response study was conducted with saline-pretreated rats to confirm the appropriateness of the challenge dose."( Transient disruption of attentional performance following escalating amphetamine administration in rats.
Burk, JA; Kondrad, RL, 2004
)
0.56
"0 mg/kg amphetamine did not alter accuracy of amphetamine-pretreated animals or of saline-pretreated animals in the dose-response experiment."( Transient disruption of attentional performance following escalating amphetamine administration in rats.
Burk, JA; Kondrad, RL, 2004
)
0.99
"0 mg/kg AMPH produced parallel dose-response curve shifts to the right."( Evidence for bidirectional cues as a function of time following treatment with amphetamine: implications for understanding tolerance and withdrawal.
Barrett, RJ; Caul, WF; Smith, RL, 2004
)
0.55
" In a primary culture of E14 murine ventral mesencephalic neurons, earlier treatment with the higher dosage of GDNF suppressed 6-OHDA-induced loss of dopaminergic neurons better than later treatment."( Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease.
Date, I; Kameda, M; Kobayashi, K; Matsui, T; Miyoshi, Y; Muraoka, K; Shingo, T; Takeuchi, A; Wenji, Y; Yano, A; Yasuhara, T, 2005
)
0.33
" When made available to rhesus monkeys (Macaca mulatta)(n = 4) for self-administration under a fixed-ratio 25 schedule, all were positive reinforcers with biphasic dose-response functions (0."( Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs.
Anderson, KG; Baumann, MH; Blough, BE; Rothman, RB; Wee, S; Woolverton, WL, 2005
)
0.55
" These include: (1) a threshold, below which there is no apparent effect; (2) the lack of a dose-response relationship, or an extremely steep dose-response curve, depending on the particular endpoint; and (3) the absence of recovery of function, such that the heavy particle-induced behavioral and neural changes are present when tested up to one year following exposure."( Heavy particle irradiation, neurochemistry and behavior: thresholds, dose-response curves and recovery of function.
Joseph, JA; Rabin, BM; Shukitt-Hale, B, 2004
)
0.32
" Stimulus-generalization curves were generated by cumulative dosing for d-amphetamine (0."( Caffeine induces differential cross tolerance to the amphetamine-like discriminative stimulus effects of dopaminergic agonists.
Holtzman, SG; Jain, R, 2005
)
0.81
" This experiment assessed the consequences of the administration of an escalating dosing regimen of amphetamine (AMPH) on attentional performance."( Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats.
Martinez, V; Parikh, V; Sarter, M, 2005
)
0.76
"Rats were trained in a sustained attention task and then treated with saline or in accordance with an escalating dosing regimen of AMPH (1-10 mg/kg)."( Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats.
Martinez, V; Parikh, V; Sarter, M, 2005
)
0.54
" Our results revealed that Sema3A was toxic to cultured DA neurons at very high dosages, but the continuous secretion of Sema3A at modest dosage in vivo did not produce Parkinsonian pathophysiologic symptoms."( Toxicity of semaphorin3A for dopaminergic neurons.
Agari, T; Borlongan, CV; Date, I; Hishikawa, T; Kameda, M; Kimura, T; Matsui, T; Miyoshi, Y; Muraoka, K; Shingo, T; Wenji, Y; Yasuhara, T,
)
0.13
" In an attempt to understand these behavioral differences at the neuronal level, the dose-response characteristics of these two psychostimulants on electrophysiologically identified VTA-DA neurons at the glutamatergic synapse were investigated."( Methylphenidate and amphetamine modulate differently the NMDA and AMPA glutamatergic transmission of dopaminergic neurons in the ventral tegmental area.
Dafny, N; Martínez-Peña, JL; Prieto-Gómez, B; Reyes-Vázquez, C; Vázquez-Alvarez, AM; Yang, PB, 2005
)
0.65
" We directly tested this possibility with human participants by varying amphetamine dosage and measuring the efficiency of cortical processing in brain regions associated with working memory."( Processing efficiency of a verbal working memory system is modulated by amphetamine: an fMRI investigation.
Cairo, TA; Liddle, PF; Ngan, ET; Phillips, AG; Tipper, CM; Woodward, TS, 2005
)
0.79
"D-amph dosage was increased cumulatively every 2 h across four scanning sessions collected in a single day."( Processing efficiency of a verbal working memory system is modulated by amphetamine: an fMRI investigation.
Cairo, TA; Liddle, PF; Ngan, ET; Phillips, AG; Tipper, CM; Woodward, TS, 2005
)
0.56
" Such a hyposensitivity did not develop after a single or multiple (at short intervals) dosing with oxotremorine (OXO), a direct muscarinic agonist, which suggests that it was not mediated by muscarinic receptors."( Behavioral sensitivity to amphetamine or scopolamine after acute administration of nicotine in the rat.
Gralewicz, S; Lutz, P, 2005
)
0.63
" In subsequent testing, dose-response curves were determined for the individual drugs, for a wide range of dose combinations of the training drugs, and for two drugs to which the pigeons had not been exposed previously (pseudoephedrine and nicotine)."( Effects of amphetamine-CNS depressant combinations and of other CNS stimulants in four-choice drug discriminations.
Li, M; McMillan, DE; Wessinger, WD, 2005
)
0.72
" In this study we assessed the utility of using dose-response properties to distinguish urine samples containing amphetamines from samples containing cross-immunoreactive species."( Differentiation of amphetamine/methamphetamine and other cross-immunoreactive sympathomimetic amines in urine samples by serial dilution testing.
Dietzen, DJ; Koenig, JW; Moyer, TP; Saunders, AN; Turk, J; Woodworth, A, 2006
)
0.87
"Use of the slope of the dose-response relationship in patient urine specimens can enhance the PPV of presumptive positive immunoassay results but does not exclude the presence of low amphetamine concentrations in samples containing high concentrations of cross-reactive species."( Differentiation of amphetamine/methamphetamine and other cross-immunoreactive sympathomimetic amines in urine samples by serial dilution testing.
Dietzen, DJ; Koenig, JW; Moyer, TP; Saunders, AN; Turk, J; Woodworth, A, 2006
)
0.85
"Animals were treated with continuous AMPH release (via osmotic mini-pumps at a dosage of 10 mg kg(-1) day(-1) for 7 days) and tested for their performance in L and PPI during withdrawal in a drug free state."( Withdrawal from continuous amphetamine administration abolishes latent inhibition but leaves prepulse inhibition intact.
Feldon, J; Peleg-Raibstein, D; Russig, H; Sydekum, E, 2006
)
0.63
" The aim of the present study was to investigate stress and AMPH- induced release of adrenocorticotropic hormone (ACTH) and corticosterone (CORT) during withdrawal from an escalating dosage schedule of AMPH known to produce depression-like effects in rats."( Amphetamine withdrawal leads to behavioral sensitization and reduced HPA axis response following amphetamine challenge.
Feldon, J; Pryce, CR; Russig, H, 2006
)
1.78
" In addition the home cage behaviour of mice administered with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) using an acute dosing regimen was also investigated."( Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
Billinton, A; Brown, M; Chapman, H; Quinn, LP; Stean, TO; Upton, N; Vidgeon-Hart, M; Virley, DJ, 2006
)
0.33
"1 mg/kg) resulted in an apparent leftward shift of the dose-response curve."( Modulation of a (+)amphetamine discriminative stimulus in rats by 8-hydroxy-2-(N,N-di-n-propylamino)tetralin (8-OH DPAT).
Bondareva, T; Glennon, RA; Wesolowska, A; Young, R, 2006
)
0.66
"5 mg/kg) were examined in the parietal cortex of rats pretreated for nine days with either saline, non-neurotoxic amphetamine, or neurotoxic AMPH dosing regimens."( A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes.
Bowyer, JF; Delongchamp, RR; Freeman, WM; O'Callaghan, JP; Patel, KM; Pogge, AR; Vrana, KE, 2007
)
0.86
" Although a number of investigations have been carried out using cathinone, the psychoactive component of khat, these may not wholly reflect the behavioral effects observed after administering khat in a dosage similar to those used traditionally."( Effect of Catha edulis foresk (khat) extracts on male rat sexual behavior.
Abdulwaheb, M; Abebe, D; Debella, A; Makonnen, E, 2007
)
0.34
" In the present experiment, prefrontal acetylcholine (ACh) release was measured in attentional task-performing and non-performing rats pretreated with an escalating dosing regimen of amphetamine (AMPH) and following challenges with AMPH."( Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats.
Brown, H; Bruno, JP; Kozak, R; Martinez, V; Sarter, M; Young, D, 2007
)
0.73
"This review of the disposition of methamphetamine in oral fluid, plasma, and urine is based on a comprehensive controlled dosing study involving five healthy, drug-free research volunteers who resided on a closed clinical ward for 12 weeks."( Methamphetamine disposition in oral fluid, plasma, and urine.
Cone, EJ; Huestis, MA, 2007
)
1.17
" It has proven superior to the open field investigations in allowing dose-response effects to be observed over a relatively short observation period (i."( Development of a home cage locomotor tracking system capable of detecting the stimulant and sedative properties of drugs in rats.
Dunne, F; Kelly, JP; O'Halloran, A, 2007
)
0.34
" We determined the dose-response relationship for amphetamine-induced psychomotor activity and Fos expression in nucleus accumbens and caudate-putamen 1 week after repeated administration of amphetamine or saline in locomotor activity chambers."( Repeated amphetamine administration outside the home cage enhances drug-induced Fos expression in rat nucleus accumbens.
Crombag, HS; Hope, BT; Kreuter, JD; Mattson, BJ; Mitchell, T; Morales, M; Simmons, DE, 2007
)
1.01
"5% (high) weekly sweat patches from the dosing week were positive for MAMP, and all patches applied after the dosing week were negative."( Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.
Barnes, AJ; Cone, EJ; Huestis, MA; Kacinko, SL; Moolchan, ET; Schwilke, EW; Smith, ML, 2008
)
0.69
" A correlation between drug-induced release and currents is also strengthened by the similar bell shape of the dose-response curves."( N,N-dimethyl-thioamphetamine and methyl-thioamphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant in vitro efficacy for the induction of transporter-mediated 5-HT release and currents.
Bonanno, G; Forray, MI; Funicello, M; Gerstbrein, K; Gobbi, M; Gysling, K; Holy, M; Mennini, T; Moya, PR; Paluzzi, S; Reyes-Parada, M; Sitte, HH; Sotomayor, R, 2008
)
0.69
" The neuronchemical index allowed to reveal the characteristic imbalance of dopamine and serotonin metabolism between the cortex and subcortical regions in the brain of August rats that, apparently, determined their stress sensitivity and clearly demonstrated the peculiarities of different amphetamine dosage effect on the animal brain neuromediator metabolism with different stress resistance."( [The influence of amphetamine on changes in the brain neuromediator metabolism].
Dovedova, EL; Khrustalev, DA; Khudoerkov, RM, 2007
)
0.85
" All three compounds decreased the [(125)I]RTI-55 B(max) value and increased the apparent K(d) value in a manner well described by a sigmoid dose-response curve."( Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release.
Ananthan, S; Dersch, CM; Pariser, JJ; Partilla, JS; Rothman, RB, 2008
)
0.57
") dosing (0."( Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose.
Hardwick, WC; Hendrickson, HP; McMillan, DE; Owens, SM, 2008
)
0.64
" The escalating amphetamine administration schedule consisted of three injections per day over a 6-day period with the dosage ranging from 1 to 8 mg/kg."( Amphetamine sensitization in rats as an animal model of schizophrenia.
Feldon, J; Knuesel, I; Peleg-Raibstein, D, 2008
)
2.13
" Overall, there is concern about risk for slowed growth in young patients who are dosed continuously, and for substance abuse in patients first medicated in late adolescence or adulthood."( Potential adverse effects of amphetamine treatment on brain and behavior: a review.
Berman, SM; Kuczenski, R; London, ED; McCracken, JT, 2009
)
0.64
"In laboratory studies, the effect of amphetamine on recovery depends on the location and extent of brain injury, the dosing and timing of amphetamine, and the type, intensity, and timing of concomitant behavioral training."( Amphetamine trials and tribulations.
Goldstein, LB, 2009
)
2.07
" Dosing regimens were based on reported or concurrently determined wake-promoting activities in canine models."( Hemodynamic and cardiac neurotransmitter-releasing effects in conscious dogs of attention- and wake-promoting agents: a comparison of d-amphetamine, atomoxetine, modafinil, and a novel quinazolinone H3 inverse agonist.
Bone, A; Fujino, N; Gilberto, D; Johnson, C; Lynch, J; Nagase, T; Regan, C; Renger, J; Sato, N; Stevens, J; Stump, G; Takenaga, N; Tannenbaum, P; Tokita, S, 2009
)
0.56
"To evaluate stimulant dosing patterns in the community treatment of children with attention-deficit/hyperactivity disorder (ADHD)."( Stimulant dosing for children with ADHD: a medical claims analysis.
Marcus, S; Olfson, M; Wan, G, 2009
)
0.35
"Among children with ADHD who continue stimulants through the first 3 months of treatment, dosing in the community treatment of ADHD tends to be lower than doses used in clinical trials."( Stimulant dosing for children with ADHD: a medical claims analysis.
Marcus, S; Olfson, M; Wan, G, 2009
)
0.35
" The poisoning dosage is 5 microg/mL in the plasma and lethal dosage is 10-40 microg/mL in the plasma according the report."( Death from accidental poisoning of methamphetamine by leaking into alimentary tract in drug traffic: a case report.
Guan, DW; Li, RB; Zhang, GH; Zhao, R; Zhu, BL, 2009
)
0.62
" Additional population-based studies that address manifestation of serious heart disease, especially after long-term use, dosage comparisons, and interactions with preexisting cardiac risk factors are needed to inform psychiatric treatment decisions."( Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
Gerhard, T; Saidi, A; Shuster, J; Winterstein, AG, 2009
)
0.62
" Amphetamine and diazepam produced an inverted U-shaped dose-response effect on different parameters of the test and demonstrate that the drug concentration which elicited a peak in mean number of entries is different from the drug concentration which elicited a peak in mean duration of entries."( Distinguishing anxiolysis and hyperactivity in an open space behavioral test.
Chazot, PL; Ennaceur, A; Michalikova, S; van Rensburg, R, 2010
)
1.27
" Seven to ten days after sensitization was complete, microdialysis of the NAcc core was performed using a cumulative dosing regimen of amphetamine (0."( Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood.
Brown, RW; Cope, ZA; Huggins, KN; Noel, DM; Roane, DS; Sheppard, AB, 2010
)
0.77
" Compared with controls, maternally separated monkeys showed lower responding during the acquisition of self-administration and in the dose-response curves for both stimulants, and significantly lower response rates during maintenance of cocaine self-administration."( Impact of early life stress on the reinforcing and behavioral-stimulant effects of psychostimulants in rhesus monkeys.
Ewing Corcoran, SB; Howell, LL, 2010
)
0.36
" The AMPH-suppressed SIP manifested again following 5-days of pretreatment with a sub-threshold dosage of AMPH (1."( Role of dopaminergic DAD1 and DAD2 receptors in the sensitization of amphetamine-suppressed schedule-induced polydipsia in rats.
Lin, PJ; Liu, YP; Tseng, CJ; Tung, CS; Wan, FJ, 2009
)
0.59
" Unfortunately, results of current ADHD pharmacogenetic studies have not been entirely consistent, possibly due to differences in study design, medication dosing regimens and outcome measures."( Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.
Froehlich, TE; McGough, JJ; Stein, MA, 2010
)
0.36
"To develop a descriptive profile of attention-deficit/hyperactivity disorder (ADHD) pharmacological treatment patterns in terms of persistence, adherence, augmentation, switching, and dosing changes; and to assess differences in treatment patterns with regard to ADHD medication type, class, and duration of action."( Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen, L; Harley, C; Hodgkins, P; Sasané, R; Tetali, S, 2010
)
0.36
" We used a conditioned place preference (CPP) paradigm to determine a dose-response curve for the behavioral effects of AMPH in female prairie voles, and found that conditioning with low to intermediate (0."( Amphetamine alters behavior and mesocorticolimbic dopamine receptor expression in the monogamous female prairie vole.
Dietz, DM; Gobrogge, KL; Kabbaj, M; Liu, Y; Wang, H; Wang, Z; Young, KA, 2011
)
1.81
" Acute amphetamine treatment in wild-type mice produced a biphasic dose-response modulation of LTP, with a low dose enhancing LTP and a high dose impairing it."( Amphetamine modulation of long-term potentiation in the prefrontal cortex: dose dependency, monoaminergic contributions, and paradoxical rescue in hyperdopaminergic mutant.
Ma, Q; Spealman, RD; Xu, TX; Yao, WD, 2010
)
2.26
"To assess the impact of a sensitizing dosage regimen of dextroamphetamine on human cortical functioning and cognition."( Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers.
Joyce, D; Murray, RM; O'Daly, OG; Shergill, SS; Stephan, KE, 2011
)
0.85
"Dextroamphetamine (20 mg) or placebo administration at 4 testing sessions, using a dosage regimen shown to induce sensitization (ie, 3 doses administered with a 48-hour interdose interval and a final dose after a 2-week washout period)."( Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers.
Joyce, D; Murray, RM; O'Daly, OG; Shergill, SS; Stephan, KE, 2011
)
1.09
" The dose-response curves were, however, different for the different behaviors."( Impulsiveness, overactivity, and poorer sustained attention improve by chronic treatment with low doses of l-amphetamine in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD).
Sagvolden, T, 2011
)
0.58
"The effects of l-amphetamine to reduce the behavioral symptoms of ADHD in the SHR were maintained over the 14 days of daily dosing with no evidence of tolerance developing."( Impulsiveness, overactivity, and poorer sustained attention improve by chronic treatment with low doses of l-amphetamine in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD).
Sagvolden, T, 2011
)
0.92
" Complete dose-response functions for the effects of the drugs on food pellet intake on days that candy was not available were determined before, during, and after the period of access to candy."( Consumption of palatable food decreases the anorectic effects of serotonergic, but not dopaminergic drugs in baboons.
Foltin, RW, 2011
)
0.37
" To examine further if NF-κB was involved, intracerebroventricular infusion of NF-κB antisense oligonucleotide was performed 1 h before the daily AMPH dosing in freely moving rats."( NF-κB knockdown can modulate amphetamine-mediated feeding response.
Chen, CH; Chen, PN; Chu, SC; Hsieh, YS; Kuo, DY; Kuo, MH, 2012
)
0.67
" Dose-response assessments demonstrated that rats housed in EE showed reduced sensitivity to the behavioural effects of DZP and DMI but increased sensitivity to the locomotor-enhancing effects of AMP compared to SC and IC; while IC animals exhibited the clearest dose-response effects to increasing doses of DMI."( The effects of isolated and enriched housing conditions on baseline and drug-induced behavioural responses in the male rat.
Kelly, JP; Simpson, J, 2012
)
0.38
" In seeking to optimize individual response and outcomes to stimulant therapy, important considerations include the selection of stimulant class, the choice of long- or short-acting stimulant formulations, addressing effectively any emergent adverse effects and strategies aimed at enhancing adherence to dosing regimen and persistence on therapy."( Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options.
Coghill, D; Hechtman, L; Hodgkins, P; Shaw, M, 2012
)
0.38
" A lower dosage (0,1 mg/kg) of haloperidol did not affect the results of the research."( [Effect of haloperidol on changes in development of spontaneous catalepsy during subchronic injections of dopamine agonists and antagonists].
Kozlovskiĭ, VL,
)
0.13
" Relative to saline, all amphetamine doses induced head movements above pre-injection levels, revealing an inverted U-shaped dose-response function."( Amphetamine's dose-dependent effects on dorsolateral striatum sensorimotor neuron firing.
Barker, DJ; Cho, J; Ma, S; Pawlak, AP; Root, DH; West, MO, 2013
)
2.14
" Dosing of olanzapine was established based on inhibition of amphetamine-induced locomotion."( Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model.
Arenovich, T; Chintoh, A; Cohn, T; Fletcher, P; Giacca, A; Guenette, M; Hahn, MK; Lam, L; Mann, S; Nobrega, J; Remington, G; Teo, C, 2014
)
0.64
" The secondary aims were to investigate a possible dose-response CPP and whether the synthetic cathinones induce higher CPP than amphetamine at equal dose."( Mephedrone, methylone and 3,4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice.
Andersson, M; Karlsson, L; Kronstrand, R; Kugelberg, FC, 2014
)
0.61
" Patterns of medication selection and dosing were compared with CMAP guidelines."( Treatment receipt and outcomes from a clinic employing the attention-deficit/hyperactivity disorder treatment guideline of the children's medication algorithm project.
McLennan, JD; Vallerand, IA; Wagner, DJ, 2014
)
0.4
"In experiments I and II, a dose-response curve for AMPH-induced 50-kHz USV was established, and the partial dependency of AMPH-induced 50-kHz USV on DA neurotransmission was validated by pretreatment with the D2-antagonist eticlopride."( Critical involvement of 5-HT2C receptor function in amphetamine-induced 50-kHz ultrasonic vocalizations in rats.
Rippberger, H; Schwarting, RK; van Gaalen, MM; Wöhr, M, 2015
)
0.67
" Dosing frequency of amphetamine was associated with its impact on sexual functions, but duration of its use had little association with that."( The Impact of Illicit Use of Amphetamine on Male Sexual Functions.
Chou, NH; Huang, YJ; Jiann, BP, 2015
)
1.03
" Relative to vehicle, SHR and WIS with adolescent d-amphetamine treatment self-administered less cocaine upon reaching acquisition criteria, and WIS additionally acquired cocaine self-administration more slowly and had downward shifts in FR and PR cocaine dose-response curves."( Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood.
Dwoskin, LP; Jordan, CJ; Kantak, KM; Lemay, C, 2016
)
1.05
"Primary outcome measures were (i) the percentage of samples purchased on-line and (ii) the chemical purity of powders (or dosage per tablet); adulteration; and the price per gram, blotter or tablet of drugs bought on-line compared with drugs bought off-line."( Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands.
Brunt, TM; van der Gouwe, D; van der Pol, P; van Laar, M, 2017
)
0.46
" We therefore assessed dose-response effects of amphetamine (0."( Effects of amphetamine on pro-social ultrasonic communication in juvenile rats: Implications for mania models.
Engelhardt, KA; Fuchs, E; Schwarting, RKW; Wöhr, M, 2017
)
1.1
" were less impulsive) with a higher rate of nose poking during the delay, and exhibited a compressed dose-response function (i."( 'Waiting impulsivity' in isolation-reared and socially-reared rats: effects of amphetamine.
Liu, YP; Robbins, TW; Wilkinson, LS, 2017
)
0.68
" A family of solutions was found, characterized by a biphasic dose-response relationship for rate of dopamine release."( Extracellular dopamine kinetic parameters consistent with amphetamine effects.
Felmer, AC; Janson, MT; Summers, KE; Wallace, LJ, 2019
)
0.76
" However, further studies are needed to provide more robust evidence on efficacy, dosage and safety for this population."( Amphetamine Use in the Elderly: A Systematic Review of the Literature.
Colpo, GD; John, V; Rocha, NP; Sassi, KLM; Teixeira, AL, 2020
)
2
"25 at study level) and amphetamine/methamphetamine urinary concentration ratios (AAFE < 2 at individual level) after dosing methamphetamine."( Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine.
Czuba, LC; Huang, W; Isoherranen, N, 2020
)
1.09
" The objective of the present study was to replicate these two latter observations using an amphetamine dosing regimen that yields only minor depletions of dopamine."( The effect of ascorbic acid pretreatment on amphetamine-induced dopamine depletion in male and female mice.
Gifford, JJ; Wagner, GC, 2020
)
1.04
" Mechanistically, amphetamine downregulates presynaptic and postsynaptic striatal monoamine (primarily dopaminergic) systems, producing alterations to key brain regions which manifest as stereotyped ridged behaviour which occurs under both acute and chronic dosing schedules and persists beyond detoxification."( Amphetamine-induced alteration to gaze parameters: A novel conceptual pathway and implications for naturalistic behavior.
Downey, LA; Hayley, AC; Shiferaw, B, 2021
)
2.4
" An optimized dose-response curve is then presented, introducing (±) amphetamine hydrochloride (0."( A Molecularly Imprinted Polymer-based Dye Displacement Assay for the Rapid Visual Detection of Amphetamine in Urine.
Arreguin-Campos, R; Caldara, M; Cleij, TJ; Diliën, H; Eersels, K; Heidt, B; Jimenez-Monroy, KL; Lowdon, JW; Rogosic, R; van Grinsven, B, 2020
)
1.01
" Subsequent dose-response testing showed clear differences in potency of the compounds."( Reinforcing effects of phenethylamine analogs found in dietary supplements.
Baumann, MH; Chojnacki, MR; McGriff, SA; Rice, KC; Schindler, CW; Thorndike, EB, 2022
)
0.72
" It is important that future research addresses the current weaknesses in this area, which include small sample sizes, variability of selection criteria, variability of the type and dosage of supplementation, and short follow-up times."( Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Gillies, D; Leach, MJ; Perez Algorta, G, 2023
)
0.91
" Intriguingly, lithium orotate (LiOr) is suggested to possess unique uptake characteristics that would allow for reduced dosing and mitigation of toxicity concerns."( Different pharmacokinetics of lithium orotate inform why it is more potent, effective, and less toxic than lithium carbonate in a mouse model of mania.
Bekar, LK; Pacholko, AG, 2023
)
0.91
" To this aim, we conducted a dose-response study in male rats and assessed AMPH-induced hyperactivity and 50-kHz ultrasonic calling in the sender and social approach behavior evoked by playback of pro-social 50-kHz USV in the receiver."( Acute anxiogenic effects of escitalopram are associated with mild alterations in D-amphetamine-induced behavior and social approach evoked by playback of 50-kHz ultrasonic vocalizations in rats.
Schwarting, RKW; Willadsen, M; Wöhr, M, 2023
)
1.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
primary amineA compound formally derived from ammonia by replacing one hydrogen atom by a hydrocarbyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 3Rattus norvegicus (Norway rat)IC50 (µMol)42.00004.90006.65008.4000AID682029
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki18.25000.00020.667710.0000AID4761; AID5000; AID5270; AID5725
Phenylethanolamine N-methyltransferaseBos taurus (cattle)IC50 (µMol)0.96000.96005.32008.0000AID1145574
Phenylethanolamine N-methyltransferaseBos taurus (cattle)Ki740.00000.00312.329310.0000AID145544; AID145546
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)3.50000.00443.889510.0000AID241172
Substance-P receptorRattus norvegicus (Norway rat)Ki10.00000.00070.12981.0000AID5000
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki18.25000.00010.601710.0000AID1442363; AID5000; AID5270; AID5535
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki7.66000.00010.739610.0000AID3695
Cytochrome P450 2A5Mus musculus (house mouse)IC50 (µMol)2.85001.00004.20259.7051AID241174
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.96000.00070.97749.7000AID1145574
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki7.66000.00031.29679.2440AID3695
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Ki7.66000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Ki7.66000.00101.67479.2000AID3695
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki26.50000.00020.590910.0000AID5000; AID5270
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki10.00000.00000.338510.0000AID1442363
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.96000.00040.16800.9772AID1145574
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki50.00000.00030.26715.0700AID204015
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd5.37030.00042.58328.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd5.37030.00012.62198.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd5.37030.00012.29338.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Kd5.37030.02342.74218.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Kd5.37030.02342.74218.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Kd5.37030.02342.74218.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd5.37030.00042.47358.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Kd5.37030.02342.74218.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Kd5.37030.00012.70068.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Kd5.37030.02342.74218.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Kd5.37030.02342.74218.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Kd5.37030.00082.62148.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Kd5.37030.02342.74218.5114AID6404; AID6406; AID6407
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Kd5.37030.00082.62148.5114AID6404; AID6406; AID6407
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
methylationPhenylethanolamine N-methyltransferaseBos taurus (cattle)
epinephrine biosynthetic processPhenylethanolamine N-methyltransferaseBos taurus (cattle)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
phenylethanolamine N-methyltransferase activityPhenylethanolamine N-methyltransferaseBos taurus (cattle)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (95)

Assay IDTitleYearJournalArticle
AID118791Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 20 mg/kg i1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID734186Inhibition of UBR protein in rabbit reticulocyte lysates assessed as inhibition of Tyr-nsP4 substrate degradation measuring substrate half life at 2 mM2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Development and characterization of monomeric N-end rule inhibitors through in vitro model substrates.
AID1133355Stimulation of dopamine receptor in Sprague-Dawley rat assessed as reduction in Dopa accumulation in at 1 mg/kg, sc by spectrofluorimetry1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pivaloyl esters of N,N-dialkylated dopamine congeners. Central dopamine-receptor stimulating activity.
AID227926Equilibrium constant for DNB complex formation1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID1135982Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]5-HT accumulation in hypothalamus after 0.5 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID188591Number of rats responding out of 5 treated rats at a dose of 3 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1145573Inhibition of [3H]norepinephrine uptake at NET expressed in rat hypothalamic homogenate containing synaptosomes after 5 mins by scintillation counting analysis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Conformationally rigid amphetamine analogs as inhibitors of monoamine uptake by brain synaptosomes.
AID5299Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID6406Affinity against 5-hydroxytryptamine receptors in rat fundus model1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Serotonin receptor affinities of psychoactive phenalkylamine analogues.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID175573Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 3 mg/kg; Disruption behavior1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID1201568Toxicity in NMRI mouse assessed as induction of exophtalmy at 2 mg/kg, ip2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
AID111358Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.04 mmol/kg)1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID682029TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in OCT3-expressing HRPE cells1998The Journal of biological chemistry, Dec-04, Volume: 273, Issue:49
Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID682271TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Amphetamine: 5000 uM) in OCTN2-expressing HeLa cells1998Biochemical and biophysical research communications, May-29, Volume: 246, Issue:3
cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family.
AID173392Behavioral stimulant activity in rat by sc administration; Slight to moderate CNS stimulation1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis of exo-3-phenylbicyclo[3.2.1]oct-3-en-2-amine and related compounds as potential analgesics.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID111357Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.02 mmol/kg)1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID118787Retention for passive avoidance learning in mice at dose 1.25 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID734192Inhibition of UBR protein in rabbit reticulocyte lysates assessed as inhibition of Tyr-nsP4 substrate degradation at 2 mM by immunoblotting analysis in presence of bestatin2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Development and characterization of monomeric N-end rule inhibitors through in vitro model substrates.
AID1135981Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]NA accumulation in hypothalamus after 0.5 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID178670Antinociceptive activity by measuring in flamed paw pressure threshold in rat1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis of exo-3-phenylbicyclo[3.2.1]oct-3-en-2-amine and related compounds as potential analgesics.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID5535Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID145543Inhibitory activity against Norepinephrine N-methyl-transferase of bovine adrenal glands1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Importance of the aromatic ring in adrenergic amines. 7. Comparison of the stereoselectivity of norepinephrine N-methyltransferase for aromatic vs. nonaromatic substrates and inhibitors.
AID1210823Selectivity for OCT2 (unknown origin) over OCT1 (unknown origin)2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID145546The inhibitory constant(Ki) value for Norepinephrine N-methyl-transferase was calculated1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Directional probes of the hydrophobic component of the aromatic ring binding site of norepinephrine N-methyltransferase.
AID1692387Hypnotic activity in mouse assessed as phenobarbital induced sleep endurance time at 2 mg/kg, sc administered 30 mins prior to phenobarbital challenge and measured for 30 mins (Rvb = 27.4 +/- 2.3 min)2020European journal of medicinal chemistry, Aug-15, Volume: 200Design, synthesis and biological evaluation of 7-substituted 4-phenyl-6H-imidazo[1,5-a]thieno[3,2-f] [1,4]diazepines as safe anxiolytic agents.
AID1136001Induction of hyperactivity in NMRI albino mouse at 2.5 mg/kg, ip in presence of alpha-methyltyrosine1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1145574Inhibition of [3H]dopamine uptake at dopamine transporter expressed in rat striatal homogenate after 5 mins by scintillation counting analysis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Conformationally rigid amphetamine analogs as inhibitors of monoamine uptake by brain synaptosomes.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID23503Partition coefficient (logP)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID5000Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID111355Stimulation of spontaneous locomotor activity of compound was measured in mice at a dose of 0.01 mmol/kg)1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID5270Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID188589Number of rats responding out of 5 treated rats at a dose of 2 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1201569Toxicity in NMRI mouse assessed as induction of irritability at 2 mg/kg, ip2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
AID6407Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Serotonin receptor affinity of cathinone and related analogues.
AID129302Antinociceptive activity by measuring inhibition of acetylcholine writhing in mouse1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis of exo-3-phenylbicyclo[3.2.1]oct-3-en-2-amine and related compounds as potential analgesics.
AID173388Behavioral stimulant activity in rat by sc administration; Marked CNS stimulation1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis of exo-3-phenylbicyclo[3.2.1]oct-3-en-2-amine and related compounds as potential analgesics.
AID241172Inhibitory concentration against human cytochrome P450 2A62005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID1135983Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]DA accumulation in hypothalamus after 0.5 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1135984Potentiation of 5-HTP-induced head twitches in ip dosed NMRI albino mouse administered 1 hr prior to 5-HTP challenge1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1136504Inhibition of PNMT in rabbit adrenal gland using norepinephrine as substrate1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
A manual method for applying the Hansch approach to drug design.
AID3696Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID188587Number of rats responding out of 5 treated rats at a dose of 1.5 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID167866Hyperthermic potency in rabbit relative to DOM1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID3695Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID1136000Induction of hyperactivity in NMRI albino mouse at 2.5 mg/kg, ip in presence of pimozide1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681708TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Amphetamine: 2500 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID118788Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 10 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID4761Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
AID738999Pshychostimulant activity in gerbil assessed as increase in spontaneous locomotor activity at 5 mg/kg, ip after 30 mins2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
AID1442363Displacement of [3H]ketanserin from rat 5HT2A expressed in mouse NIH/3T3 cell membranes after 30 mins by scintillation counting method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID118789Retention for passive avoidance learning in mice at dose 2.5 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1135979Inhibition of noradrenaline transporter in NMRI albino mouse brain assessed as [3H]NA accumulation in hypothalamus after 5 mins1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID175419Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 1 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID175568Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 2 mg/kg; Disruption behavior1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID122556Modification of circling behavior in mice with unilateral striatal lesions produced by 6-hydroxydopamine injection was measured at a dose of 0.027 mmol/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution.
AID5798Affinity against serotonergic receptor in the isolated rat stomach fundus1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID234846Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues.
AID1201567Toxicity in NMRI mouse assessed as induction of hyperactivity at 2 mg/kg, ip2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID241174Inhibitory concentration against mouse cytochrome P450 2A52005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID1135980Inhibition of 5-HT transporter in NMRI albino mouse brain assessed as [3H]5-HT accumulation in hypothalamus after 5 mins1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID188586Number of rats responding out of 5 treated rats at a dose of 1 mg/Kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID204015Binding affinity towards sigma opioid receptor was determined in rat cerebral homogenate using [3H]haloperidol as radioligand1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Identification and exploitation of the sigma-opiate pharmacophore.
AID64045-hydroxytryptamine receptor binding affinity was determined in rats1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID145544Inhibitory activity against bovine adrenal norepinephrine N-methyl-transferase was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Probes of the active site of norepinephrine N-methyltransferase: effect of hydrophobic and hydrophilic interactions on side-chain binding of amphetamine and alpha-methylbenzylamine.
AID175420Dose required to produce 50% hallucinogenic potency in rat was determined at a dose of 1.5 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Behavioral and serotonin receptor properties of 4-substituted derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane.
AID5725Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12,114)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906249 (51.58)18.7374
1990's1707 (14.09)18.2507
2000's1992 (16.44)29.6817
2010's1687 (13.93)24.3611
2020's479 (3.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 109.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index109.93 (24.57)
Research Supply Index9.50 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index210.72 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (109.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials329 (2.52%)5.53%
Reviews699 (5.35%)6.00%
Case Studies252 (1.93%)4.05%
Observational9 (0.07%)0.25%
Other11,782 (90.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (89)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2) [NCT05011760]Early Phase 130 participants (Anticipated)Interventional2021-01-31Recruiting
An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression [NCT04235686]Phase 290 participants (Anticipated)Interventional2020-07-17Recruiting
Adaptive Response to Intervention (RTI) for Students With ADHD [NCT03511976]Phase 4300 participants (Anticipated)Interventional2018-05-14Recruiting
A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users With Stimulant Experience, Under Fed Con [NCT03200080]Phase 126 participants (Actual)Interventional2017-09-18Terminated(stopped due to New Safety Information)
A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the CNS After Single-Dose Oral Administration [NCT02959892]Phase 112 participants (Actual)Interventional2016-12-05Completed
A Sequenced Behavioral and Medication Intervention for Cocaine Dependence [NCT01986075]Phase 1/Phase 2145 participants (Actual)Interventional2014-01-31Completed
Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants [NCT03893032]Phase 280 participants (Anticipated)Interventional2019-07-17Recruiting
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]5,000 participants (Anticipated)Observational2020-03-05Recruiting
A Randomized, Double-Blind, Double-Dummy, Placebo-, Active-Controlled, 4 Period, 4 Way Crossover Study to Evaluate the Abuse Potential of Manipulated Abuse-Deterrent Dextroamphetamine Sulfate Immediate Release (ADAIR) Formulation Compared to Dextroampheta [NCT04647903]Phase 155 participants (Actual)Interventional2020-10-05Completed
Exploration of Mechanisms of Effects of Prenatal Cocaine Exposure in Young Adults [NCT03606473]Early Phase 113 participants (Actual)Interventional2018-01-24Completed
Effect of D-amphetamine on Reward Functioning [NCT03369015]Phase 168 participants (Actual)Interventional2018-01-24Completed
2/2 Treating Mothers With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial [NCT04240756]Phase 3240 participants (Anticipated)Interventional2020-08-06Recruiting
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder [NCT04170738]Phase 444 participants (Anticipated)Interventional2019-11-05Recruiting
[NCT02144415]Phase 180 participants (Actual)Interventional2014-05-31Completed
Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder [NCT02210728]200 participants (Anticipated)Interventional2006-04-30Active, not recruiting
A Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) [NCT00151996]Phase 275 participants (Actual)Interventional2004-08-16Completed
Targeting Anhedonia in Cocaine Use Disorder - Treatment Study [NCT02773212]Phase 280 participants (Anticipated)Interventional2017-02-01Recruiting
Imaging of Cortical Dopamine Transmission in Cocaine Dependence [NCT03349606]Early Phase 130 participants (Anticipated)Interventional2010-06-02Completed
Randomized Study to Evaluate Strategies to Address Cognitive Fog in Long-COVID-19 Patients [NCT05597722]Phase 47 participants (Actual)Interventional2023-04-04Terminated(stopped due to Due to the evolving nature of COVID-related cognitive fog, it was determined that the study would be terminated at this time. The team agreed that it isn't feasible to collect enough data to evaluate the efficacy of the treatments.)
The Reinforcing Mechanisms of Smoking in Adult ADHD [NCT00573859]Phase 1/Phase 227 participants (Actual)Interventional2006-09-30Completed
A Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of AR19 (Amphetamine Sulfate) in Adult Subjects (Ages 18-55) With Attention Deficit Hyperactivity Disorder (ADHD) [NCT03659929]Phase 3320 participants (Actual)Interventional2018-09-13Completed
A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo- and Active-Controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder [NCT00928148]Phase 286 participants (Actual)Interventional2004-06-14Completed
Double-blind Trial of Acute and Intermediate-term Dextro-amphetamine Versus Caffeine Augmentation in Treatment Resistant Obsessive Compulsive Disorder (OCD) [NCT00363298]24 participants (Actual)Interventional2006-08-31Completed
A Randomized, Double-Blind, Single-Site Phase II 2-Arm Study to Compare the Safety and Preliminary Efficacy of Manualized MDMA-Assisted Therapy to Low Dose D-Amphetamine Assisted Therapy in Veterans For The Treatment of Moderate to Severe PTSD [NCT05790239]Phase 240 participants (Anticipated)Interventional2023-10-31Not yet recruiting
A Phase I, Open-Label, Randomized, Four Period Crossover Drug Interaction Study to Evaluate the Pharmacokinetic Profiles of VYVANSE™ and ADDERALL XR When Each is Administered Alone and in Combination With the Proton Pump Inhibitor Prilosec OTC™ in Healthy [NCT00746733]Phase 124 participants (Actual)Interventional2008-09-08Completed
Endocrine and Emotional Effects of Lisdexamfetamine and d- Amphetamine: a Placebo-controlled Study in Healthy Subjects (LisDexStudy) [NCT02668926]Phase 124 participants (Actual)Interventional2016-05-31Completed
Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine, a Post-authorization Safety Study [NCT04132557]430,000 participants (Actual)Observational2019-10-09Completed
Neurobiological Principles Applied to the Rehabilitation of Stroke Patients [NCT00715520]33 participants (Actual)Interventional2007-04-30Completed
A Cognitive Behavioral Therapy Group Intervention for Adolescents With Attention-Deficit / Hyperactivity Disorder [NCT02566824]Phase 4216 participants (Anticipated)Interventional2010-10-31Recruiting
A Pilot, Randomized, Double-Blind, Active-Controlled, 2-Treatment, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Abuse Liability of Dextroamphetamine Sulfate From an Abuse-Deterrent Immediate-Release Formulation (ADAIR) [NCT04232644]Phase 116 participants (Actual)Interventional2019-05-27Completed
Smoked Marijuana Discrimination and Marijuana Choice in Humans: A Laboratory Mode [NCT00943930]29 participants (Actual)Observational2009-04-30Completed
The Relative Efficacy of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) Versus Medication Only and the Combination of the Two: A Pilot Study [NCT02788851]70 participants (Anticipated)Interventional2016-04-30Active, not recruiting
A Phase I, Randomized, Double Blind, Three-Period Crossover, Estimation Study Using Lisdexamfetamine Dimesylate, Immediate Release Mixed Amphetamine Salts and Placebo to Evaluate the Utility of a Standardized Computer Battery of Tests in Adults With Atten [NCT01010750]Phase 118 participants (Actual)Interventional2010-01-05Completed
A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). [NCT00152022]Phase 3412 participants Interventional2005-04-25Completed
Sleep and Tolerability of Extended Release Dexmethylphenidate vs. Mixed Amphetamine Salts: A Double Blind, Placebo Controlled Study (SAT STUDY) [NCT00393042]Phase 377 participants (Actual)Interventional2006-01-31Completed
A CTSC Clinical Research Center Study: A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine [NCT00314340]Phase 412 participants (Actual)Interventional2005-11-30Completed
Amphetamine-Enhanced Stroke Recovery [NCT01905371]Phase 299 participants (Actual)Interventional2001-04-30Completed
A Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Treatment, 3-Period, Crossover Study With One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR, or Placebo in Children Aged 6 to 12 Years With Attention-Deficit H [NCT00557011]Phase 252 participants (Actual)Interventional2004-09-30Completed
General Evaluation of Eligibility for Substance Abuse/Dependence Research [NCT00439049]7,500 participants (Anticipated)Observational2005-10-31Recruiting
Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder [NCT02478788]Phase 4153 participants (Actual)Interventional2015-11-30Completed
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents With ADHD [NCT01711021]Phase 2110 participants (Actual)Interventional2012-10-31Completed
Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications [NCT00697138]Phase 146 participants (Actual)Interventional2006-06-30Completed
A Phase III, Randomized, Double-blind, Multi-center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). [NCT00150579]Phase 3240 participants Interventional2005-01-27Completed
A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With ADDERALL XR and STRATTERA Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With Attention Deficit Hyperactivity Disorder (ADHD [NCT00557960]Phase 336 participants (Actual)Interventional2004-02-25Completed
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years With Attention-deficit/Hyperactivity Disorder [NCT03610464]Phase 45 participants (Actual)Interventional2018-05-07Completed
A Randomized, Double-Blind, Parallel-Group, Analog Classroom Study, Evaluating ADDERALL XR Versus STRATTERA, Dosed Once Daily, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) [NCT00506727]Phase 4215 participants (Actual)Interventional2003-08-05Completed
A Phase III, Randomized, Multicenter, Double-blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of ADDERALL XR With an Open Label Extension, in the Treatment of Adolescents Aged 13-17 With ADHD [NCT00507065]Phase 3329 participants (Actual)Interventional2003-05-28Completed
Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder [NCT00228046]Phase 440 participants (Anticipated)Interventional2004-01-31Completed
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD [NCT03834766]Phase 3130 participants (Actual)Interventional2019-02-06Completed
A Phase II, Randomized, Double-Blind, Multi-center, Placebo-controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) [NCT00202605]Phase 272 participants Interventional2005-09-29Completed
Pharmacotherapy for Cocaine Dependence - 1 [NCT00218348]Phase 2186 participants (Actual)Interventional2003-09-30Completed
Reading ICARD: Interventions for Children With Attention and Reading Disorders [NCT01133847]Phase 4222 participants (Actual)Interventional2010-11-30Completed
Adderall-XR Versus Concerta For Cancer Treatment-Related Neurocognitive Sequelae And Depression In Pediatric Patients: A Randomized Phase II Study [NCT00069927]Phase 212 participants (Actual)Interventional2003-08-31Terminated(stopped due to Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility)
A Phase III, Multi-center, 12-month, Open-label Safety Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). [NCT00152035]Phase 3505 participants (Actual)Interventional2005-03-10Completed
WAKIX® (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring [NCT05536011]1,329 participants (Anticipated)Observational [Patient Registry]2021-08-24Recruiting
Experiment 1: Adenosine Receptor A2A Antagonists and Cocaine Dependence [NCT00733993]Phase 1/Phase 223 participants (Actual)Interventional2008-04-30Completed
Driving Performance in Patients Aged 18 to 25 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) After a Single-Dose of Amphetamine Extended-Release Tablets: A Pilot, Double-Blind, Placebo-Controlled Study [NCT04027361]Phase 241 participants (Actual)Interventional2019-10-01Completed
A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended Release (Adderall XR) in Children and Adolescents With ADHD [NCT00889915]Phase 4228 participants (Actual)Interventional2009-04-30Completed
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis [NCT02634684]Phase 282 participants (Actual)Interventional2014-07-01Completed
Stimulant Enhancement of Well-Being Therapy for Depression [NCT01478113]5 participants (Actual)Interventional2012-02-29Terminated(stopped due to PI left the institution and was no funding to continue study.)
Impact of Combined Medication and Behavioral Treatment in Young Children With Comorbid ASD and ADHD [NCT03242772]Phase 218 participants (Actual)Interventional2018-12-14Terminated(stopped due to The study stopped recruitment of new participants due to COVID. A substudy was developed with adaptations to the main design.)
A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence [NCT00553319]Phase 2/Phase 3139 participants (Actual)Interventional2007-12-31Completed
[NCT01740206]50 participants (Actual)Interventional2012-11-30Completed
Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer [NCT02383043]Early Phase 118 participants (Actual)Interventional2015-02-01Completed
Neurobehavioral Mechanisms of Cocaine Choice [NCT04296006]Early Phase 118 participants (Anticipated)Interventional2021-01-15Recruiting
Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder [NCT05916339]Phase 4500 participants (Anticipated)Interventional2023-10-01Not yet recruiting
Dextroamphetamine as an Adjunct in Cocaine Treatment [NCT00000304]Phase 2120 participants (Actual)Interventional1997-08-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Adjunctive, Flexible-Dose Mixed Salts Amphetamine in Adult Outpatients With Major Depressive Disorder (MDD) Responding Inadequately to Current Antidepressant Therapy [NCT02058693]Phase 441 participants (Actual)Interventional2010-12-31Completed
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With DESR Traits: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial [NCT01399827]Phase 22 participants (Actual)Interventional2012-02-29Completed
Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls [NCT02203786]Phase 260 participants (Actual)Interventional2009-09-30Completed
D-amphetamine-Cocaine Behavioral Intervention [NCT00000308]Phase 254 participants (Actual)Interventional1995-09-30Completed
Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers [NCT02348385]49 participants (Actual)Observational2012-12-31Completed
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder [NCT02803229]Phase 2/Phase 333 participants (Actual)Interventional2016-07-31Completed
Hypomania, Amphetamine, and Preferences for Sweets [NCT03810703]Phase 193 participants (Actual)Interventional2017-02-09Completed
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit [NCT03088267]Phase 318 participants (Actual)Interventional2017-02-11Completed
Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion [NCT01699607]10 participants (Actual)Interventional2012-06-30Completed
A Preliminary Investigation of Individual Differences in Subjective Responses to D-amphetamine, Alcohol, and Delta-9-tetrahydrocannabinol [NCT02485158]28 participants (Actual)Interventional2013-07-31Completed
Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines [NCT03772314]Phase 244 participants (Actual)Interventional2019-04-15Completed
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Study of Stimulant-induced Dopamine Release Using [11C]-PHNO PET in Healthy Humans [NCT03103750]Phase 124 participants (Actual)Interventional2017-08-15Completed
Pharmacotherapy Dosing Regimen (Cocaine Dependence Population) [NCT00218062]Phase 273 participants (Actual)Interventional2006-03-31Completed
Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing [NCT03019822]Early Phase 128 participants (Actual)Interventional2017-02-01Completed
High Incidence of Adult Respiratory Distress Syndrome Associated With Amphetamine Use in the Burn Population [NCT05611385]49 participants (Actual)Observational2019-01-01Completed
Monoamine Contributions to Neurocircuitry in Eating Disorders [NCT02020408]Phase 488 participants (Actual)Interventional2011-05-31Completed
Dopaminergic Neuromodulation of Decision Making in Young and Middle-Aged Adults [NCT03512171]Phase 165 participants (Actual)Interventional2016-03-31Completed
A Pilot Study of Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and Deficits in Emotional Self-Regulation [NCT02204410]Phase 421 participants (Actual)Interventional2014-07-31Completed
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study [NCT02083783]Phase 3108 participants (Actual)Interventional2014-03-31Completed
A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) With ADHD in a Laboratory Classroom [NCT01986062]Phase 497 participants (Actual)Interventional2013-12-31Completed
A Randomized, Placebo- and Comparator-controlled, Double-blind, Multiple (Ascending) Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Subjects [NCT02515955]Phase 176 participants (Actual)Interventional2015-08-31Completed
Stimulant Medication Effects on Auditory Sensitivity and Acoustic Reflex in Adolescents With ADHD [NCT04577417]70 participants (Actual)Observational2020-09-13Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00151996 (5) [back to overview]Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) Total Score at 6 Weeks
NCT00151996 (5) [back to overview]Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Total Score at 6 Weeks
NCT00151996 (5) [back to overview]Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
NCT00151996 (5) [back to overview]Number of Participants With Improvement on Parent Global Assessment (PGA) Scores
NCT00151996 (5) [back to overview]Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF50) Scores at 6 Weeks
NCT00218062 (5) [back to overview]Retention as Indicated by the Number of Participants Who Completed 16 Weeks of Treatment
NCT00218062 (5) [back to overview]Medication Compliance as Indicated by Percentage of Riboflavin-positive Urine Samples
NCT00218062 (5) [back to overview]Medication Compliance as Indicated by Percentage of Pills Taken According to Self-report
NCT00218062 (5) [back to overview]Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment
NCT00218062 (5) [back to overview]Retention as Indicated by the Number of Participants Who Remained in the Study
NCT00314340 (1) [back to overview]3 Scores on the Addiction Research Center Inventory (ARCI)
NCT00363298 (2) [back to overview]Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2
NCT00363298 (2) [back to overview]Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score
NCT00393042 (6) [back to overview]Weiss Functional Impairment Rating Scale (WFIRS)
NCT00393042 (6) [back to overview]Sleep Start Time, and End Time as Determined by Actigraph and Sleep Diary Over 8 Weeks.
NCT00393042 (6) [back to overview]Dopamine Active Transporter (DAT) 1 Gene Type Effects on ADHD Symptoms
NCT00393042 (6) [back to overview]ADHD Parent Rating Scale-IV
NCT00393042 (6) [back to overview]Sleep Duration
NCT00393042 (6) [back to overview]Clinical Global Impression - Severity
NCT00553319 (2) [back to overview]Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use
NCT00553319 (2) [back to overview]ADHD Symptoms Based on ADHD Rating Scale
NCT00573859 (3) [back to overview]The Interacting Effects of Smoking and Overnight Abstinence With ADHD Medication and Placebo on Continuous Performance Task (CPT) Errors of Omission.
NCT00573859 (3) [back to overview]The Effects of ADHD Medication Versus Placebo on Cotinine Levels
NCT00573859 (3) [back to overview]The Interacting Effects of Smoking and Abstinence With ADHD Medication and Placebo on Nicotine Withdrawal Measured by the Shiffman-Jarvik Withdrawal Questionnaire.
NCT00715520 (6) [back to overview]Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) for rTMS Treatment With Respect to Frequency
NCT00715520 (6) [back to overview]Aim 1: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)
NCT00715520 (6) [back to overview]Aim 1: Mean Peak Acceleration of Wrist Extension Movements
NCT00715520 (6) [back to overview]Aim 2: Mean Peak Acceleration for rTMS Treatment With Respect to Frequency
NCT00715520 (6) [back to overview]Aim 2: Mean Peak Acceleration of Wrist Extension Movements With Respect to Pulse
NCT00715520 (6) [back to overview]Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) With Respect to Pulse
NCT00733993 (7) [back to overview]Systolic and Diastolic Blood Pressure
NCT00733993 (7) [back to overview]Saliva Caffeine and Paraxanthine Levels
NCT00733993 (7) [back to overview]Heart Rate
NCT00733993 (7) [back to overview]Drug Effects Questionnaire Rating of Subjective Ratings of Drug Effects
NCT00733993 (7) [back to overview]Probabalistic Feedback Selection Task
NCT00733993 (7) [back to overview]Addiction Research Center Inventory Subjective Rating of Drug Effects
NCT00733993 (7) [back to overview]Visual Analog Scale Subjective Rating of Drug Effects
NCT00746733 (19) [back to overview]Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Systolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Pulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Electrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Drug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.
NCT00746733 (19) [back to overview]DRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]DRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Diastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
NCT00746733 (19) [back to overview]Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
NCT00889915 (3) [back to overview]Clinical Global Improvements-Acceptability (CGI-A) Scale
NCT00889915 (3) [back to overview]Dichotomized Clinical Global Impression-Effectiveness (CGI-E) Scale
NCT00889915 (3) [back to overview]Clinical Global Impressions-Improvement (CGI-I) Scale
NCT01010750 (6) [back to overview]CAARS-S:S Subscale T-Score: Impulsivity/Emotional Liability
NCT01010750 (6) [back to overview]Conners Adult ADHD Rating Scales-Self Report: Short Version (CAARS-S:S) Subscale Total Score (T-Score): Inattention/Memory Problems
NCT01010750 (6) [back to overview]Power of Attention Score
NCT01010750 (6) [back to overview]CAARS-S:S Subscale T-Score: Hyperactivity/Restlessness
NCT01010750 (6) [back to overview]CAARS-S:S Subscale T-Score: Attention Deficit Hyperactivity Disorder (ADHD) Index
NCT01010750 (6) [back to overview]CAARS-S:S Subscale T-Score: Problems With Self-Concept
NCT01133847 (11) [back to overview]Wechsler Individual Achievement Test-III (WIAT-III) Reading Comprehension Subtest
NCT01133847 (11) [back to overview]Dynamic Indicators of Basic Early Literacy Skills Oral Reading Fluency Subtest (DIBELS ORF)
NCT01133847 (11) [back to overview]Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Hyperactivity-impulsivity
NCT01133847 (11) [back to overview]Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Inattention
NCT01133847 (11) [back to overview]Wechsler Individual Achievement Test-III (WIAT-III) Word Reading Subtest
NCT01133847 (11) [back to overview]Test of Word Reading Efficiency (TOWRE) - Sight Word Efficiency
NCT01133847 (11) [back to overview]Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Hyperactivity-impulsivity
NCT01133847 (11) [back to overview]Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Inattention
NCT01133847 (11) [back to overview]Test of Word Reading Efficiency (TOWRE) - Phonemic Decoding Efficiency
NCT01133847 (11) [back to overview]Wechsler Individual Achievement Test-III (WIAT-III) Pseudoword Decoding Subtest
NCT01133847 (11) [back to overview]Test of Silent Reading Fluency and Comprehension (TOSREC)
NCT01399827 (5) [back to overview]Efficacy Measured by Mean Change From Baseline to Endpoint on Adult ADHD Investigator Rating Scale (AISRS) Total Score
NCT01399827 (5) [back to overview]Efficacy Measured by Mean Change From Baseline to Endpoint on Clinical Global Impression (CGI) Scale
NCT01399827 (5) [back to overview]Efficacy Measured by Mean Change From Baseline to Endpoint on the Global Assessment of Functioning (GAF) Scale
NCT01399827 (5) [back to overview]Mean Change From Baseline to Endpoint on the BRIEF-A Emotional Control Scale
NCT01399827 (5) [back to overview]Efficacy Measured by Mean Change From Baseline to Endpoint on BRIEF-A Subscales
NCT01699607 (1) [back to overview]Change in Dopamine Levels at Baseline and After Amphetamine Administration as Measured by Percent Change in PET Tracer Binding Potential.
NCT01711021 (7) [back to overview]Permanent Product Measure of Performance (PERMP) Scores Including PREMP-C and PREMP-A From Different Timepoints Post-dose
NCT01711021 (7) [back to overview]Change in the Clinician-rated Scale of ADHD Symptoms Based on DSM-IV-TR Criteria (ADHD-RS-IV).
NCT01711021 (7) [back to overview]Conners Parent Rating Scale Revised Short Form (CPRS-R:S) Total Scores From Week 6 and Week 7
NCT01711021 (7) [back to overview]Duration of Effect for d-Amphetamine and Placebo Treatment
NCT01711021 (7) [back to overview]Mean Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score During the Double-Blind Treatment Period
NCT01711021 (7) [back to overview]Number of Responders Evaluated by Clinical Global Impression (CGI-I) Scale by Treatments From the Double-blind Treatment Period
NCT01711021 (7) [back to overview]Onset of Efficacy Measured by Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score
NCT01740206 (6) [back to overview]mYPAS Measurement in Patients Receiving Midazolam
NCT01740206 (6) [back to overview]Diastolic Blood Pressure
NCT01740206 (6) [back to overview]Heart Rate
NCT01740206 (6) [back to overview]Mean Blood Pressure
NCT01740206 (6) [back to overview]mYPAS Measurement in Patients Not Receiving Midazolam
NCT01740206 (6) [back to overview]Systolic Blood Pressure
NCT01986062 (6) [back to overview]SKAMP Subscale - Deportment Scores
NCT01986062 (6) [back to overview]SKAMP-Combined Scores
NCT01986062 (6) [back to overview]SKAMP Subscale - Attention Scores
NCT01986062 (6) [back to overview]PERM-P Scores - Number of Problems Correct
NCT01986062 (6) [back to overview]PERM-P Scores - Number of Problems Attempted
NCT01986062 (6) [back to overview]SKAMP-Combined Scores
NCT01986075 (1) [back to overview]Those Achieving Three Consecutive Weeks of Cocaine Abstinence at the End of the Trial.
NCT02020408 (2) [back to overview]5-HT Transporter Binding as Measured During the PET Scan
NCT02020408 (2) [back to overview]Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration
NCT02058693 (3) [back to overview]Change in Scores of the Montgomery Asberg Depression Rating Scale (MADRS)
NCT02058693 (3) [back to overview]Change in Scores on the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ)
NCT02058693 (3) [back to overview]Change in Scores on the Quick Inventory of Depressive Symptomatology Self Report 16 (QIDS-SR-16)
NCT02083783 (2) [back to overview]PERMP (Permanent Product Measure of Performance).
NCT02083783 (2) [back to overview]SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale)
NCT02203786 (6) [back to overview]Speed of Play on Slot Machine Game
NCT02203786 (6) [back to overview]Diastolic Blood Pressure (DBP)
NCT02203786 (6) [back to overview]Cognitive Task Performance
NCT02203786 (6) [back to overview]Betting Behaviour in Laboratory-based Slot Machine Game
NCT02203786 (6) [back to overview]Subjective Reinforcement Self-report Scales
NCT02203786 (6) [back to overview]Winnings on Slot Machine Upon Completion of Game
NCT02204410 (2) [back to overview]Clinical Global Impression (CGI) Improvement for Deficient Emotional Self-Regulation (DESR)
NCT02204410 (2) [back to overview]Emotional Control Subscale of the Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent)
NCT02348385 (1) [back to overview]Percent Change in Binding Potential of Dopamine Release During PET Scan Post Amphetamine Administration
NCT02383043 (1) [back to overview]The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Capsule Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 210 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 120 Minutes After Drink Administraion
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 210 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 180 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 150 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 90 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 90 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 120 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 150 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 180 Minutes After Drink Administration
NCT02634684 (3) [back to overview]Prepulse Inhibition (PPI)
NCT02634684 (3) [back to overview]Targeted Cognitive Training (TCT): PositScience, Inc.
NCT02634684 (3) [back to overview]MATRICS Consensus Cognitive Battery Performance (MCCB)
NCT02803229 (2) [back to overview]Reduction in ADHD Symptoms
NCT02803229 (2) [back to overview]Marijuana Abstinence
NCT02959892 (2) [back to overview]Change in BP-ND in the TAK-041+AMPH Condition Compared to AMPH Alone as a Function of the Dose of TAK-041 Administered
NCT02959892 (2) [back to overview]Change in Non-displaceable Binding Potential (BP-ND) in the TAK-041+AMPH Condition Compared to AMPH Alone
NCT03088267 (2) [back to overview]Change in Permanent Product Measure of Performance (PERMP-C) Score (Problems Answered Correctly)
NCT03088267 (2) [back to overview]Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose
NCT03242772 (2) [back to overview]Change in ADHD Symptoms Using Preschool or School Age ADHD Rating Scale (ADHD-RS) Total Score
NCT03242772 (2) [back to overview]Change in Mean Composite Score (Socialization and Communication Subscales Standard Scores) of the Vineland Adaptive Behavior Scale - 3rd Edition, Interview Version (VABS-3)
NCT03610464 (1) [back to overview]Plasma Concentrations of d- and L-amphetamine
NCT03810703 (1) [back to overview]"Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ)."
NCT03834766 (5) [back to overview]Change From Baseline to Visit 5 on DSST
NCT03834766 (5) [back to overview]Lean Squares Mean (± Standard Error) of Math Test Score Over All Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the Administration of Serial Math Tests at Visit 5 (Week 5)
NCT03834766 (5) [back to overview]Change From Baseline in AISRS Total Score at Each Post-baseline Visit
NCT03834766 (5) [back to overview]Change From Baseline in CGI-S Total Score at Each Post-baseline Visit
NCT03834766 (5) [back to overview]Change From Baseline on Total Math Test Score Over Each Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the Administration of Serial Math Tests at Visit 5 (Week 5)

Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) Total Score at 6 Weeks

The Conner's Parent Rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior. (NCT00151996)
Timeframe: Baseline and 6 weeks

InterventionUnits on a Scale (Mean)
Methylphenidate + SPD503-22.18
Amphetamine + SPD503-16.28

[back to top]

Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Total Score at 6 Weeks

Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00151996)
Timeframe: Baseline and 6 weeks

InterventionUnits on a Scale (Mean)
Methylphenidate + SPD503-17.8
Amphetamine + SPD503-13.8

[back to top]

Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00151996)
Timeframe: 6 weeks

InterventionParticipants (Number)
Methylphenidate + SPD50328
Amphetamine + SPD50318

[back to top]

Number of Participants With Improvement on Parent Global Assessment (PGA) Scores

Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). The PGA is designed to capture parent's opinions of their child's disease (ADHD) severity and improvement. Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00151996)
Timeframe: 6 weeks

InterventionParticipants (Number)
Methylphenidate + SPD50332
Amphetamine + SPD50321

[back to top]

Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF50) Scores at 6 Weeks

The Child Health Questionnaire-Parent Form (CHQ-PF50) was developed to measure the physical and psychosocial well-being of children aged 5 years of age and older. Total scoring ranges from 0-100 for each. Increases in scores represent improved well-being in subjects as assessed by their parents. (NCT00151996)
Timeframe: Baseline and 6 weeks

,
InterventionUnits on a scale (Mean)
Physical Summary ScorePsychosocial Summary Score
Amphetamine + SPD5030.2211.56
Methylphenidate + SPD503-0.388.98

[back to top]

Retention as Indicated by the Number of Participants Who Completed 16 Weeks of Treatment

(NCT00218062)
Timeframe: 16 weeks

Interventionparticipants (Number)
D-Amphetamine 60mg + Therapy7
Modafinil 400mg + Therapy4
Modafinil 200mg + D-Amphetamine 30mg + Therapy3
Placebo + Therapy3

[back to top]

Medication Compliance as Indicated by Percentage of Riboflavin-positive Urine Samples

(NCT00218062)
Timeframe: 16 weeks

Intervention% of riboflavin-positive urine samples (Number)
D-Amphetamine 60mg + Therapy67.1
Modafinil 400mg + Therapy70
Modafinil 200mg + D-Amphetamine 30mg + Therapy76.8
Placebo + Therapy66.7

[back to top]

Medication Compliance as Indicated by Percentage of Pills Taken According to Self-report

(NCT00218062)
Timeframe: 16 weeks

Interventionpercentage of pills taken (Number)
D-Amphetamine 60mg + Therapy80.2
Modafinil 400mg + Therapy34.5
Modafinil 200mg + D-Amphetamine 30mg + Therapy65.8
Placebo + Therapy73.2

[back to top]

Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment

(NCT00218062)
Timeframe: 16 weeks

Interventionnumber of cocaine negative urines (Mean)
D-Amphetamine 60mg + Therapy9.25
Modafinil 400mg + Therapy6.09
Modafinil 200mg + D-Amphetamine 30mg + Therapy6
Placebo + Therapy4.91

[back to top]

Retention as Indicated by the Number of Participants Who Remained in the Study

(NCT00218062)
Timeframe: 16 weeks

Interventionparticipants (Number)
D-Amphetamine 60mg + Therapy7
Modafinil 400mg + Therapy4
Modafinil 200mg + D-Amphetamine 30mg + Therapy3
Placebo + Therapy3

[back to top]

3 Scores on the Addiction Research Center Inventory (ARCI)

The subjective effects of the study drug were evaluated with 3 subscales of the Addiction Research Center Inventory (ARCI). The subscales studied included Morphine-Benzedrine Group which measured euphoria (0-16 with higher numbers indicating more euphoria), the Phenobarbital-Chorpromazine-Alcohol Group which measured sedation (-3 to +11 with higher scores indicating more sedation), and the Lysergic Acid Diethylmide Group which measured dysphoria and agitation (-4 to +10 with higher scores indicating more dysphoria). This inventory consists of 49 true/ false questions which survey major domains of drug effects. The ARCI was measured at six timepoints. Of interest were trough sedation, peak euphoria, and trough dysphoria. (NCT00314340)
Timeframe: 0, 60, 120, 180, 240, or 300 minutes

,,
Interventionscores on a scale (Mean)
trough sedationpeak euphoriatrough agitation
ER Morphine Tablets, 45mg7.63.34.7
Hydrocodone 30 mg Plus N-acetyl-para-aminophenol 975 mg5.44.64.2
Placebo5.23.53.6

[back to top]

Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2

Clinical Global Impressions Scale Improvement Score = 1 (very much improved), or 2 (much improved). Additional possible scale scores are 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). (NCT00363298)
Timeframe: At end of week 5, except 1 d-amphetamine subject rated at end of week 2

Interventionparticipants (Number)
D-amphetamine6
Caffeine Pills7

[back to top]

Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score

"Yale-Brown Obsessive-Compulsive Scale score by blinded investigator in direct interview. The scale score is the sum of ten items (5 for obsessions and 5 for compulsions: time occupied, degree of interference with functioning, degree of distress, effort to resist the symptom, success in resisting), each rated from 0 to 4, with higher scores indicating more severe OCD. Maximum score is 40. Scores of 14 and below are often described as subclinical, though patients with these scores may still exhibit troubling symptoms and mild to moderate distress. A total score of 8 or less is often termed remission. A decrease in total score from baseline to endpoint of either 25% or 35% is often used as a responder criterion in clinical trials." (NCT00363298)
Timeframe: At end of week 5, except 1 d-amphetamine subject rated at end of week 2

Interventionunits on a scale (Mean)
D-amphetamine13.3
Caffeine Pills13.0

[back to top]

Weiss Functional Impairment Rating Scale (WFIRS)

The WFIRS consists of 50 questions where respondents are asked to rate their child's functional impairment. The items of the WFIRS are scored on a four point Likert-type rating scale: 0 (never or not at all), 1 (sometimes or somewhat), 2 (often or much) or 3 (very often or very much) and aggregated to produce six domain scores: Family (ranges between 0-24), Learning or School (ranges between 0-33), Self-Concept (ranges between 0-15), Social Activities (ranges between 0-27), Life Skills (ranges between 0-36), and Risky Activities (ranges between 0-42). The subscales are scored by summing the responses in the subsection. The Total score is the sum of all the responses and it ranges between 0-150. The higher the score in each of the subscales the more impairment is recorded, this is also true for the total score. (NCT00393042)
Timeframe: 8-10 weeks

,,,,,,,
Interventionunits on a scale (Mean)
Family subscale scoreLearning subscale scoreLife skills subscale scoreSelf-concept subscale scoreSocial activities subscale scoreRisky activities subscale scoreTotal score
Adderall XR - 10 mg7.028.757.911.593.911.9431.06
Adderall XR - 20 mg6.356.867.441.422.982.2427.32
Adderall XR - 25/30mg6.706.217.341.063.061.6826.23
Adderall XR - Placebo6.726.747.431.113.512.1927.70
Focalin XR - 10 mg7.359.257.651.193.851.9631.13
Focalin XR - 20 mg6.507.548.301.333.541.7829.20
Focalin XR - 25/30mg6.507.397.601.313.171.6727.45
Focalin XR - Placebo7.399.308.301.253.731.9120.91

[back to top]

Sleep Start Time, and End Time as Determined by Actigraph and Sleep Diary Over 8 Weeks.

Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep. The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep. (NCT00393042)
Timeframe: 8-10 weeks

,,,,,
InterventionHHMM.SS (Mean)
Sleep start timeSleep End time
10mg of Either Focalin XR or Adderall XR23040728
20mg of Either Focalin XR or Adderall XR23190735
25/30mg of Either Focalin XR or Adderall XR23250732
Adderall XR All Dose Levels23090735
Focalin XR All Dose Levels23090734
Placebo22490742

[back to top]

Dopamine Active Transporter (DAT) 1 Gene Type Effects on ADHD Symptoms

Three variations of the DAT 1 gene were observed, the 9/9 allele, the 9/10 allele and the 10/10 allele. The ADHD Rating Scale (ADHD-RS) and Clinical Global Impressions - Severity (CGI-S) measures were used to evaluate how the DAT 1 gene allele type altered the efficacy of the medication. The DAT 1 genotype did not predict differential response to Focalin XR or Adderall XR so the dose levels of each drug was combined to examine how the genotype interacted with the dose level. The ADHD-RS evaluates the severity of the participant's ADHD symptoms and includes two subscales: Inattention and Hyperactivity/Impulsivity. Both subscale scores range from 0 to 27 with a higher score representing more severe symptoms. The subscales are summed to calculate the total score which can range from 0 to 54. The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill. (NCT00393042)
Timeframe: 8-10 weeks

,,,,,,,,,,,,,,,,,,,,,,,
Interventionunits on a scale (Mean)
ADHD-RS Inattention subscale scoreADHD-RS Hyperactivity/Impulsivity subscale scoreADHD-RS total scoreCGI-S score
10/10 Allele: 10 mg of Adderall XR16.139.6325.774.07
10/10 Allele: 10 mg of Focalin XR16.5610.6327.194.19
10/10 Allele: 20 mg of Adderall XR9.367.0716.433.21
10/10 Allele: 20 mg of Focalin XR12.568.4120.963.52
10/10 Allele: 25/30 mg of Adderall XR11.967.5019.463.54
10/10 Allele: 25/30mg of Focaling XR11.158.6519.813.31
10/10 Allele: Placebo of Adderall XR15.0711.8726.934.17
10/10 Allele: Placebo of Focalin XR16.4413.7430.194.15
9/10 Allele: 10 mg of Adderall XR16.2710.6726.804.07
9/10 Allele: 10 mg of Focalin XR16.938.2725.204.27
9/10 Allele: 20 mg of Adderall XR15.868.3624.213.71
9/10 Allele: 20 mg of Focalin XR13.366.7320.093.58
9/10 Allele: 25/30 mg of Adderall XR13.436.4319.863.50
9/10 Allele: 25/30 mg of Focalin XR13.707.0020.703.90
9/10 Allele: Placebo of Adderall XR18.649.3628.004.36
9/10 Allele: Placebo of Focalin XR18.088.9227.084.31
9/9 Allele: 10 mg of Adderall XR18.8318.3337.174.33
9/9 Allele: 10 mg of Focalin XR22.2017.4039.604.60
9/9 Allele: 20 mg Adderall XR19.0014.8033.804.80
9/9 Allele: 20 mg of Focalin XR16.7514.0030.754.50
9/9 Allele: 25/30 mg of Focalin XR12.509.0024.004.00
9/9 Allele: 25/30mg of Adderall XR15.4010.4025.804.00
9/9 Allele: Placebo of Adderall XR18.6012.8031.404.40
9/9 Allele: Placebo of Focalin XR19.3317.3336.674.67

[back to top]

ADHD Parent Rating Scale-IV

Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms. (NCT00393042)
Timeframe: completed weekly over 8-10 weeks

,,,,,,,
Interventionunits on a scale (Mean)
Inattention Symptom Subscale ScoresHyperactivity/Impulsivity Symptom subscale scoresTotal Symptoms scores
Adderall XR - 10 mg6.4010.7827.15
Adderall XR - 20 mg12.27.9220.12
Adderall XR - 25/30mg12.747.6720.40
Adderall XR - Placebo16.6111.4128.02
Focalin XR - 10 mg17.5110.8428.35
Focalin XR - 20 mg13.338.4921.82
Focalin XR - 25/30mg12.118.4920.41
Focalin XR - Placebo17.3113.2430.58

[back to top]

Sleep Duration

Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep.The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep. (NCT00393042)
Timeframe: 8-10 weeks

Interventionminutes (Mean)
Placebo459.6
10mg of Either Focalin XR or Adderall XR446.7
20 mg of Either Focalin XR or Adderall XR432.17
25/30mg of Either Focalin XR or Adderall XR425.5
Adderall XR All Dose Levels438.82
Focalin XR All Dose Levels443.2

[back to top]

Clinical Global Impression - Severity

The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill. (NCT00393042)
Timeframe: 8-10 weeks

Interventionunits on a scale (Mean)
Adderall XR - Placebo4.26
Adderall XR - 10 mg4.09
Adderall XR - 20 mg3.48
Adderall XR - 25/30 mg3.56
Focalin XR - Placebo4.24
Focalin - 10 mg4.24
Focalin XR - 20 mg3.63
Focalin XR - 25/30 mg3.55

[back to top]

Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use

Each week after randomization was scored dichotomously as cocaine positive or negative. Cocaine use was positive if any urine or self-report was positive. Cocaine use was negative if all urines (BE <300 ng/ml) and all self-report were negative. Weeks with no urine or no self-report were designated missing. (NCT00553319)
Timeframe: weekly for 14 weeks of trial or for length of participation

Interventionpercentage of participants (Number)
Placebo7
Adderall-XR 60 mg18
Adderall-XR 80 mg30

[back to top]

ADHD Symptoms Based on ADHD Rating Scale

The proportion of subjects exhibiting >30% reduction of AISRS score at last enrollment week compared to week 0 (NCT00553319)
Timeframe: measured once per week for 14 weeks or length of study participation

Interventionparticipants (Number)
Placebo17
Adderall-XR 60 mg30
Adderall-XR 80 mg25

[back to top]

The Interacting Effects of Smoking and Overnight Abstinence With ADHD Medication and Placebo on Continuous Performance Task (CPT) Errors of Omission.

In the morning of each monitoring day, approximately 60 minutes after medication or placebo pill administration, participants were asked to either abstain from smoking or smoke their first cigarette of the day 5 minutes prior to starting the CPT. (NCT00573859)
Timeframe: 4 days

Interventionerrors (Mean)
ADHD medication + SmokingADHD medication + AbstinencePlacebo + SmokingPlacebo + Abstinence
ADHD Medication Versus Placebo0.401.081.002.8

[back to top]

The Effects of ADHD Medication Versus Placebo on Cotinine Levels

Salivary cotinine was measured across two days on ADHD medication versus two days on placebo. (NCT00573859)
Timeframe: 4 days

Interventionng/ml (Mean)
ADHD medicationPlacebo
ADHD Medication Versus Placebo180.7274.0

[back to top]

The Interacting Effects of Smoking and Abstinence With ADHD Medication and Placebo on Nicotine Withdrawal Measured by the Shiffman-Jarvik Withdrawal Questionnaire.

The Shiffman-Jarvik withdrawal questionnaire measures nicotine withdrawal and was completed after each CPT assessment. The questionnaire consists of 25 items using 8-point scales. Total scores range from 0 to 200 and higher scores reflect higher levels of nicotine withdrawal. (NCT00573859)
Timeframe: 4 days

Interventionscores on a scale (Median)
ADHD medication + SmokingADHD medication + AbstinencePlacebo + SmokingPlacebo + Abstinence
ADHD Medication Versus Placebo92.791.397.0102.0

[back to top]

Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) for rTMS Treatment With Respect to Frequency

Mean sum of normalized MEP for the different frequencies of rTMS treatment (placebo at 0.1 Hz, 0.1 Hz, 0.25 Hz, 0.5 Hz) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. (NCT00715520)
Timeframe: Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)

Interventionmillivolts (Mean)
Baseline - PlaceboPost-Training 1 - PlaceboPost-Training 2 - PlaceboPost-Training 3 - PlaceboBaseline - .1 HzPost-Training 1 - .1 HzPost-Training 2 - .1 HzPost-Training 3 - .1 HzBaseline - .25 HzPost-Training 1 - .25 HzPost-Training 2 - .25 HzPost-Training 3 - .25 HzBaseline - .5 HzPost-Training 1 - .5 HzPost-Training 2 - .5 HzPost-Training 3 - .5 Hz
Aim 2.67.93.941.02.711.061.061.14.67.90.90.98.64.92.90.84

[back to top]

Aim 1: Mean Parameter Estimate for Maximal Motor Evoked Potential (MEPmax) Derived From Stimulus Response Curves (SRC)

Motor evoked potential (MEP) amplitudes were measured prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2), and 60 minutes after the treatment (post-training 3).The MEP is elicited by transcranial magnetic stimulation (TMS) at increased intensity. Its amplitude is measured from peak to peak and expressed in millivolts (mV). Measured MEP amplitudes were plotted against the intensity to create a stimulus response curve (SRC). SRCs were modeled by a 3- parameter sigmoid function and MEPmax was extracted. Long-lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning. (NCT00715520)
Timeframe: Baseline, Post-Training 1 (Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)

InterventionmV (Mean)
Baseline Placebo - MEPmaxPost-Training 1 Placebo - MEPmaxPost-Training 2 Placebo - MEPmaxBaseline - Amphetamine Sulfate - MEPmaxPost-Training 1 Ampletamine Sulfate - MEPmaxPost-Training 2 Amphetamine Sulfate - MEPmaxBaseline Methylphenidate - MEPmaxPost-Training 1 Methylphenidate - MEPmaxPost-Training 2 Methylphenidate - MEPmaxBaseline Carbidopa-Levodopa - MEPmaxPost-Training 1 Carbidopa-Levodopa - MEPmaxPost-Training 2 Carbidopa-Levodopa - MEPmax
Aim 11.011.631.29.731.221.081.041.101.221.811.411.53

[back to top]

Aim 1: Mean Peak Acceleration of Wrist Extension Movements

Mean peak acceleration was measured across study drug conditions prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface. (NCT00715520)
Timeframe: Baseline, Post-Training 1 (Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)

Interventiong (Mean)
Baseline - PlaceboPost-Training 1 - PlaceboPost-Training 2 - PlaceboBaseline - Amphetamine SulfatePost-Training 1 - Amphetamine SulfatePost-Training 2 - Amphetamine SulfateBaseline - MethylphenidatePost-Training 1 - MethylphenidatePost-Training 2 - MethylphenidateBaseline - Carbidopa-LevodopaPost-Training 1 - Carbidopa-LevodopaPost-Training 2 - Carbidopa-Levodopa
Aim 11.321.331.241.241.281.291.351.271.221.221.231.37

[back to top]

Aim 2: Mean Peak Acceleration for rTMS Treatment With Respect to Frequency

Mean peak acceleration for the different frequencies of rTMS treatment (placebo, 0.1 Hz, 0.25 Hz, 0.5 Hz) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface. (NCT00715520)
Timeframe: Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)

Interventiong (Mean)
Baseline - PlaceboPost-Training 1 - PlaceboPost-Training 2 - PlaceboPost-Training 3 - PlaceboBaseline - .1 HzPost-Training 1 - .1 HzPost-Training 2 - .1 HzPost-Training 3 - .1 HzBaseline - .25 HzPost-Training 1 - .25 HzPost-Training 2 - .25 HzPost-Training 3 - .25 HzBaseline - .5 HzPost-Training 1 - .5 HzPost-Training 2 - .5 HzPost-Training 3 - .5 Hz
Aim 21.441.361.351.331.331.431.501.531.381.351.401.341.321.291.251.29

[back to top]

Aim 2: Mean Peak Acceleration of Wrist Extension Movements With Respect to Pulse

Mean peak acceleration of wrist movements for repeated TMS (rTMS) conditions with respect of the TMS pulse (-100, +300, placebo, zero) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Increases in the mean peak acceleration of the trained wrist extension movements indicate motor learning. Acceleration was measured in g; a symbol for the average acceleration produced by gravity at the Earth's surface. (NCT00715520)
Timeframe: Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)

Interventiong (Mean)
Baseline - Pulse (zero)Post-Training 1 - Pulse (zero)Post-Training 2 - Pulse (zero)Post-Training 3 - Pulse (zero)Baseline - Pulse (placebo)Post-Training 1 - Pulse (placebo)Post-Training 2 - Pulse (placebo)Post-Training 3 - Pulse (placebo)Baseline - Pulse (-100)Post-Training 1 - Pulse (-100)Post-Training 2 - Pulse (-100)Post-Training 3 - Pulse (-100)Baseline - Pulse (+300)Post-Training 1 - Pulse (+300)Post-Training 2 - Pulse (+300)Post-Training 3 - Pulse (+300)
Aim 21.331.431.511.531.441.361.351.331.511.51.461.471.401.321.381.40

[back to top]

Aim 2: Mean Sum of Normalized Motor Evoked Potentials (MEPs) With Respect to Pulse

Mean sum of normalized MEP for repeated TMS (rTMS) conditions with respect to the pulse (-100, +300, placebo, zero) prior to treatment (baseline), immediately after the treatment (post-training 1), 30 minutes after the treatment (post-training 2) and 60 minutes after the treatment (post-training 3). Its amplitude is measured from peak to peak and expressed in mV. Long- lasting increases in MEP amplitude indicate increases in motor cortex excitability and are associated with motor learning. (NCT00715520)
Timeframe: Baseline, Post-Training 1(Immediately), Post-Training 2 (30 Minutes), Post-Training 3 (60 Minutes)

Interventionmillivolts (Mean)
Baseline - Pulse (zero)Post-Training 1 - Pulse (zero)Post-Training 2 - Pulse (zero)Post-Training 3 - Pulse (zero)Baseline - Pulse (placebo)Post-Training 1 - Pulse (placebo)Post-Training 2 - Pulse (placebo)Post-Training 3 - Pulse (placebo)Baseline - Pulse (-100)Post-Training 1 - Pulse (-100)Post-Training 2 - Pulse (-100)Post-Training 3 - Pulse (-100)Baseline - Pulse (+300)Post-Training 1 - Pulse (+300)Post-Training 2 - Pulse (+300)Post-Training 3 - Pulse (+300)
Aim 2.39.66.63.69.40.54.51.52.39.56.60.61.38.54.48.51

[back to top]

Systolic and Diastolic Blood Pressure

Sitting Blood Pressure (NCT00733993)
Timeframe: Average across 7 time points: Immediately after dose and every 30 minutes for 3 hours

,,,
InterventionmmHg (Mean)
SBP Control (N=10)SBP Cocaine (N=13)DBP Control (N=10)DBP Cocaine (N=13)
Amphetamine 20mg119.27120.3077.8378.16
Caffeine 150 Mg115.9122.1075.3379.98
Caffeine 300 mg117.36123.8477.9482.81
Placebo115.64120.1874.8279.66

[back to top]

Saliva Caffeine and Paraxanthine Levels

"Due to insufficient oral volume or breakage during sample transfer, data were lost or incomplete for two cocaine-dependent subjects.~Analyses for the saliva data represent 11 cocaine-dependent subjects and 10 controls." (NCT00733993)
Timeframe: 30 minutes prior to dose, 30/90/150 minutes post dose.

,,
Interventionng/mL (Mean)
Caffeine -30 min Control (N=10)Caffeine 30 min Control (N=10)Caffeine 90 min Control (N=10)Caffeine 150 min Control (N=10)Caffeine -30 min Cocaine (N=11)Caffeine 30 min Cocaine (N=11)Caffeine 90 min Cocaine (N=11)Caffeine 150 min Cocaine (N=11)Parathanxine -30 min Control (N=10)Parathanxine 30 min Control (N=10)Parathanxine 90 min Control (N=10)Parathanxine 150 min Control (N=10)Parathanxine -30 min Cocaine (N=11)Parathanxine 30 min Cocaine (N=11)Parathanxine 90 min Cocaine (N=11)Parathanxine 150 min Cocaine (N=11)
Caffeine 150 Mg510271522251910998212520771909274301402411401465601605
Caffeine 300 mg33528953510327012013510372032051982023974624086569851014
Placebo1000983984984990780625510440410411410334320321296

[back to top]

Heart Rate

Sitting heart rate (NCT00733993)
Timeframe: Average across 7 time points: Immediately after dose and every 30 minutes for 3 hours

,,,
InterventionBeats per minute (Mean)
Control (N=10)Cocaine (N=13)
Amphetamine 20mg65.5563.51
Caffeine 150 Mg62.4762.60
Caffeine 300 mg61.3361.57
Placebo66.1063.08

[back to top]

Drug Effects Questionnaire Rating of Subjective Ratings of Drug Effects

Assessments measured using a 4 item Drug Effects Questionnaire (DEQ) Ranges from 0 to 100 with higher numbers showing greater effect for each scale. (NCT00733993)
Timeframe: Immediately after dose

,,,
Interventionunits on a scale (Mean)
Feel effects:Control (N=10)Feel effects:Cocaine (N=13)Like effects:Control (N=10)Like effects:Cocaine (N=13)High:Control (N=10)High:Cocaine (N=13)Like more:Control (N=10)Like more:Cocaine (N=13)
Amphetamine 20 mg11.3718.6842.2532.047.1714.6425.6526.16
Caffeine 150 Mg20.2520.7335.6239.9412.1716.1425.6225.68
Caffeine 300 mg9.4517.6252.1743.757.1715.8732.9228.71
Placebo16.7517.3039.9237.1810.7714.3525.7725.96

[back to top]

Probabalistic Feedback Selection Task

Accuracy on a range from 0 to 1 of correctly performing a learning task, with 1 being the highest degree of accuracy. (NCT00733993)
Timeframe: 75 minutes after dose

,,,
Interventionaccuracy (Mean)
Control (N=10)Cocaine (N=13)
Amphetamine 20mg0.610.56
Caffeine 150 Mg0.550.56
Caffeine 300 mg0.560.58
Placebo0.560.54

[back to top]

Addiction Research Center Inventory Subjective Rating of Drug Effects

"Addiction Research Center Inventory (ARCI 49). T/F scales with 49 items.~Includes the following subscales:~Morphine-Benzedrine Group (MBG), includes euphoria (0 to +16, higher numbers = more euphoria) Phenobarbital-Chorpromazine-Alcohol Group (PCAG), includes sedation (-3 to +11, higher scores = more sedation) Lysergic Acid Diethylmide Group (LSD) , includes dysphoria and agitation (-4 to +10, higher scores = more dysphoria) Amphetamine Group (A), includes stimulation ( 0 to +11, higher scores = more stimulation) Benzedrine Group (BG), includes energy and intellectual efficiacy (+4 to +9, higher scores = more energy)" (NCT00733993)
Timeframe: Immediately after dose

,,,
Interventionunits on a scale (Mean)
PCAG: Control (N=10)PCAG: Cocaine (N=13)A: Control (N=10)A: Cocaine (N=13)BG: Control (N=10)BG: Cocaine (N=13)MGB: Control (N=10)MGB: Cocaine (N=13)LSD: Control (N=10)LSD: Cocaine (N=13)
Amphetamine 20 mg3.642.433.223.695.835.574.045.181.700.98
Caffeine 150 Mg3.621.833.603.396.355.774.345.622.430.48
Caffeine 300 mg3.522.953.803.196.055.075.144.311.231.05
Placebo3.871.953.203.306.005.694.095.291.780.89

[back to top]

Visual Analog Scale Subjective Rating of Drug Effects

Visual Analog Scale Rating. Scores range from 0 to 100 with higher scores meaning greater intensity of response being rated. (NCT00733993)
Timeframe: Immediately after dose

,,,
Interventionunits on a scale (Mean)
Elation: Control (N=10)Elation: Cocaine (N=13)Anxious: Control (N=10)Anxious: Cocaine (N=13)Vigor: Control (N=10)Vigor: Cocaine (N=13)Tension: Control (N=10)Tension: Cocaine (N=13)Fatigue: Control (N=10)Fatigue: Cocaine (N=13)Depression: Control (N=10)Depression: Cocaine (N=13)
Amphetamine 20 mg10.4325.7111.6821.718.2810.311.531.883.601.170.101.10
Caffeine 150 Mg9.8532.5410.4521.358.5010.851.600.963.000.540.100.62
Caffeine 300 mg13.6521.658.5025.279.789.271.622.383.441.690.411.96
Placebo8.6525.9910.1519.648.2510.421.051.633.850.680.101.05

[back to top]

Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionng/ml (Mean)
Adderall XR7.91
Adderall XR + Prilosec OTC8.10

[back to top]

Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionng.h/ml (Mean)
Vyvanse626.27
Adderall XR473.70
Vyvanse + Prilosec OTC687.00
Adderall XR + Prilosec OTC472.35

[back to top]

AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

(NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionng.h/ml (Mean)
Adderall XR145.28
Adderall XR + Prilosec OTC145.83

[back to top]

AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

Total amphetamine is the d- and l-amphetamines. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionng.h/ml (Mean)
Adderall XR620.68
Adderall XR + Prilosec OTC620.91

[back to top]

Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionh (Mean)
Vyvanse9.7
Adderall XR10.25
Vyvanse + Prilosec OTC10.4
Adderall XR + Prilosec OTC10.91

[back to top]

Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

Total amphetamine is the d- and l-amphetamines. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionng/ml (Mean)
Adderall XR36.56
Adderall XR + Prilosec OTC38.05

[back to top]

Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionng/ml (Mean)
Vyvanse45.04
Adderall XR28.66
Vyvanse + Prilosec OTC46.34
Adderall XR + Prilosec OTC29.97

[back to top]

T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionh (Mean)
Adderall XR11.98
Adderall XR + Prilosec OTC13.06

[back to top]

T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

Total amphetamine is the d- and l-amphetamines. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionh (Mean)
Adderall XR10.38
Adderall XR + Prilosec OTC11.05

[back to top]

Systolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

(NCT00746733)
Timeframe: Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing

,,,
InterventionmmHg (Mean)
Pre-dose1 h2 h4 h8 h12 h24 h48 h72 h96 h
Adderall XR115.3121.0122.2120.8122.4121.9118.1112.6114.8114.5
Adderall XR + Prilosec OTC113.9122.6124.7124.2119.2118.4115.6113.6116.0116.1
Vyvanse115.6122.8127.9127.6126.0123.4114.0114.6113.7114.0
Vyvanse + Prilosec OTC114.8121.7125.5125.2123.5122.2114.7114.4115.1114.8

[back to top]

Pulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

(NCT00746733)
Timeframe: Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing

,,,
Interventionbpm (Mean)
Pre-dose1 h2 h4 h8 h12 h24 h48 h72 h96 h
Adderall XR69.070.075.274.579.182.374.774.073.370.4
Adderall XR + Prilosec OTC71.473.880.578.481.582.776.475.072.773.9
Vyvanse70.969.778.279.084.886.479.973.272.270.7
Vyvanse + Prilosec OTC73.373.483.484.487.789.180.475.172.072.5

[back to top]

Electrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation. (NCT00746733)
Timeframe: Pre-dose, 2 and 8 hours after dosing

,,,
Interventionmsec (Mean)
Pre-dose2 h8 h
Adderall XR398.3394.6393.8
Adderall XR + Prilosec OTC399.8396.1394.4
Vyvanse399.8395.0390.0
Vyvanse + Prilosec OTC399.3397.9395.4

[back to top]

Drug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.

Question 2: How much do you like the effects you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs. (NCT00746733)
Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing

,
Interventionunits on a scale (Mean)
Pre-dose0.5 h1 h1.5 h2 h2.5 h3 h3.5 h4 h5 h6 h8 h12 h24 h
Adderall XR + Prilosec OTC1.02.02.02.22.52.31.51.31.41.31.21.31.11.0
Vyvanse + Prilosec OTC1.01.21.84.64.63.93.52.71.72.41.41.41.21.3

[back to top]

DRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC

Question 3: Do you dislike the drug effect you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs. (NCT00746733)
Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing

,
Interventionunits on a scale (Mean)
Pre-dose0.5 h1 h1.5 h2 h2.5 h3 h3.5 h4 h5 h6 h8 h12 h24 h
Adderall XR + Prilosec OTC1.02.12.01.81.41.41.21.31.31.31.21.11.21.0
Vyvanse + Prilosec OTC1.02.01.84.34.53.83.42.61.82.31.61.61.31.1

[back to top]

DRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC

Question 1: How much do you feel the drug now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs. (NCT00746733)
Timeframe: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing

,
Interventionunits on a scale (Mean)
Pre-dose0.5 h1 h1.5 h2 h2.5 h3 h3.5 h4 h5 h6 h8 h12 h24 h
Adderall XR + Prilosec OTC1.01.31.92.33.53.52.72.12.11.91.51.31.21.0
Vyvanse + Prilosec OTC1.01.32.15.26.06.05.34.93.83.13.43.04.41.6

[back to top]

Diastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

(NCT00746733)
Timeframe: Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing

,,,
InterventionmmHg (Mean)
Pre-dose1 h2 h4 h8 h12 h24 h48 h72 h96 h
Adderall XR74.176.475.477.774.178.576.873.574.775.7
Adderall XR + Prilosec OTC75.880.481.982.079.277.875.474.477.978.3
Vyvanse76.079.279.079.978.679.675.974.575.174.5
Vyvanse + Prilosec OTC77.780.582.082.080.378.775.077.276.175.7

[back to top]

Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

Total amphetamine is the d- and l-amphetamines. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionh (Mean)
Adderall XR5.30
Adderall XR + Prilosec OTC3.29

[back to top]

Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionh (Mean)
Adderall XR5.6
Adderall XR + Prilosec OTC3.5

[back to top]

Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity. (NCT00746733)
Timeframe: 0 through 96 hours after dosing

Interventionh (Mean)
Vyvanse3.5
Adderall XR5.2
Vyvanse + Prilosec OTC3.5
Adderall XR + Prilosec OTC3.3

[back to top]

Clinical Global Improvements-Acceptability (CGI-A) Scale

The CGI-A score at the subject's last study visit at or before Week 6 is one of the 3 secondary endpoints that contribute to the primary endpoint (CGI-E). The CGI-A will be used to assess the acceptability of the study medication with respect to the subject's experience with the formulation of medication. The 7-point rating for the CGI-A will be: 1=very high acceptability, 2=high acceptability, 3=above average acceptability, 4=average acceptability, 5=low acceptability, 6=very low acceptability, 7=extremely low acceptability (NCT00889915)
Timeframe: Measured at each participant's last visit, which can occur at or before Week 6

InterventionUnits on a scale (Median)
Daytrana (Methylphenidate Transdermal System3.0
Vyvanse (Lisdexamfetamine Dimesylate)2.0
Concerta (Osmotic-release Oral System Methylphenidate)2.0
Adderall (Mixed Amphetamine Salts Extended Release)2.0

[back to top]

Dichotomized Clinical Global Impression-Effectiveness (CGI-E) Scale

The CGI-E is the value at which the participant's Therapeutic Benefit and Adverse Impact to the study drug intersect. This number is determined by combining each participant's scores for the degree of Therapeutic Benefit versus the degree to which problems with Tolerability and/or Acceptability adversely impact the subject. Participants are then determined to be Responders or Non-responders to the study medication. For example, a subject who is very much improved (CGI-I=1) or much improved (CGI-I=2) therapeutically and whose adverse impact rating is none (score 1,5) or mild (score 2,6) will be categorized as a Responder. All others whose adverse impact rating is moderate (score 3,7,11,15)or outweighs therapeutic effect (score 4,8,12,16) will be categorized as Non-responders to study medication. The CGI scores are totaled for each participant and a mean score is calculated. A median total score was calculated for each treatment group. (NCT00889915)
Timeframe: Measured at each participant's last visit, which can occur at or before Week 6

InterventionUnits on a scale (Median)
Daytrana (Methylphenidate Transdermal System7.0
Vyvanse (Lisdexamfetamine Dimesylate)5.0
Concerta (Osmotic-release Oral System Methylphenidate)6.0
Adderall (Mixed Amphetamine Salts Extended Release)6.0

[back to top]

Clinical Global Impressions-Improvement (CGI-I) Scale

The CGI-I score at the subject's last study visit at or before Week 6, is one of the 3 secondary endpoints that contribute to the primary endpoint (CGI-E). The CGI-I scale will be used to rate improvement in the subject's condition (benefits) since baseline using the following 7-point scale: 1=very much improved, 2=much improved, 3=minimally improved, 4=not changed, 5=minimally worse, 6=much worse; 7=very much worse. (NCT00889915)
Timeframe: Measured at each participant's last visit, which can occur at or before Week 6

InterventionUnits on a scale (Median)
Daytrana (Methylphenidate Transdermal System2.0
Vyvanse (Lisdexamfetamine Dimesylate)2.0
Concerta (Osmotic-release Oral System Methylphenidate)2.0
Adderall (Mixed Amphetamine Salts Extended Release)2.0

[back to top]

CAARS-S:S Subscale T-Score: Impulsivity/Emotional Liability

Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7

,,
InterventionUnits on a scale (Mean)
2 hours post-dose14 hours post-dose
LDX 50 mg55.4657.82
MAS-IR 20 mg54.5851.53
Placebo54.6655.78

[back to top]

Conners Adult ADHD Rating Scales-Self Report: Short Version (CAARS-S:S) Subscale Total Score (T-Score): Inattention/Memory Problems

Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7

,,
InterventionUnits on a scale (Mean)
2 hours post-dose14 hours post-dose
LDX 50 mg66.1665.78
MAS-IR 20 mg63.3964.45
Placebo64.9266.33

[back to top]

Power of Attention Score

The Power of Attention score reflects the ability to focus attention, and is calculated as the sum of the reaction time, measured in milliseconds, from 3 attention tests (Simple Reaction Time, Choice Reaction Time, and Digit Vigilance Speed). Faster performance (lower times) reflects more intense concentration. A decrease in the Power of Attention score indicates improvement. (NCT01010750)
Timeframe: pre-dose and at 1, 2, 3, 4, 5, 8, 12, 14 and 16 hours post-dose on Day 7

,,
Interventionmilliseconds (Mean)
half an hour prior to dosing1 hour post-dose2 hours post-dose3 hours post-dose4 hours post-dose5 hours post-dose8 hours post-dose12 hours post-dose14 hours post-dose16 hours post-dose
LDX 50 mg1260.71244.61315.51219.11225.91179.61212.01232.41199.31202.6
MAS-IR 20 mg1324.11307.41255.01229.61236.51251.41259.31239.31270.11255.9
Placebo1272.81253.11296.21301.01275.41330.31304.51262.11270.51270.3

[back to top]

CAARS-S:S Subscale T-Score: Hyperactivity/Restlessness

Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7

,,
InterventionUnits on a scale (Mean)
2 hours post-dose14 hours post-dose
LDX 50 mg64.2165.08
MAS-IR 20 mg63.6263.41
Placebo63.2865.74

[back to top]

CAARS-S:S Subscale T-Score: Attention Deficit Hyperactivity Disorder (ADHD) Index

Consists of 12 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7

,,
InterventionUnits on a scale (Mean)
2 hours post-dose14 hours post-dose
LDX 50 mg64.8266.56
MAS-IR 20 mg63.9063.09
Placebo64.5964.85

[back to top]

CAARS-S:S Subscale T-Score: Problems With Self-Concept

Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7

,,
InterventionUnits on a scale (Mean)
2 hours post-dose14 hours post-dose
LDX 50 mg58.7159.68
MAS-IR 20 mg59.7859.54
Placebo58.4059.68

[back to top]

Wechsler Individual Achievement Test-III (WIAT-III) Reading Comprehension Subtest

The WIAT-III is an individually-administered test of academic achievement. This subtest involves reading sentences and longer passages and then answering a set of literal and inferential comprehension questions about the text. Scores reported here are standardized scores with a mean of 100 and standard deviation of 15. Higher scores represent a better outcome. (NCT01133847)
Timeframe: Week 16, End of Active Treatment Phase

Interventionstandardized scores (Least Squares Mean)
ADHD Treatment88.27
Intensive Reading Instruction84.70
Combined ADHD Treatment and Reading Instruction86.35

[back to top]

Dynamic Indicators of Basic Early Literacy Skills Oral Reading Fluency Subtest (DIBELS ORF)

DIBELS ORF measures oral reading fluency in connected text. Students are presented with a passage on their grade level to read orally, and the score is the number of words of the passage read correctly in a one-minute period. Students in this study read two passages at each test administration, and the mean score for the two passages was the dependent variable analyzed. A research synthesis of studies reporting psychometric properties for DIBELS ORF determined that reliability coefficients in these studies exceeded .80 and that the measure demonstrated moderate to high concurrent and predictive validity across studies (Goffreda & DiPerna, 2010). (NCT01133847)
Timeframe: Week 16 (End of Active Treatment Phase) and Follow-Up

,,
Interventionwords read correctly per minute (Mean)
16-Week OutcomesFollow-Up
ADHD Treatment53.6763.06
Combined ADHD Treatment and Reading Instruction53.8359.05
Intensive Reading Instruction50.7157.40

[back to top]

Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Hyperactivity-impulsivity

Rating Scale of ADHD symptomology completed by parents and teachers. Raters evaluate how well each DSM-IV (Diagnostic and Statistical Manual) ADHD symptom describes a child on a four-point Likert scale (0=Not at all, 1=Just a little, 2=Quite a bit, 3=Very much). The measure shows adequate internal consistency (.94) and test-retest reliability (Bussing et al., 2008; Gau et al., 2008). (NCT01133847)
Timeframe: 16 weeks (end of Active Treatment phase), and follow-up

,,
Interventionunits on a scale (Least Squares Mean)
16-Week OutcomesFollow-up Outcomes
ADHD Treatment0.80.9
Combined ADHD Treatment and Reading Instruction0.60.7
Intensive Reading Instruction1.31.4

[back to top]

Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Inattention

Rating Scale of ADHD symptomology completed by parents and teachers. Raters evaluate how well each DSM-IV (Diagnostic and Statistical Manual) ADHD symptom describes a child on a four-point Likert scale (0=Not at all, 1=Just a little, 2=Quite a bit, 3=Very much). The measure shows adequate internal consistency (.94) and test-retest reliability (Bussing et al., 2008; Gau et al., 2008). (NCT01133847)
Timeframe: 16 weeks (end of Active Treatment phase), and follow-up

,,
InterventionUnits on a scale (Least Squares Mean)
16-Week OutcomesFollow-up Outcomes
ADHD Treatment1.11.3
Combined ADHD Treatment and Reading Instruction1.01.0
Intensive Reading Instruction1.71.6

[back to top]

Wechsler Individual Achievement Test-III (WIAT-III) Word Reading Subtest

The WIAT-III is an individually-administered test of academic achievement. In the Word Reading subtest students read a list of increasingly difficult words. Scores reported here are standardized scores with a mean of 100 and standard deviation of 15. (NCT01133847)
Timeframe: Week 16 (End of Active Treatment Phase) and Follow-Up

,,
Interventionstandardized scores, M=100, SD = 15 (Least Squares Mean)
16-Week OutcomesFollow-Up
ADHD Treatment76.977.1
Combined ADHD Treatment and Reading Instruction79.978.8
Intensive Reading Instruction79.078.1

[back to top]

Test of Word Reading Efficiency (TOWRE) - Sight Word Efficiency

The TOWRE Sight Word Efficiency subtest measures fluency of reading words in lists. The raw score is the number of words or nonwords identified correctly in 45 seconds. Standard scores with a mean of 100 and standard deviaion of 15 are reported here. Higher scores represent a better outcome. (NCT01133847)
Timeframe: Week 16 (End of Active Treatment Phase) and Follow-Up

,,
Interventionstandardized scores (Least Squares Mean)
16-Week OutcomesFollow-Up
ADHD Treatment80.883.57
Combined ADHD Treatment and Reading Instruction83.584.15
Intensive Reading Instruction82.785.04

[back to top]

Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Hyperactivity-impulsivity

Rating Scale of ADHD symptomology completed by parents and teachers. Raters evaluate how well each DSM-IV ADHD symptom describes a child on a four-point Likert scale (0=Not at all, 1=Just a little, 2=Quite a bit, 3=Very much). The measure shows adequate internal consistency (.94) and test-retest reliability (Bussing et al., 2008; Gau et al., 2008). (NCT01133847)
Timeframe: Week 16 (End of Active Treatment Phase) and Follow-Up

,,
InterventionUnits on a scale (Least Squares Mean)
16-Week OutcomesFollow-up
ADHD Treatment0.70.8
Combined ADHD Treatment and Reading Instruction0.80.8
Intensive Reading Instruction1.11.1

[back to top]

Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Inattention

Rating Scale of ADHD symptomology completed by parents and teachers. Raters evaluate how well each DSM-IV ADHD symptom describes a child on a four-point Likert scale (0=Not at all, 1=Just a little, 2=Quite a bit, 3=Very much). The measure shows adequate internal consistency (.94) and test-retest reliability (Bussing et al., 2008; Gau et al., 2008). (NCT01133847)
Timeframe: Week 16 (End of Active Treatment Phase) and Follow-Up

,,
InterventionUnits on a scale (Least Squares Mean)
16-week OutcomesFollow-Up
ADHD Treatment1.21.5
Combined ADHD Treatment and Reading Instruction1.41.5
Intensive Reading Instruction1.71.9

[back to top]

Test of Word Reading Efficiency (TOWRE) - Phonemic Decoding Efficiency

The TOWRE Phonemic Decoding Efficiency measures the student's fluent decoding of nonsense words that follow the spelling rules of the English language. The raw score is the number of nonwords identified correctly in 45 seconds. Standardized scores with a mean of 100 and standard deviaion of 15 are reported here. Higher scores represent a better outcome. (NCT01133847)
Timeframe: Week 16 (End of Active Treatment Phase) and Follow-Up

,,
Interventionstandardized scores (Least Squares Mean)
16-Week OutcomesFollow-Up
ADHD Treatment80.481.49
Combined ADHD Treatment and Reading Instruction82.984.32
Intensive Reading Instruction83.484.50

[back to top]

Wechsler Individual Achievement Test-III (WIAT-III) Pseudoword Decoding Subtest

The WIAT-III is an individually-administered test of academic achievement. In the Pseudoword Decoding subtest students read a list of increasingly difficult nonsense words as a test of their ability to use phonics to decode unknown words. Scores reported here are standardized scores with a mean of 100 and standard deviation of 15. Higher scores represent a better outcome. (NCT01133847)
Timeframe: Week 16 (End of Active Treatment Phase) and Follow-Up

,,
Interventionstandardized scores (Least Squares Mean)
16-Week OutcomesFollow-Up
ADHD Treatment78.377.1
Combined ADHD Treatment and Reading Instruction83.081.9
Intensive Reading Instruction83.882.6

[back to top]

Test of Silent Reading Fluency and Comprehension (TOSREC)

The TOSREC measures sentence-level comprehension and silent reading fluency. It is a sentence verification task; children are presented with a list of sentences and must tell whether they are true or false. Items are based on common knowledge (e.g., All apples are blue). The raw score is the number of items answered correctly in 3 minutes. Standardized with a mean of 100 and standard deviation of 15 are reported here. Higher scores represent a better outcome. (NCT01133847)
Timeframe: Week 16, End of Active Treatment Phase

Interventionstandardized scores (Least Squares Mean)
ADHD Treatment17.40
Intensive Reading Instruction17.70
Combined ADHD Treatment and Reading Instruction18.57

[back to top]

Efficacy Measured by Mean Change From Baseline to Endpoint on Adult ADHD Investigator Rating Scale (AISRS) Total Score

"The Adult ADHD Investigator Rating Scale (AISRS) measures ADHD symptoms in adults. This scale is an investigator rated scale. Higher scores on this scale indicate more severe ADHD-like symptoms. Patients symptoms are rated as never, rarely, sometimes, often, or very often by the investigator. Total score ranges from 0 to 54. T-scores range from 30 to 100, with scores ≥65 indicating clinical impairment. A reduction in score indicates improvement." (NCT01399827)
Timeframe: baseline to 12 weeks

InterventionT-Score (Number)
Omega-3 Fatty Acids-14
Placebo-23

[back to top]

Efficacy Measured by Mean Change From Baseline to Endpoint on Clinical Global Impression (CGI) Scale

The Clinical Global Impression (CGI) is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response (CGIE). Scores range from 0 to 7 on each subscale. Total scores range from 0 to 21. T-scores range from 30 to 100, with scores ≥65 indicating clinical impairment. A reduction in score indicates improvement. (NCT01399827)
Timeframe: baseline to 12 weeks

InterventionT-Score (Number)
Omega-3 Fatty Acids5
Placebo1

[back to top]

Efficacy Measured by Mean Change From Baseline to Endpoint on the Global Assessment of Functioning (GAF) Scale

The Global Assessment of Functioning (GAF) scale is used to rate how serious a mental illness may be. Lower scores on this scale indicate a lower level of functioning and higher severity of symptoms. Total scores range from 0 to 100. (NCT01399827)
Timeframe: baseline to 12 weeks

Interventionunits on a scale (Number)
Omega-3 Fatty Acids11
Placebo8

[back to top]

Mean Change From Baseline to Endpoint on the BRIEF-A Emotional Control Scale

The BRIEF-A is a 75-item questionnaire that assesses and adult's cognitive, emotional, and behavioral functions within the past month. The subject rates each question on a 3-point scale (1=Never, 2=Sometimes, 3=Often). Raw scores are calculated and used to generate T-scores for 8 scales (Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials), 2 summary index scales (Behavioral Regulation Index and Metacognition Index), and one scale reflecting overall functioning (Global Executive Composite). T-scores range from 30 to 100, with scores ≥65 indicating clinical impairment. A reduction in score indicates improvement. (NCT01399827)
Timeframe: Baseline to 12 weeks

InterventionT-Score (Number)
Omega-3 Fatty Acids-7
Placebo-33

[back to top]

Efficacy Measured by Mean Change From Baseline to Endpoint on BRIEF-A Subscales

The BRIEF-A is a 75-item questionnaire that assesses and adult's cognitive, emotional, and behavioral functions within the past month. The subject rates each question on a 3-point scale (1=Never, 2=Sometimes, 3=Often). Raw scores are calculated and used to generate T-scores for 8 scales (Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials), 2 summary index scales (Behavioral Regulation Index and Metacognition Index), and one scale reflecting overall functioning (Global Executive Composite). T-scores range from 30 to 100, with scores ≥65 indicating clinical impairment. A reduction in score indicates improvement. (NCT01399827)
Timeframe: baseline to 12 weeks

,
Interventionunits on a scale (Number)
Change in BRIEF-A Inhibit Scale T-Scores from BaseChange in BRIEF-A Shift Scale T-Scores from BaseliChange in BRIEF-A Self Monitor Scale T-Scores fromChange in BRIEF-A Initiate Scale T-Scores from BasChange in BRIEF-A Working Memory Scale T-Scores frChange in BRIEF-A Plan/Organize Scale T-Scores froChange in BRIEF-A Task Monitor Scale T-Scores fromChange in BRIEF-A Organization of Materials ScaleChange in BRIEF-A BRI Scale T-Scores from BaselineChange in BRIEF-A MI Scale T-Scores from BaselineChange in BRIEF-A GEC Scale T-Scores from Baseline
Omega-3 Fatty Acids-1400-17-11-11-5-6-7-12-11
Placebo-28-13-13-9-30-19-32-22-29-46-29

[back to top]

Change in Dopamine Levels at Baseline and After Amphetamine Administration as Measured by Percent Change in PET Tracer Binding Potential.

PET images will be obtained in subjects at baseline and after amphetamine administration. Dopamine release will be measured as a percent change in binding potential. Increased dopamine release will result in decreased radiotracer binding because dopamine will displace the radiotracer. (NCT01699607)
Timeframe: first 90 minute scan at baseline, second 90 minute scan start 150 minutes post amphetamine administration

Interventionpercent change in binding potential (Mean)
Smoking Subjects-21
Nonsmoking Subjects-29

[back to top]

Permanent Product Measure of Performance (PERMP) Scores Including PREMP-C and PREMP-A From Different Timepoints Post-dose

To assess efficacy of d-ATS compared to placebo as measured by the PERMP-C (number of correct answers) and PERMP-A (number of attempted answers) score. The PERMP is an age-adjusted written math test, of 10 minutes' duration administered at multiple time points. Subjects are given 5 pages of 80 math problems (400 total problems) and are instructed to work at their desks and to complete as many problems as possible in 10 minutes. Performance is measured as the number of problems attempted (PERMP-A) and the number of problems worked correctly (PERMP-C). The scores range from 0-800 with higher scores indicating better performance. (NCT01711021)
Timeframe: 1,2, 3, 4.5,6,7,9,10 and 12 hours post-dose from double-blind treatment period

,
Interventionscore on a scale (Least Squares Mean)
PERMP-C at 1 hourPERMP-C at 2 hoursPERMP-C at 3 hoursPERMP-C at 4.5 hoursPERMP-C at 6 hoursPERMP-C at 7 hoursPERMP-C at 9 hoursPERMP-C at 10 hoursPERMP-C at 12 hoursPERMP-A at 1 hourPERMP-A at 2 hoursPERMP-A at 3 hoursPERMP-A at 4.5 hoursPERMP-A at 6 hoursPERMP-A at 7 hoursPERMP-A at 9 hoursPERMP-A at 10 hoursPERMP-A at 12 hours
d-Amphetamine Transdermal Patch124.0139.8141.2141.5139.7139.7139.0132.4135.3126.6142.7144.0144.0142.0142.3141.7134.7137.4
Placebo Patch113.1103.893.797.994.396.2102.998.996.4116.3106.397.4100.996.898.9106.8102.1100.1

[back to top]

Change in the Clinician-rated Scale of ADHD Symptoms Based on DSM-IV-TR Criteria (ADHD-RS-IV).

"The ADHD-RS-IV is based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria to assess efficacy of d-ATS compared to placebo. The ADHD-RS-IV scale was developed to measure the behaviors of children with ADHD, and it consists of 18 items designed to reflect current symptomatology of ADHD based on DSM-IV criteria. Each item is scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0 to 54.~Note: Week 6 is the first week of the double-blind treatment period, week 7 is the second week of the double-blind treatment period." (NCT01711021)
Timeframe: Averaged from week 6 and week 7 results during the Double-Blind Cross-Over treatment period.

Interventionscore on a scale (Least Squares Mean)
d-Amphetamine Transdermal Patch-23.4
Placebo Patch-10.3

[back to top]

Conners Parent Rating Scale Revised Short Form (CPRS-R:S) Total Scores From Week 6 and Week 7

"The CPRS-R:S evaluates problem behaviors as reported by the parent or alternative caregivers. The CPRS-R:S total score comprises 27 items and covers a subset of the subscales and items on the long parent form. The score ranges from 0-81 calculated from summed subscales scores. Higher score is considered a worse outcome for ADHD patients.~Note: Week 6 is the first week of the double-blind treatment period, week 7 is the second week of the double-blind treatment period." (NCT01711021)
Timeframe: Combined analysis by treatment groups from week 6 and week 7 (averaged)

Interventionscore on a scale (Least Squares Mean)
d-Amphetamine Transdermal Patch23.5
Placebo Patch39.5

[back to top]

Duration of Effect for d-Amphetamine and Placebo Treatment

Duration of Effect is the difference between the End of Effect and Onset of Effect in hours, where End of Effect is the first time point after Onset of Effect at which the 50% reduction in SKAMP total score from pre-dose is not observed. (NCT01711021)
Timeframe: Duration of Effect was from onset (2 hours post-dose) and up to 12 hours post-dose (p<0.001)

InterventionHours (Least Squares Mean)
d-Amphetamine Transdermal Patch2.6
Placebo Patch1.7

[back to top]

Mean Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score During the Double-Blind Treatment Period

The SKAMP total score comprises all 13 items. The SKAMP was designed for independent observers to rate 13 items representing 2 factors of classroom behavior: attention (SKAMP-A) and deportment (SKAMP-D), as well as quality of work. Items are specific to place (classroom setting) & time (during a typical classroom period), & the scale is used to assess multiple ratings taken within a day. The SKAMP-D subscale evaluates deportment, including interacting with other children, interacting with adults, remaining quiet according to classroom rules, & staying seated according to classroom rules. The SKAMP-A subscale is a measure of attention & evaluates getting started on assignments, sticking with tasks, attending to an activity, and making activity transitions. The SKAMP quality of work subscale includes 3 items: completing assigned work, performing work accurately, and being careful and neat while writing or drawing. Scores range from 0-78 with higher scores indicating worse impairment. (NCT01711021)
Timeframe: Mean SKAMP Total Score of SKAMP Total Scores from 9 different time points including (1, 2, 3, 4.5, 6, 7, 9, 10, 12 hours post-dose)

Interventionscore on a scale (Least Squares Mean)
d-Amphetamine Transdermal Patch12.81
Placebo Patch18.67

[back to top]

Number of Responders Evaluated by Clinical Global Impression (CGI-I) Scale by Treatments From the Double-blind Treatment Period

"The CGI scale permits a global evaluation of the subject's improvement over time. During the Dose Optimization Period and the Double-Blind Treatment Period, the investigator assessed the subject's improvement relative to symptoms prior to dosing, using the CGI-I Scale.~For CGI-I scale, the responders are defined as subjects achieving a score of~Very much improved or~Much improved or~The non-responders are defined as subjects achieving a score of~Minimally improved on the clinician-rated CGI global improvement item or~No change or~Minimally worse or~Much worse or~Very much worse~Then the number of responders are calculated by treatment arms. Note: Week 6 is the first week of the double-blind treatment period, week 7 is the second week of the double-blind treatment period." (NCT01711021)
Timeframe: the double-blind treatment period

InterventionParticipants (Count of Participants)
d-Amphetamine Transdermal Patch89
Placebo Patch25

[back to top]

Onset of Efficacy Measured by Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score

"Onset of efficacy defined as the time of the first assessment time showing statistical significance between d-ATS and placebo. The time point for the reported data are SKAMP scores (LS mean) from 2 hours post-dose.~The SKAMP total score comprises all 13 items. The SKAMP was designed for independent observers to rate 13 items representing 2 factors of classroom behavior: attention (SKAMP-A) and deportment (SKAMP-D), as well as quality of work. Items are specific to place (classroom setting) & time (during a typical classroom period), & the scale is used to assess multiple ratings taken within a day. Scores range from 0-78 with higher scores indicating worse impairment." (NCT01711021)
Timeframe: Onset of efficacy defined as the time of the first assessment time showing statistical significance between d-ATS and placebo. 2 hours post-dose in Double-Blind Treatment Period

Interventionscore on a scale (Least Squares Mean)
d-Amphetamine Transdermal Patch12.2
Placebo Patch19.0

[back to top]

mYPAS Measurement in Patients Receiving Midazolam

"modified Yale Preoperative Anxiety Scale (mYPAS), which is commonly used for assessing anxiety during the induction of anesthesia, administered to patients who received midazolam prior to anesthesia induction.~Assessment items: Activity (A) 1-4 points (A = score/4), Vocalizations (V) 1-6 points (V = score/6), Emotional expressivity (E) 1-4 points (E = score/4), State of arousal (S) 1-4 points (S = score/4), Use of parent (U) 1-4 points (U = score/4). Final score = [(A + V + E + S +U)/5] x 100. Higher score = more anxiety." (NCT01740206)
Timeframe: Day 1

Interventionscores on a scale (Median)
Patients Taking ADHD Medication30
Patients Not Taking ADHD Medication26

[back to top]

Diastolic Blood Pressure

Diastolic blood pressure prior to anesthetic induction (NCT01740206)
Timeframe: Day 1

InterventionmmHg (Mean)
Patients Taking ADHD Medication71.1
Patients Not Taking ADHD Medication67.9

[back to top]

Heart Rate

Heart rate prior to anesthetic induction (NCT01740206)
Timeframe: Day 1

InterventionBPM (Mean)
Patients Taking ADHD Medication96.7
Patients Not Taking ADHD Medication88

[back to top]

Mean Blood Pressure

Mean blood pressure prior to anesthetic induction (NCT01740206)
Timeframe: Day 1

InterventionmmHg (Mean)
Patients Taking ADHD Medication85.3
Patients Not Taking ADHD Medication81.7

[back to top]

mYPAS Measurement in Patients Not Receiving Midazolam

"modified Yale Preoperative Anxiety Scale (mYPAS), which is commonly used for assessing anxiety during the induction of anesthesia, administered to patients who did not receive midazolam prior to anesthesia induction.~Assessment items: Activity (A) 1-4 points (A = score/4), Vocalizations (V) 1-6 points (V = score/6), Emotional expressivity (E) 1-4 points (E = score/4), State of arousal (S) 1-4 points (S = score/4), Use of parent (U) 1-4 points (U = score/4). Final score = [(A + V + E + S +U)/5] x 100. Higher score = more anxiety." (NCT01740206)
Timeframe: Day 1

Interventionscores on a scale (Median)
Patients Taking ADHD Medication28
Patients Not Taking ADHD Medication28

[back to top]

Systolic Blood Pressure

Systolic blood pressure prior to anesthetic induction (NCT01740206)
Timeframe: Day 1

InterventionmmHg (Mean)
Patients Taking ADHD Medication113.6
Patients Not Taking ADHD Medication109.2

[back to top]

SKAMP Subscale - Deportment Scores

The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Deportment subscale score is comprised of four of the 13 items with a maximum score of 24. (NCT01986062)
Timeframe: 0.75, 2, 4, 6, 8, and 10 hours post-dose

,
Interventionunits on a scale (Mean)
0.75 hours post-dose2.0 hours post-dose4.0 hours post-dose6.0 hours post-dose8.0 hours post-dose10.0 hours post-dose
AR11 (Amphetamine Sulfate)2.11.62.13.13.53.1
Placebo3.94.04.74.34.94.9

[back to top]

SKAMP-Combined Scores

Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale [SKAMP]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment. (NCT01986062)
Timeframe: 0.75, 4, 6, 8, 10 hours post-dose

,
Interventionunits on a scale (Mean)
0.75 hours post-dose4 hours post-dose6 hours post-dose8 hours post-dose10 hours post-dose
AR11 (Amphetamine Sulfate)11.811.614.516.016.5
Placebo17.319.820.222.020.8

[back to top]

SKAMP Subscale - Attention Scores

The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Attention subscale score is comprised of four of the 13 items with a maximum score of 24. (NCT01986062)
Timeframe: 0.75, 2, 4, 6, 8, and 10 hours post-dose

,
Interventionunits on a scale (Mean)
0.75 hours post-dose2.0 hours post-dose4.0 hours post-dose6.0 hours post-dose8.0 hours post-dose10.0 hours post-dose
AR11 (Amphetamine Sulfate)2.21.92.22.32.83.2
Placebo3.43.44.03.64.14.0

[back to top]

PERM-P Scores - Number of Problems Correct

Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400). (NCT01986062)
Timeframe: 0.75, 2, 4, 6, 8, and 10 hours post-dose

,
Interventionnumber of problems correct (Mean)
0.75 hours post-dose2.0 hours post-dose4.0 hours post-dose6.0 hours post-dose8.0 hours post-dose10.0 hours post-dose
AR11 (Amphetamine Sulfate)104.5107.1107.095.692.789.9
Placebo83.978.979.970.571.572.3

[back to top]

PERM-P Scores - Number of Problems Attempted

Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400). (NCT01986062)
Timeframe: 0.75, 2, 4, 6, 8, and 10 hours post-dose

,
Interventionnumber of problems attempted (Mean)
0.75 hours post-dose2.0 hours post-dose4.0 hours post-dose6.0 hours post-dose8.0 hours post-dose10.0 hours post-dose
AR11 (Amphetamine Sulfate)111.6113.4113.2101.398.295.2
Placebo91.285.785.174.976.476.3

[back to top]

SKAMP-Combined Scores

Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale [SKAMP]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment. (NCT01986062)
Timeframe: 2 hours post-dose

Interventionunits on a scale (Mean)
AR11 (Amphetamine Sulfate)10.0
Placebo17.8

[back to top]

Those Achieving Three Consecutive Weeks of Cocaine Abstinence at the End of the Trial.

The primary outcome measure will be a binary indicator (yes or no) of at least 3 consecutive weeks of urine toxicology confirmed self-reported abstinence during the last three weeks of the trial. (NCT01986075)
Timeframe: weeks 12-14 of trial

InterventionParticipants (Count of Participants)
Computer-assisted CBT Plus Mixed-Amphetamine Salts- Extended Release (MAS-ER)7
Computer-assisted CBT Plus Placebo5

[back to top]

5-HT Transporter Binding as Measured During the PET Scan

"Use PET and [11C]DASB to explore 5-HTT receptor binding potential midbrain and striatal regions of interest in eating disorder subtypes.~The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) -1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume]. The binding of the 5-HTT on PET presumably reflects 5-HTT density and/or affinity." (NCT02020408)
Timeframe: 90 minute PET scan

,,,
Interventionbinding potential (BPND) (Mean)
[11C]DASB BPND anteroventral striatum[11C]DASB BPND post dorsal caudate[11C]DASB BPND posterior putamen[11C]DASB BPND predorsal caudate[11C]DASB BPND anterior putamen[11C]DASB BPND midbrain
[11C]DASB Binding Potential Control Women1.680.441.361.081.702.21
[11C]DASB Binding Potential in REC AN1.540.351.270.991.592.06
[11C]DASB Binding Potential in REC ANBN1.460.391.170.991.491.98
[11C]DASB Binding Potential in REC BN1.600.371.320.981.572.17

[back to top]

Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration

Use PET and [11C]raclopride to explore Dopamine D2/D3 receptor binding potential (BPND) in striatal regions of interest in eating disorder subtypes after amphetamine administration. The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) -1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume]. (NCT02020408)
Timeframe: 90 min PET scan

,,
Interventionbinding potential (BPND) (Mean)
[11C]raclopride BPND anteroventral striatum[11C]raclopride BPND post dorsal caudate[11C]raclopride BPND anterior putamen[11C]raclopride BPND posterior putamen[11C]raclopride BPND predorsal caudate
[11C]Raclopride Binding Potential Control Women2.091.692.712.532.48
[11C]Raclopride Binding Potential in REC AN2.011.622.652.462.40
[11C]Raclopride Binding Potential in REC ANBN1.941.692.602.472.47

[back to top]

Change in Scores of the Montgomery Asberg Depression Rating Scale (MADRS)

"The group treated with mixed salt amphetamine (MSA) adjunctive to antidepressant therapy (ADT) will show a greater mean change from baseline to endpoint as compared to the group treated with placebo (PBO) adjunctive to ADT as measure by the change ion the MADRS scores.~The MADRS is clinician-rated and consists of 10 items; each item is rated on a 0-6 scale, resulting in a maximum total score of 60 points, with higher scores indicative of greater depressive symptomology. The MADRS scoring instructions indicate that a total score ranging from 0 to 6 indicates that the patient is in the normal range (no depression), a score ranging from 7 to 19 indicates mild depression, 20 to 34 indicates moderate depression, a score of 35 and greater indicates severe depression. There is evidence that an improvement of two points or more on the MADRS is considered clinically relevant." (NCT02058693)
Timeframe: Baseline (Visit 2); End Phase I (Visit 5, Week 3): End Phase II (Visit 8, Week 6)

,
InterventionScores on a scale (Mean)
Baseline (V2)End of Phase I (V5; W3)End of Phase II (V8; W6)
Group 1(A): Placebo/MSA24.1811.557.10
Group 2(B): MSA/MSA2718.3110.17

[back to top]

Change in Scores on the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ)

The CPFQ is a seven-item self-administered questionnaire with higher scores indicating increased impairment in cognitive and physical functioning; score range being 7-42. (NCT02058693)
Timeframe: Baseline (Visit 2); End Phase I (Visit 5, Week 3): End Phase II (Visit 8, Week 6)

,
InterventionScores on a scale (Mean)
Baseline (V2)End Phase I (V5; W3)End Phase II (V8; W6)
Group 1(A): Placebo/MSA27.522.616
Group 2(B): MSA/MSA292521

[back to top]

Change in Scores on the Quick Inventory of Depressive Symptomatology Self Report 16 (QIDS-SR-16)

"The group with mixed salt amphetamine (MSA) adjunctive to antidepressant therapy (ADT) will show statistically significant improvement in core residual symptoms of major depressive disorder (MDD) extant on monotherapy ADT as measured by the Quick Inventory of Depressive Symptomatology Self Report 16.~16 items comprising 9 domains; each domain is scored from 0 to 3, with higher scores reflecting greater psychopathology. Total scores range from 0 to 27. Scoring procedure is to include ONLY the highest score on among the 4 sleep items (items 1 to 4); include ONLY the highest score among the 4 weight items (items 6 to 9); include ONLY the highest score on either of the 2 psychomotor items (15 and 16). The scores for these 3 domains are then added to the scores (0-3) for each of the 6 MDD symptom domains for a total score of 0-27." (NCT02058693)
Timeframe: Baseline (Visit 2); End Phase I (Visit 5, Week 3): End Phase II (Visit 8, Week 6)

,
InterventionScores on a scale (Mean)
Baseline (V2; W1)End of Phase I (V5; W3)End of Phase II (V7; W6)
Group 1(A): Placebo/MSA12.57.85
Group 2(B): MSA/MSA148.75.3

[back to top]

PERMP (Permanent Product Measure of Performance).

The PERMP is a math test that measures effortful performance without a learning curve (Wigal and Wigal 2006). The test determines the number of problems attempted and the number of problems correctly answered. In this study, the primary efficacy measure was a PERMP evaluation done 4 hours after taking study medication, a time selected a priori to coincide with the known pharmacodynamic effects based on prior research and to minimize the impact of repeated measures on adjustment of multiplicity (Wigal et al. 1998; Pelham et al. 2001). The PERMP consists of 400 math questions and each are scored. PERMP scores are expressed as the number of questions correct. Predose PERMP Tests are compared with post-dose PERMP scores at prespecfied timepoints. (NCT02083783)
Timeframe: Absolute change from baseline in PERMP questions answered correctly, measured from baseline to 4 hours postdose.

InterventionPERMP questions answered correctly (Least Squares Mean)
TRI10225.3
Placebo-13.6

[back to top]

SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale)

Change from baseline in SKAMP-Combined Scores measured approximately 4 hours after dose (active or placebo). The SKAMP-Combined score is obtained by summing 13 assessment items, where each item is rated on a 7-point scale (0 = normal to 6 = maximal impairment). This gives an overall (combined) SKAMP Score of 0= normal to 78 which indicates maximal impairment. The endpoint is assessed as a change from baseline in the overall score on the 78-point scale. (NCT02083783)
Timeframe: Absolute change from baseline in SKAMP-C score from baseline to 4 hours after dose

Interventionscore on a scale (Mean)
TRI102-9.1
Placebo5.6

[back to top]

Speed of Play on Slot Machine Game

Number of individual spins in a 15-minute slot machine game. Each spin corresponds to one wager. (NCT02203786)
Timeframe: 15-minutes

,,,
Interventionindividual spins/15-minutes (Mean)
Spins/15-minutes under DrugSpins/15-minutes under Placebo
Fluphenazine - Controls71.866.7
Fluphenazine - Pathological Gamblers78.568.4
Haloperidol - Controls66.472.2
Haloperidol - Pathological Gamblers76.988.6

[back to top]

Diastolic Blood Pressure (DBP)

Measure changes from baseline, especially physiologic reactivity to the slot machine and amphetamine. (NCT02203786)
Timeframe: At key points in testing: immediately after the slot machine game (change from session baseline), and at expected peak subjective-behavioral effects for amphetamine (90-minutes post-capsule administration)(change from session baseline).

,,,
Interventionmm Hg (Mean)
Drug-Change in DBP pre-to-post slot machinePlacebo-Change in DBP pre-to-post slot machineDrug-Change in DBP pre-amphetamine to peak amphPlacebo-Change in DBP pre-amphetamine to peak amp
Fluphenazine - Controls23.61932.736.3
Fluphenazine - Pathological Gamblers2221.632.135.2
Haloperidol - Controls15.119.128.526.6
Haloperidol - Pathological Gamblers20.222.527.233.6

[back to top]

Cognitive Task Performance

Response time to words (gambling, alcohol, positive affect, negative affect) as a percentage of neutral categorized words (parts of a building). This provides an index of the relative salience of stimuli from these four categories against a baseline of reaction to words with no clinical relevance or emotional valence. Smaller scores indicate faster relative response time to the test stimuli vs. neutral stimuli (i.e., greater salience) (NCT02203786)
Timeframe: At key points during testing: immediately after the slot machine, at expected peak subjective-behavioral effects for amphetamine (90-minutes post-capsule administration)

,,,
Interventionpercentage of neutral categorized words (Mean)
post-slots-GAM words under drugpost-slots-ALC words under drugpost-slots POS words under drugpost-slots NEG words under drugpost-slots GAM words under placebopost-slots ALC words under placebopost-slots POS words under placebopost-slots NEG words under placebopeak AMPH GAM words under drugpeak AMPH ALC words under drugpeak AMPH POS words under drugpeak AMPH NEG words under drugpeak AMPH GAM words under placebopeak AMPH ALC words under placebopeak AMPH POS words under placebopeak AMPH NEG words under placebo
Fluphenazine - Controls91.093.188.387.992.193.386.884.797.0100.396.398.796.997.595.196.7
Fluphenazine - Pathological Gamblers94.098.195.396.595.099.094.997.295.899.598.799.497.999.997.7100.0
Haloperidol - Controls94.896.593.789.697.297.093.792.398.199.197.296.896.8100.297.898.1
Haloperidol - Pathological Gamblers91.695.591.389.191.694.892.793.096.7101.298.299.595.099.998.499.0

[back to top]

Betting Behaviour in Laboratory-based Slot Machine Game

Risk taking was operationally defined as credits wagered per spin (mean computed for total spins) (NCT02203786)
Timeframe: 1x per test session (total of 4 test sessions) for duration of the study: 4 weeks (1 session/week)

,,,
Interventioncredits/spin on slot machine (Mean)
Mean bet under drugMean bet under placebo
Fluphenazine - Controls14.412.2
Fluphenazine - Pathological Gamblers16.016.1
Haloperidol - Controls11.69.5
Haloperidol - Pathological Gamblers12.810.4

[back to top]

Subjective Reinforcement Self-report Scales

Self-reported Confidence to Refrain from Gambling (0 - 10) was assessed at test session baseline, before the slot machine and after the slot machine (Phase 1); and before amphetamine and at peak amphetamine (Phase 2). The maximum score (10) denotes complete confidence to refrain from gambling (i.e., NO urge or compulsion to gamble); the minimum score (0) denotes complete lack of confidence to refrain from gambling (i.e., overwhelming urge to gamble). Scores between 10 and 0 denote intermediate confidence to refrain from gambling with LOWER scores denoting less confidence to refrain from gambling -- i.e., GREATER urge or compulsive motivation to gamble. Scores shown are based on single item visual analogue ratings 0-10 from each participant at the specified time point. The mean (SD) of these single item ratings is presented for each sub-group. (NCT02203786)
Timeframe: At key points in testing: immediately after the slot machine game, and at expected peak subjective-behavioral effects for amphetamine (90-minutes post-capsule administration).

,,,
Interventionunits on a scale (Mean)
Drug - Confidence not to gamble after slot machinePlacebo - Confidence not to gamble after slot machDrug - Confidence not to gamble at peak amphetaminPlac -Confidence not to gamble at peak amphetamine
Fluphenazine - Controls9.38.29.89.3
Fluphenazine - Pathological Gamblers4.84.86.45.7
Haloperidol - Controls9.599.89.4
Haloperidol - Pathological Gamblers4.84.25.25.5

[back to top]

Winnings on Slot Machine Upon Completion of Game

Credits (NCT02203786)
Timeframe: 15-minutes

,,,
Interventioncredits (Mean)
Winnings (Final Credit Tally) under drugWinnings (Final Credit Tally) under Placebo
Fluphenazine - Controls544.3215
Fluphenazine - Pathological Gamblers277.8140.8
Haloperidol - Controls449.1339.2
Haloperidol - Pathological Gamblers239562.4

[back to top]

Clinical Global Impression (CGI) Improvement for Deficient Emotional Self-Regulation (DESR)

"The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment (collected at all study visits). We examined the CGI Improvement specifically. The CGI Improvement for Deficient Emotional Self-Regulation (DESR) was reported at baseline and completion. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. It is rated as:~Very much improved~Much improved~Minimally improved~No change~Minimally worse~Much worse~Very much worse" (NCT02204410)
Timeframe: Baseline and 12 Weeks

Interventionunits on a scale (Mean)
CGI Improvement for DESR BaselineCGI Improvement for DESR Endpoint
Omega-3 Fatty Acids and Stimulant Treatment4.63.0

[back to top]

Emotional Control Subscale of the Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent)

"The Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent) is a 75-item checklist with a large normative sample, internal consistency, test-retest reliability, inter-rater reliability, and external and concurrent validity, divided into nine empirically and theoretically derived and T-scored subscales. The Emotional Control subscale measures the impact of executive function problems on emotional expression and assesses a child's ability to modulate or control his or her emotional responses. It is a 10-item subscale, and each item is scored Never, Sometimes, or Often. Raw scores for all scales are computed with Software Portfolio (BRIEF-SP), which provides a raw score and T score (based on child's age) for each scale. Higher scores represent more greater emotional dysregulation." (NCT02204410)
Timeframe: Baseline and 12 Weeks

Interventionunits on a scale (Mean)
Emotional Control Subscale T Score BaselineEmotional Control Subscale T Score Endpoint
Omega-3 Fatty Acids and Stimulant Treatment65.358.4

[back to top]

Percent Change in Binding Potential of Dopamine Release During PET Scan Post Amphetamine Administration

Percent change in binding potential of dopamine release during PET scan post amphetamine administration.Binding potential (BP) is the PET neuroimaging outcome measure that is computed as a proxy for availability of dopamine D2/3 receptors in a given region-of-interest. (NCT02348385)
Timeframe: After 2 PET Scans (1 day)

Interventionpercentage change in binding potential (Mean)
Male Healthy Tobacco Smokers14
Male Healthy Nonsmokers11.2
Female Healthy Tobacco Smokers1.9
Female Healthy Nonsmokers9.3

[back to top]

The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative

The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Lile et al., 2016) in which subjects made 9 choices between each available cocaine dose and money (US$6.00). Reinforcing effects are measured for each cocaine dose during both d-amphetamine and placebo maintenance. (NCT02383043)
Timeframe: 9 choice trials per cocaine dose level with each trial separated by 30 minutes

,,
Interventioncocaine choices (Mean)
Placebo Cocaine3 mg/70 kg Cocaine10 mg/70 kg Cocaine30 mg/70kg Cocaine
30 mg d-Amphetamine0.060.881.884.69
60 mg d-Amphetamine0.750.561.505.19
Placebo Treatment0.942.505.136.00

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Capsule Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm0.25-0.290.33-0.751.290.83
ALC Placebo Arm-0.17-0.670.08-0.920.920.33
AMP Arm-0.17-0.580.13-0.460.580.08
AMP Placebo Arm-0.25-0.580.13-1.171.960.5
THC Arm-0.04-0.710.38-0.792.920.42
THC Placebo Arm0.540.33-0.170.250.420.42

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 210 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.71-1.170.33-1.253.170.08
ALC Placebo Arm-0.54-0.791.67-0.380.21-0.17
AMP Arm1.01.380.630.83-0.290.96
AMP Placebo Arm-0.170.130.25-0.17-0.290
THC Arm-0.46-0.880.54-0.831.040.21
THC Placebo Arm0.080.040.04-0.130.13-0.08

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 120 Minutes After Drink Administraion

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm43.9223.7944.9229.3817.5
ALC Placebo Arm7.964.8311.085.086.54
AMP Arm27.0843.7511.9218.8845.38
AMP Placebo Arm11.927.0413.385.043.13
THC Arm24.081819.6321.969.92
THC Placebo Arm7.888.678.884.839.88

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm12.8318.6711.718.8313.5
ALC Placebo Arm9.3810.0411.05.53.71
AMP Arm4.7916.084.213.2914.21
AMP Placebo Arm12.179.010.716.965.63
THC Arm11.0811.7512.3810.586.54
THC Placebo Arm4.59.670.833.6711.0

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 210 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm12.887.3322.719.214.54
ALC Placebo Arm0.960.251.290.833.83
AMP Arm11.0818.388.546.2532.5
AMP Placebo Arm2.171.967.460.332.25
THC Arm5.794.886.834.968.79
THC Placebo Arm1.084.384.540.426.17

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 180 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm22.219.0429.514.137.0
ALC Placebo Arm2.081.754.291.254.04
AMP Arm16.1331.0811.5411.6738.38
AMP Placebo Arm3.52.544.251.632.46
THC Arm15.677.3316.1311.7910.04
THC Placebo Arm2.544.04.631.045.04

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 150 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm30.8321.3340.7520.4612.58
ALC Placebo Arm4.632.424.292.135.04
AMP Arm19.7939.511.2516.3344.08
AMP Placebo Arm5.836.748.092.872.87
THC Arm18.6311.7117.7914.759.38
THC Placebo Arm4.634.966.421.966.21

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm1.921.382.63-0.883.713.42
ALC Placebo Arm-0.33-1.170.29-0.961.540.29
AMP Arm2.883.711.131.63-13.21
AMP Placebo Arm000.33-0.832.250.42
THC Arm0.17-0.541.54-1.382.962.04
THC Placebo Arm0.710.880.130.041.130.96

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 90 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm0.29-0.381.79-2.546.212.25
ALC Placebo Arm-0.58-1.290.29-1.131.920.13
AMP Arm2.963.671.082.17-1.212.63
AMP Placebo Arm-0.33-0.29-0.04-1.292.670.42
THC Arm0-0.831.42-1.713.542.04
THC Placebo Arm-0.08-0.130.08-0.671.580.29

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm76.8345.0843.9650.3824.75
ALC Placebo Arm17.8314.3816.6811.510.0
AMP Arm43.4253.8815.7130.542.17
AMP Placebo Arm21.5816.6317.7112.5410.96
THC Arm38.2528.7525.6331.7517.46
THC Placebo Arm18.6325.2915.7912.9618.96

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 90 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm61.2129.9250.4641.8325.88
ALC Placebo Arm12.7511.3815.337.257.71
AMP Arm34.9255.6716.5427.9250.21
AMP Placebo Arm16.4610.4217.546.836.54
THC Arm31.5420.0823.2529.2116.54
THC Placebo Arm13.1713.2515.967.5812.88

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 120 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.33-1.130.79-2.045.461.08
ALC Placebo Arm-0.71-1.290.04-0.831.63-0.04
AMP Arm2.173.330.381.67-1.081.83
AMP Placebo Arm-0.17-0.125-0.13-11.710.25
THC Arm-0.08-0.961-1.542.881.42
THC Placebo Arm-0.04-0.08-0.08-0.381.080.17

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 150 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.54-1.540.79-2.045.460.75
ALC Placebo Arm-0.54-1.25-0.13-0.671.58-0.21
AMP Arm2.292.960.51.75-11.54
AMP Placebo Arm-0.130.130.09-0.430.650.22
THC Arm-0.17-0.960.58-1.292.580.83
THC Placebo Arm-0.08-0.08-0.17-0.420.790.08

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 180 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.75-1.290.54-1.53.630.08
ALC Placebo Arm-0.33-1.08-0.04-0.380.71-0.13
AMP Arm1.581.920.461.13-0.461.21
AMP Placebo Arm-0.040.330.04-0.330.210.13
THC Arm-0.21-0.670.54-1.292.130.71
THC Placebo Arm-0.17-0.170.04-0.290.42-0.08

[back to top]

Prepulse Inhibition (PPI)

"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Intervention% inhibition of startle (Mean)
PlaceboAmphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo50.62653.029
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine50.62645.822
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo41.16239.545
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine22.62932.656

[back to top]

Targeted Cognitive Training (TCT): PositScience, Inc.

"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionmsec (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo-2.11329.190
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine5.91135.905
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo-50.158101.000
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine-15.11852.647

[back to top]

MATRICS Consensus Cognitive Battery Performance (MCCB)

The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionstandardized T-score (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo57.87056.000
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine54.47655.476
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo39.89538.105
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine31.89533.842

[back to top]

Reduction in ADHD Symptoms

The primary ADHD outcome measure will be the number of individuals who achieve at least a 30% reduction in symptom severity as measured by the Adult ADHD Interview Rating Scale (AISRS). (NCT02803229)
Timeframe: Change from baseline compared to last week of trial on maintained dose during the 12 week trial (week 11 for completers) or last week of participants' participation during the 12 week trial for those who drop out of study prior to week 11.

InterventionParticipants (Count of Participants)
Placebo10
Adderall-XR10

[back to top]

Marijuana Abstinence

Number of participants who achieve abstinence from marijuana during the last two weeks of the trial as recorded by the Timeline Followback method and confirmed by urine toxicology. (NCT02803229)
Timeframe: Change from baseline compared to last 2 weeks of the 12 week study on maintained dose (weeks 10 and 11 for completers) or last 2 weeks of participants' participation during the study for participants who drop out of the study before weeks 10 and 11

InterventionParticipants (Count of Participants)
Placebo0
Adderall-XR2

[back to top]

Change in BP-ND in the TAK-041+AMPH Condition Compared to AMPH Alone as a Function of the Dose of TAK-041 Administered

The effect of predosing with TAK-041 on the AMPH challenge was calculated as the relative change in the percentage reduction in specific binding in ROI in the AMPH+TAK-041 condition compared to AMPH alone. (NCT02959892)
Timeframe: Baseline (Day 1 of Confinement Period 1), and Day 1 post-TAK-041 and AMPH dose in Confinement Period 2

,
Interventionpercentage of reduction (Mean)
PuVst
TAK-041 20 mg1714
TAK-041 40 mg3623

[back to top]

Change in Non-displaceable Binding Potential (BP-ND) in the TAK-041+AMPH Condition Compared to AMPH Alone

The AMPH-induced change in binding potential relative to the non-displaceable component in the basal ganglia (putamen [Pu], ventral striatum [VSt]) which was the region of interest (ROI) was calculated as the percentage of reduction in specific binding from Baseline to postdose following AMPH. (NCT02959892)
Timeframe: Baseline (Day 1 of Confinement Period 1) and Day 2 post-AMPH dose in Confinement Period 1

,
Interventionpercentage of reduction (Mean)
PuVSt
TAK-041 20 mg1714
TAK-041 40 mg3623

[back to top]

Change in Permanent Product Measure of Performance (PERMP-C) Score (Problems Answered Correctly)

Change from pre-dose in PERMP-C scores (Permanent Product Measure of Performance; defined as the number of problems attempted and number of problems solved correctly) at 30 minutes post-dose and at 3 hours post-dose. The PERMP-C is designed to assess compliance and academic productivity in school children. It is a 10-minute timed test in which the number of problems attempted and correct are assessed prior to and after an intervention. Scoring is based on problems attempted and correct. An increase in numerical score is indicative of improvement. (NCT03088267)
Timeframe: 30 minutes postdose and 3 hours postdose

,
InterventionChange from baseline in PERMP score (Least Squares Mean)
Change from predose in PERMP-C at 30 minutesChange from predose in PERMP-C at 3 hours
Active Treatment14.452.4
Placebo Treatment-4.7-7.9

[back to top]

Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose

Change in SKAMP-C (Swanson, Kotkin, Agler, M-Flynn, and Pelham combined) score from pre-dose, by treatment. The SKAMP-C is a rating scale that assesses functional impairment related to ADHD in the classroom, including the performance of academic tasks, following class rules, and interacting with peers and adults in the classroom. The SKAMP-C is a 13-item, 7-score rating system (0=normal to 7=maximal impairment). The higher the score, the worse the impairment. A decrease from baseline in the combined (all 13 items) score indicates improvement. The SKAMP-C is used to assess the time course of treatment effects in laboratory classroom studies. (NCT03088267)
Timeframe: Change in SKAMP-C score from baseline to 30 minutes postdose.

Interventionnumber of questions answered correctly (Least Squares Mean)
Active Treatment-6.1
Placebo Treatment2.5

[back to top]

Change in ADHD Symptoms Using Preschool or School Age ADHD Rating Scale (ADHD-RS) Total Score

ADHD Rating Scale (ADHD-RS) will assess symptom frequency using data from clinician completed ADHD-RS and parent completed ADHD-RS. The ADHD-RS includes 18 items, each rated on a 4 point scale (0-3);Total Score is the sum of all responses (0-54). An Inattention subscale and Hyperactivity/Impulsivity subscale (each range 0-27) are calculated based on individual items assessing those symptoms. Higher values represent worse outcomes for the subscales and the total scale. Clinically significant scores in boys are 14 for inattention and 17 for hyperactivity/impulsivity items; thresholds in girls are 12 and 14 respectively. If subscales are used, they would be summed to compute the total score. *Baseline measures occur on visits weeks -1 and week 0 in the study. (NCT03242772)
Timeframe: Baseline (Week 0), Week 10

Interventionscore on a scale (Mean)
ESDM Informed Parent Coaching + Amphetamine-10.00
ESDM Informed Parent Coaching + Placebo Oral Tablet-4.75

[back to top]

Change in Mean Composite Score (Socialization and Communication Subscales Standard Scores) of the Vineland Adaptive Behavior Scale - 3rd Edition, Interview Version (VABS-3)

Mean of standard scores for VABS-3 (socialization subscale and communication subscales) assess how the participant actually has been functioning over the preceding month with regard to communication and social behaviors. The VABS-3 comprehensive form will be administered as a semi-structured interview by a trained and research reliable staff member. The standard score is based on the participant's age and is normed from a large sample of typically developing children. The standard score has a mean of 100 and a standard deviation of 15. The composite score range is 20-140; higher scores represent more adaptive functioning and lower scores represent less adaptive functioning. (NCT03242772)
Timeframe: Baseline (Week -1), Endpoint (Week 10)

Interventionscore on a scale (Mean)
ESDM Informed Parent Coaching + Amphetamine5.92
ESDM Informed Parent Coaching + Placebo Oral Tablet1.86

[back to top]

Plasma Concentrations of d- and L-amphetamine

Plasma Concentration of d- and l-amphetamine measured at 0, 1, 3, 4, 6, 8, 10, 12, and 28 hours postdose. (NCT03610464)
Timeframe: 0-28 hours postdose

,
Interventionng/mL (Geometric Mean)
0 hours postdose1 hour postdose3 hours postdose4 hours postdose6 hours postdose8 hours postdose10 hours postdose12 hours postdose28 hours postdose
Plasma Concentration of d-Amphetamine03.519.920.217.516.914.411.62.2
Plasma Concentration of l-Amphetamine01.16.26.45.75.64.83.90.9

[back to top]

"Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ)."

"Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: Feel Drug, Feel High, Like Drug, and Want More. All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome." (NCT03810703)
Timeframe: End of study (Baseline - time 0 and approximately 4 weeks later)

,,
Interventionscore on a scale (Mean)
FeelLikeDislikeHighMore
Amphetamine 10 mg Arm35.2550.6927.1924.8845.38
Amphetamine 20 mg Arm45.7552.8116.2532.6952.44
Placebo Arm18.8837.4419.0017.5029.19

[back to top]

Change From Baseline to Visit 5 on DSST

The Digit Symbol Substitution Test (DSST) is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The DSST is sensitive to the presence of cognitive dysfunction as well as to change in cognitive function. The DSST is a 90 second test requiring participants to match symbols with numbers according to a code. Potential scores range from 0 to 100, and lower scores indicate worse performance. (NCT03834766)
Timeframe: From baseline to week 5

InterventionScore on a scale (Mean)
AMPH ER Tab4.8
Matching Placebo6.5

[back to top]

Lean Squares Mean (± Standard Error) of Math Test Score Over All Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the Administration of Serial Math Tests at Visit 5 (Week 5)

The Total Math Score is the sum of the number of math problems attempted plus the number of math problems answered correctly and it provides an objective measure of performance that is time-sensitive, ADHD medication-sensitive, and well documented as a measure to evaluate ADHD medication effectiveness throughout the day. The Total Math Score ranges from 0-800 with higher scores indicating better performance. (NCT03834766)
Timeframe: Pre-dose to 14 hour post-dose

InterventionScore on a scale (Mean)
AMPH ER Tab259.5
Matching Placebo260.6

[back to top]

Change From Baseline in AISRS Total Score at Each Post-baseline Visit

AISRS scale was developed to better capture symptoms of ADHD in adult patients. The scale has 18 items scored as follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe). The maximum total score for the scale is 54 points. (NCT03834766)
Timeframe: Baseline, Visit 1 (week 1), Visit 2 (week 2), Visit 3 (week 3), Visit 4 (week 4), Visit 5 (week 5)

,
InterventionScore on a scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
AMPH ER Tab-7.2-11.2-15-15.4-15.9
Matching Placebo-5.3-8.1-8.8-9.3-9.5

[back to top]

Change From Baseline in CGI-S Total Score at Each Post-baseline Visit

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. (NCT03834766)
Timeframe: Baseline, Visit 1 (week 1), Visit 2 (week 2), Visit 3 (week 3), Visit 4 (week 4), Visit 5 (week 5)

,
InterventionScore on a scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
AMPH ER Tab-0.6-1.0-1.3-1.4-1.3
Matching Placebo-0.3-0.6-0.6-0.8-0.7

[back to top]

Change From Baseline on Total Math Test Score Over Each Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the Administration of Serial Math Tests at Visit 5 (Week 5)

The Total Math Score is the sum of the number of math problems attempted plus the number of math problems answered correctly and it provides an objective measure of performance that is time-sensitive, ADHD medication-sensitive, and well documented as a measure to evaluate ADHD medication effectiveness throughout the day. The Total Math Score ranges from 0-800 with higher scores indicating better performance. (NCT03834766)
Timeframe: Visit 5 (week 5)

,
InterventionScore on a scale (Mean)
0.5 hours1 hours2 hours4 hours8 hours10 hours12 hours13 hours14 hours
AMPH ER Tab64.567.984.481.778.881.285.288.889
Matching Placebo39.727.847.053.048.253.858.347.762.9

[back to top]